Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-12-451638.txt : 20121105 0001193125-12-451638.hdr.sgml : 20121105 20121105152809 ACCESSION NUMBER: 0001193125-12-451638 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20120930 FILED AS OF DATE: 20121105 DATE AS OF CHANGE: 20121105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEOGENOMICS INC CENTRAL INDEX KEY: 0001077183 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-TESTING LABORATORIES [8734] IRS NUMBER: 742897368 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54384 FILM NUMBER: 121179920 BUSINESS ADDRESS: STREET 1: 1726 MEDICAL BOULEVARD, SUITE 201 STREET 2: SUITE 201 CITY: NAPLES STATE: FL ZIP: 34108 BUSINESS PHONE: 9419231949 MAIL ADDRESS: STREET 1: 1726 MEDICAL BOULEVARD, SUITE 201 STREET 2: SUITE 201 CITY: NAPLES STATE: FL ZIP: 34108 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN COMMUNICATIONS ENTERPRISES INC DATE OF NAME CHANGE: 19990120 10-Q 1 d398503d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012.

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 000-54384

NEOGENOMICS, INC.

(Exact name of registrant as specified in its charter)


Nevada		74-2897368
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

12701 Commonwealth Drive, Suite 9, Fort Myers, Florida		33913
(Address of principal executive offices)		(Zip Code)

(239) 768-0600

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of October 30, 2012, the registrant had 45,270,280 shares of Common Stock, par value $0.001 per share outstanding.

TABLE OF CONTENTS


PART I FINANCIAL INFORMATION
Item 1. Financial Statements (unaudited)			4
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			14
Item 3. Quantitative and Qualitative Disclosures About Market Risk			26
Item 4. Controls and Procedures			26
PART II OTHER INFORMATION
Item 1. Legal Proceedings			26
Item 1A. Risk Factors			27
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			27
Item 3. Defaults Upon Senior Securities			27
Item 4. Mine Safety Disclosures			27
Item 5. Other Information			27
Item 6. Exhibits			28
SIGNATURES			29

FORWARD-LOOKING STATEMENTS

The information in this Quarterly Report on Form 10-Q contains “forward-looking statements” and information within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) relating to NeoGenomics, Inc., a Nevada corporation (the “Parent” or the “Parent Company”), and its subsidiary, NeoGenomics Laboratories, Inc., a Florida corporation (“NEO”, “NeoGenomics Laboratories” or the “Subsidiary”) (collectively referred to as “we”, “us”, “our”, “NeoGenomics”, or the “Company”), which are subject to the “safe harbor” from liabilities created by those sections under the Private Securities Litigation Reform Act. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements can generally be identified as such because the context of the statement typically addresses future events or conditions. We may not actually achieve the projections, goals, plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that could cause our actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the risks set forth in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 12, 2012.

Forward-looking statements in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:

•

Our ability to implement our business strategy;

•

The expected reimbursement levels from governmental payers and private insurers;

•

The application, to our business and the services we provide, of existing laws, rules and regulations, including without limitation, Medicare laws, anti-kickback laws, Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) regulations, state medical privacy laws, federal and state false claims laws and corporate practice of medicine laws;

•

Regulatory developments in the United States;

•

Our ability to maintain our license under Clinical Laboratory Improvement Amendments of 1988 (“CLIA”);

•

Our ability to expand our operations and increase our market share;

•

Our ability to expand our service offerings by adding new testing capabilities;

•

Our ability to meet our future capital requirements;

•

The impact of internalization of testing by customers;

•

Our ability to compete with other diagnostic laboratories;

•

Our ability to hire and retain sufficient managerial, sales, clinical and other personnel to meet our needs;

•

Our ability to successfully scale our business, including expanding our facilities, our backup systems and infrastructure; and

•

The accuracy of our projections and estimates regarding reimbursements, expenses, future revenues and capital requirements.

Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time and it is not possible for management to predict all of such factors, nor can it assess the impact of each such factor on the business of the Company or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

NEOGENOMICS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

(unaudited)


	September 30, 2012			December 31, 2011
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	2,038		$	2,628
Restricted cash		300			500
Accounts receivable (net of allowance for doubtful accounts of $2,551 and $2,150, respectively)		12,013			7,894
Inventories		1,906			1,202
Other current assets		864			954

Total current assets		17,121			13,178

PROPERTY AND EQUIPMENT (net of accumulated depreciation of $9,202 and $6,653 respectively)		9,234			6,642

INTANGIBLE ASSETS (net of accumulated amortization of $126 and $0 , respectively)		2,856			—
OTHER ASSETS		91			129

TOTAL ASSETS	$	29,302		$	19,949

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES
Accounts payable	$	3,238		$	2,529
Accrued compensation		2,194			2,137
Accrued expenses and other liabilities		690			773
Short-term portion of equipment capital leases		2,513			2,107
Revolving credit line		8,035			3,898

Total current liabilities		16,670			11,444

LONG TERM LIABILITIES
Long-term portion of equipment capital leases		3,410			2,608

TOTAL LIABILITIES		20,080			14,052

Commitments and contingencies
STOCKHOLDERS’ EQUITY
Common stock, $.001 par value, (100,000,000 shares authorized; 45,268,905 and 43,416,200 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively)		45			43
Additional paid-in capital		31,635			28,490
Accumulated deficit		(22,458	)		(22,636	)

Total stockholders’ equity		9,222			5,897

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	29,302		$	19,949

See notes to unaudited consolidated financial statements.

NEOGENOMICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(unaudited)


	For the three months ended September 30,						For the nine months ended September 30,
	2012			2011			2012			2011
NET REVENUE	$	14,202		$	11,320		$	44,973		$	30,591

COST OF REVENUE		8,310			6,246			24,571			16,996

GROSS PROFIT		5,892			5,074			20,402			13,595

OPERATING EXPENSES
General and administrative		3,929			3,182			11,745			8,801
Research and development		808			125			1,833			416
Sales and marketing		1,839			1,725			5,809			5,162

Total operating expenses		6,576			5,032			19,387			14,379

INCOME (LOSS) FROM OPERATIONS		(684	)		42			1,015			(784	)

INTEREST AND OTHER INCOME (EXPENSE) – NET		(291	)		(185	)		(837	)		(545	)

NET INCOME (LOSS) BEFORE TAXES		(975	)		(143	)		178			(1,329	)

INCOME TAXES		—			—			—			—

NET INCOME (LOSS)	$	(975	)	$	(143	)	$	178		$	(1,329	)

NET INCOME (LOSS) PER SHARE
- Basic	$	(0.02	)	$	(0.00	)	$	0.00		$	(0.03	)

- Diluted	$	(0.02	)	$	(0.00	)	$	0.00		$	(0.03	)

WEIGHTED AVG NUMBER OF SHARES OUTSTANDING
- Basic		45,175			43,104			44,944			42,570

- Diluted		45,175			43,104			48,226			42,570

See notes to unaudited consolidated financial statements.

NEOGENOMICS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)


	For the Nine Months Ended September 30,
	2012			2011
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$	178		$	(1,329	)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Provision for bad debts		2,434			1,740
Amortization of intangibles		126			—
Depreciation of property and equipment		2,549			1,484
Amortization of debt issue costs		29			30
Stock-based compensation – options		488			257
Stock-based compensation – warrants and restricted stock		211			121
Changes in assets and liabilities, net:
(Increase) decrease in accounts receivable, net of write-offs		(6,552	)		(3,870	)
(Increase) decrease in inventories		(704	)		(208	)
(Increase) decrease in other current assets		61			286
(Increase) decrease in other assets		38			(37	)
Increase (decrease) in accounts payable and other liabilities		649			356

NET CASH (USED) IN OPERATING ACTIVITIES		(493	)		(1,170	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of intangible assets		(1,037	)		—
Purchases of property and equipment		(2,263	)		(338	)

NET CASH (USED) IN INVESTING ACTIVITIES		(3,300	)		(338	)

CASH FLOWS FROM FINANCING ACTIVITIES
Restricted cash		200			—
Advances (payments) on credit facility, net		4,137			1,030
Repayment of capital leases		(1,637	)		(1,146	)
Issuance of common stock and warrants for cash, net of transaction expenses		503			3,176

NET CASH PROVIDED BY FINANCING ACTIVITIES		3,203			3,060

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(590	)		1,552
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		2,628			1,097

CASH AND CASH EQUIVALENTS, END OF PERIOD	$	2,038		$	2,649

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Interest paid	$	809		$	519

Income taxes paid	$	—		$	—

NON-CASH INVESTING AND FINANCING ACTIVITIES
Equipment leased under capital leases	$	2,845		$	1,255

Common stock issued for intangible asset purchase	$	1,945		$	—

See notes to unaudited consolidated financial statements.

NEOGENOMICS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 30, 2012

NOTE A — NATURE OF BUSINESS AND BASIS OF FINANCIAL STATEMENT PRESENTATION

Nature of Business

NeoGenomics, Inc., a Nevada corporation (the “Parent” or the “Parent Company”), and its subsidiary, NeoGenomics Laboratories, Inc., a Florida corporation (“NeoGenomics Laboratories” or the “Subsidiary”) (collectively referred to as “we”, “us”, “our”, “NeoGenomics”, or the “Company”), operates as a certified “high complexity” clinical laboratory in accordance with the federal government’s Clinical Laboratory Improvement Act, as amended (“CLIA”), and is dedicated to the delivery of clinical diagnostic services to pathologists, oncologists, urologists, hospitals, and other laboratories throughout the United States.

Basis of Presentation

The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. These financial statements include the accounts of the Parent and the Subsidiary. All intercompany transactions and balances have been eliminated in the accompanying financial statements.

Certain information and footnote disclosures normally included in the Company’s annual audited consolidated financial statements and accompanying notes have been condensed or omitted in these interim financial statements. Accordingly, the unaudited consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company’s annual report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission on March 12, 2012.

The results of operations presented in this quarterly report on Form 10-Q are not necessarily indicative of the results of operations that may be expected for any future periods. In the opinion of management, these unaudited consolidated financial statements include all adjustments and accruals, consisting only of normal recurring adjustments that are necessary for a fair statement of the results of all interim periods reported herein.

Certain amounts in the prior year’s consolidated financial statements have been reclassified to conform to the current year presentation.

NOTE B — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America. These principles require management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the consolidated financial statements. Actual results and outcomes may differ from management’s estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these consolidated financial statements include, but are not limited to, those related to revenues, accounts receivable and related reserves, contingencies, useful lives and recovery of long-term and intangible assets, income taxes, and the fair value of stock-based compensation. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected in the consolidated financial statements prospectively from the date of the change in estimate.

Research and Development

Research and development costs are expensed as incurred. Research and development expenses consist of cash and equity compensation and benefits for research and development personnel, amortization of intangibles, related supplies, inventory and payment for samples to complete validation studies. These expenses were incurred to develop new genetic tests.

Intangible Assets

Intangible assets with finite useful lives are recorded at fair value which is our cost, less accumulated amortization. Amortization is recognized over the estimated useful lives of the assets. The Company’s intangible assets are related to our license agreement with Health Discovery Corporation.

Concentrations of Credit Risk

Concentrations of credit risk with respect to revenue and accounts receivable are primarily limited to certain clients to whom the Company provides a significant volume of its services, and to specific payers of our services such as Medicare and individual insurance companies. The Company’s client base consists of a large number of geographically dispersed clients diversified across various customer types. Over the last year, we have expanded our relationship with a large oncology practice with multiple office locations. For the three months ended September 30, 2012, all of the affiliated locations from this oncology practice combined represented approximately 12.9% of our revenue compared to 13.5% of revenue for the quarter ended September 30, 2011 and for the nine months ended September 30, 2012 represented approximately 15.4% of our revenue compared to 8.8% of revenue for the nine months ended September 30, 2011. All other clients were less than 5% of total revenue individually.

Income Taxes

We compute income taxes in accordance with applicable accounting standards. Deferred taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities. Also, the effect on deferred taxes of a change in tax rates is recognized in income in the period that included the enactment date. Temporary differences between financial and tax reporting arise primarily from the use of different depreciation methods for property and equipment, stock based compensation expense and the timing of recognition of bad debts.

We evaluate tax positions that have been taken or are expected to be taken in our tax returns, and record a liability for uncertain tax positions. As of September 30, 2012 we had no provision for related income taxes because we have large Net Operating Loss positions to offset our current net income.

NOTE C — REVOLVING CREDIT AND SECURITY AGREEMENT

On March 26, 2012, the Parent Company, NeoGenomics Laboratories (“Borrower”), and CapitalSource Finance LLC (“Capital Source”) entered into a First Amendment (the “Amendment”) to the Amended and Restated Revolving Credit and Security Agreement, dated April 26, 2010 (the “Amended and Restated Credit Agreement” or the “Credit Facility”). The Amended and Restated Credit Agreement amended and restated the original Revolving Credit and Security Agreement dated February 1, 2008, as amended, among the Parent Company, Borrower and CapitalSource (the “Original Credit Agreement”). The terms of the Amendment and the Amended and Restated Credit Agreement are substantially similar except that the Amendment, among other things:

I.)

Increased the maximum principal amount of the revolving credit facility (the “Facility Cap”) to $8.0 million from $5.0 million; provided, that the Borrower may request to increase the Facility Cap twice during the term of the Amended and Restated Credit Agreement in increments of $1.0 million to a maximum of $10,000,000;

II.)	Extended the term of the Amended and Restated Credit Agreement to March 26, 2015;

III.)

Revised the definition of “Minimum Termination Fee” to be:

2.5% of the Facility Cap if the “Revolver Termination” (as defined in the Agreement) is at any time before March 26, 2013;

1.5% of the Facility Cap if the Revolver Termination is after March 26, 2013 but before March 26, 2014;

0.5% of the Facility Cap if the Revolver Termination is on or after March 26, 2014; and

That there shall be no Minimum Termination Fee if the Revolver Termination occurs within five (5) days of the end of the term.

IV.)	Modified the definition of “Permitted Indebtedness” and “Fixed Charge Coverage Ratio”; and

V.)	Amended Section 3.1 of the Amended and Restated Credit Agreement by deleting “the LIBOR shall be not less than 2.0%” and replacing it with “the LIBOR shall be not less than 1.0%”.

We paid Capital Source a commitment fee of $80,000 in connection with the Amendment.

On July 27, 2012 the Facility Cap was increased from $8.0 million to $9.0 million.

Interest on outstanding advances under the Credit Facility are payable monthly in arrears on the first day of each calendar month and has an effective rate of interest of 5.25%.

On September 30, 2012 the available credit under the Credit Facility was approximately $0.3 million and the outstanding borrowing was $8.0 million after netting compensating cash on hand.

NOTE D — INTANGIBLE ASSETS

On January 6, 2012, we entered into a Master License Agreement (the “License Agreement”) with Health Discovery Corporation, a Georgia corporation (“HDC”). We were granted an exclusive worldwide license to certain of HDC’s “Licensed Patents” and “Licensed Know-How” (as defined in the License Agreement) to, among other things, use, develop, make, have made, sell, offer to sell, modify, and commercially exploit “Licensed Uses” (as defined in the License Agreement) and “Licensed Products” (as defined in the License Agreement), in the fields of laboratory testing, molecular diagnostics, clinical pathology, anatomic pathology and digital image analysis (excluding non-pathology-related radiologic and photographic image analysis) relating to the development, marketing production or sale of any “Laboratory Developed Tests” or LDTs (as defined in the License Agreement) or other products used for diagnosing, ruling out, predicting a response to treatment, and/or monitoring treatment of any or all hematopoietic and solid tumor cancers excluding cancers affecting the retina and breast cancer (collectively with certain other qualifications as defined in the License Agreement, the “Field” or “Field of Use”); provided, that the exclusion for breast cancer shall be in effect only so long as that certain license agreement between HDC and the licensee of the technology for breast cancer applications is in full force and effect and such licensee is not in material breach of any its obligations under that agreement.

The License Agreement allows us, among other things, to develop and sell, without limitation, any gene, gene-product or protein-based LDTs using HDC’s technology in the Field and provides for sublicensing rights and the assignment of the License Agreement, in whole or in part, in our sole discretion. The License Agreement further provides us with access to certain HDC personnel and consulting resources in the fields of mathematics and in genetic and molecular test development. The Licensed Know-How also includes, among other things, certain tests, algorithms and computer software which have already been developed by HDC.

We have agreed to use our best efforts to commercialize certain products within one year of the date of the License Agreement, subject to two one-year extensions per product if needed, including LDTs for prostate, colon and pancreatic cancer and software to automate the interpretation of cytogenetics and flow cytometry (collectively, the “Initial Licensed Products”).

If we have not generated $5.0 million of net revenue from products, services and sublicensing arrangements pursuant to the License Agreement within five years of the effective date, HDC may, at its option, revoke the exclusivity with respect to any one or more of the Initial Licensed Products, subject to certain conditions.

We had no intangible assets on December 31, 2011 and at September 30, 2012 intangible assets consisted of the following (in thousands):


	Weighted Average Amortization Period	September 30, 2012
		COST		Accumulated Amortization		Net
Support Vector Machine (SVM) technology	108 months	$	500	$	42	$	458
Laboratory developed test (LDT) technology	164 months	$	1,482	$	54	$	1,428
Flow Cytometry and Cytogenetics technology	202 months	$	1,000	$	30	$	970

Total		$	2,982	$	126	$	2,856

We recorded approximately $56,000 and $126,000 in straight-line amortization expense of intangibles for the three and nine months ended September 30, 2012 as a research and development expense in the consolidated statement of operations. We will record all amortization of intangibles in that category until the time that we have products, services or cost savings directly attributable to these intangible assets that would require that it be recorded in cost of goods sold. We continually review the estimated pattern in which the economic benefits will be consumed and adjust the amortization period and our pattern to match our estimate.

The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of September 30, 2012 is as follows (in thousands):


Year Ending December 31,
Remainder of 2012	$	56
2013		223
2014		223
2015		223
2016		223
2017		223
Thereafter		1,685

Total	$	2,856

NOTE E — NET INCOME (LOSS) PER SHARE

Basic net income (loss) per share is computed using the weighted average number of common shares outstanding during the applicable period. Diluted net income per share is computed using the weighted average number of common shares outstanding during the applicable period, plus the dilutive effect of potential common stock. Potential common stock consists of shares issuable pursuant to stock options and warrants. Diluted net (loss) per share is computed using the weighted average number of common shares outstanding during the applicable period. Potential common stock is excluded from diluted net (loss) per share as such amounts are anti-dilutive. Calculations of net income (loss) per share are done using the treasury stock method.

The following table provides the computation of basic and diluted net income (loss) per share for the three and nine month periods ending September 30, 2012 and 2011: (in thousands, except per share amounts)


	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012		2011
Net income (loss)	$	(975	)	$	(143	)	$	178	$	(1,329	)

Basic weighted average shares outstanding		45,175			43,104			44,944		42,570
Effect of potentially dilutive securities		—			—			3,282		—

Diluted weighted average shares outstanding		45,175			43,104			48,226		42,570

Basic net income (loss) per share	$	(0.02	)	$	(0.00	)	$	0.00	$	(0.03	)

Diluted net income (loss) per share	$	(0.02	)	$	(0.00	)	$	0.00	$	(0.03	)

For the nine months ended September 30, 2012 there were no outstanding options or warrants excluded from the calculation of diluted earnings per share due to anti-diluted affects, as all options and warrants were less than the average market price of the Company’s common stock for the nine months ended September 30, 2012.

NOTE F — STOCK OPTIONS

On January 9, 2012, Dr. Maher Albitar, our Chief Medical Officer was granted stock options to purchase 250,000 shares of the Company’s common stock at an exercise price per share of $1.43, which was the closing price per share on the last trading day prior to his start date. The stock options have a five year term and become 25% vested on each of the first four anniversaries of his start date. The stock options also fully vest upon a change of control of the Company. Dr. Albitar works in our California laboratory location, and the State of California has certain regulations that prohibit the corporate practice of medicine. As a result of this regulation, Dr. Albitar is not an employee, but rather is a full-time consulting physician to NeoGenomics. Thus, these stock options are non-employee consultant options and as such are being revalued at the end of every reporting period using a trinomial lattice model. At September 30, 2012 these stock options were valued at $428,000 and we recorded $118,400 and $158,000 of stock compensation expense related to the stock options in the three and nine months ended September 30, 2012, respectively.

On February 14, 2012, Mr. VanOort, our Chief Executive Officer was granted supplemental non-qualified stock options to purchase 800,000 shares of common stock at an exercise price of $1.71 per share which have a five year term so long as Mr. VanOort remains an employee of the Company (the “Supplemental Options”). The Supplemental Options are scheduled to vest according to the passage of time with 200,000 shares vesting each year on the anniversary of the grant date for the first four years after the grant. The Supplemental Options are valued at $505,000 based on a trinomial lattice model and we recorded $60,225 and $149,999 of stock compensation expense related to the Supplemental Options in the three and nine months ended September 30, 2012.

In the event of a change of control of the Company in which the consideration payable to common stockholders of the Company has a deemed value of at least $4.00 per share, any unvested portion of the Supplemental Options will immediately vest in full.

As of September 30, 2012, stock options to purchase 5,826,135 shares of our common stock were outstanding. The exercise prices of these options range from $0.25 to $1.71 per share and have a weighted average exercise price $1.02 per share.

NOTE G — COMMON STOCK WARRANTS

Albitar Warrant

On January 9, 2012 Dr. Maher Albitar was granted performance incentive warrants to purchase 200,000 shares of the Company’s common stock (the “Albitar Warrants”) at an exercise price per share of $1.43, which was the closing price per share on the last trading day prior to his start date. These warrants are being treated as non-employee consultant warrants and as such are being revalued, with assumptions for meeting performance, at the end of every reporting period using a trinomial lattice model. The Albitar Warrants have a five year term and vest in accordance with the performance criteria as follows:

(i)

80,000 will vest upon the commercial launch of the Company’s gene-based plasma prostate cancer test licensed from Health Discovery Corp (“HDC”) or similar test based on our mutual agreement.

(ii)

40,000 will vest upon the commercial launch of the Company’s gene-based colon cancer test licensed from HDC or similar test based on our mutual agreement.

(iii)

40,000 will vest upon the commercial launch of the Company’s gene-based pancreatic cancer test licensed from HDC or similar test based on our mutual agreement.

(iv)

20,000 will vest upon successful consummation of a sublicensing agreement with an instrument manufacturer to commercialize the cytogenetics automated image analysis technology licenses from HDC.

(v)

20,000 will vest upon successful consummation of a sublicensing agreement with an instrument manufacturer to commercialize the flow cytometry automated image analysis technology licenses from HDC.

On September 30, 2012 the Albitar Warrants were valued at $342,500 and we recorded approximately $95,800 and $128,000 of stock compensation expense related to the Albitar Warrants for the three and nine months ended September 30, 2012.

Warrant exercises

For the nine months ended September 30, 2012, 650,000 warrants previously issued to members of our board of directors and 348,417 warrants issued in June 2007 as part of a common stock offering were exercised or expired as follows:


Type of Exercise	Warrant Shares		Exercise Price /Share		Cash Received		Common Stock Shares Issued
For cash		175,000	$	1.50	$	262,500		175,000
Cashless net exercise		725,000	$	1.50	$	—		75,066
Expired unexercised		98,417	$	1.50	$	—		—

Warrant activity for the nine months ended September 30, 2012 is summarized as follows:


	Shares			Weighted Average Exercise Price
Warrants outstanding, December 31, 2011		2,156,750		$	1.34
Granted		200,000			1.43
Exercised		(900,000	)		1.50
Expired		(98,417	)		1.50
Cancelled		—			—

Warrants outstanding, September 30, 2012		1,358,333		$	1.24

NOTE H — CAPITAL LEASES

On September 9, 2011, we entered into a master lease agreement for an equipment lease line of credit with Garic, Inc. The facility had a 12 month draw down period and each schedule has a thirty six month term. The lease had a fair market value option at the end of the term at a price not to exceed fifteen percent of the equipment cost or the right to return the equipment. The facility expired and we had borrowed $658,000 over the life of the line at an interest rate of 16.12%.

In June 2012, we entered into a five year, $1 buyout equipment lease of approximately $495,000 for the purchase of laboratory equipment with Wells Fargo Lease Equipment Financing. The lease has an interest rate of approximately 6%.

During the nine months ended September 30, 2012, we entered into several vendor lease arrangements for approximately $1,555,000, primarily for the acquisition of lab equipment and to a lesser extent computer hardware. These capital leases are for 36 to 60 month terms, have either $1 purchase options or were fair market value at the end of the term, and had approximate interest rates between 8% and 16%.

NOTE I — OTHER RELATED PARTY TRANSACTIONS

During the three months ended September 30, 2012 and 2011, Steven C. Jones, a director of the Company, earned approximately $52,500 and $50,000, respectively, for various consulting work performed in connection with his duties as Executive Vice President of Finance. During the nine months ended September 30, 2012 and 2011, he earned approximately $155,000 and $148,500, respectively, for various consulting work performed in connection with his duties as Executive Vice President of Finance. Mr. Jones also received $55,000 and $2,500 for the nine months ended September 30, 2012 and 2011 as payment of his annual bonus compensation for the previous fiscal year.

NOTE J — INCOME TAXES

On July 17, 2012 the Internal Revenue Service completed its audit of our fiscal year 2009 and 2010 tax returns. The audit resulted in a small proposed adjustment to our Net Operating Loss carry forward which resulted from the Therapeutic Discovery Grant being considered as a reduction of expenses for tax purposes. As a result of the audit our net operating loss tax carry forward of federal and state income taxes changed to $16,249,164 at December 31, 2011 from $16,683,683 as previously disclosed in our Annual Report on Form 10K as filed with the Securities and Exchange Commission on March 12, 2012. Since we did not meet the standard established by ASC Topic 740 at December 31, 2011 we had a valuation allowance to fully reserve our deferred tax asset and that reserve will also change to $16,249,164 as well.

END OF FINANCIAL STATEMENTS.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

NeoGenomics, Inc., a Nevada corporation (referred to individually as the “Parent Company” or collectively with all of its subsidiaries as “NeoGenomics” or the “Company” in this Form 10-Q) is the registrant for SEC reporting purposes. Our common stock is quoted on the OTC Bulletin Board and the OTCQB under the symbol “NGNM.”

Introduction

The following discussion and analysis should be read in conjunction with the unaudited consolidated financial statements, and the notes thereto included herein. The information contained below includes statements of the Company’s or management’s beliefs, expectations, hopes, goals and plans that, if not historical facts, are forward-looking statements subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in such forward-looking statements. For a discussion on forward-looking statements, see the information set forth in the introductory note to this Quarterly Report on Form 10-Q under the caption “Forward Looking Statements”, which information is incorporated herein by reference.

Overview

We operate a network of cancer-focused testing laboratories whose mission is to improve patient care through exceptional genetic and molecular testing services. Our vision is to become America’s premier cancer testing laboratory by delivering uncompromising quality, exceptional service and innovative products and solutions. The Company has laboratory locations in Ft. Myers and Tampa, Florida; Irvine, California; and Nashville, Tennessee, and currently offers the following types of testing services:

Cytogenetics testing - the study of normal and abnormal chromosomes and their relationship to disease. Cytogenetic studies are often utilized to assist in refining treatment options for hematopoietic cancers such as leukemia and lymphoma;

Fluorescence In-Situ Hybridization (“FISH”) testing - a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes;

Flow cytometry testing - a rapid way to measure the characteristics of cell populations. Cells from peripheral blood, bone marrow aspirate, lymph nodes, and other areas are labeled with selective fluorescent antibodies and quantified according to their surface antigens. These fluorescent antibodies bind to specific cell surface antigens and are used to identify malignant cell populations. Flow cytometry is typically performed in conjunction with morphology testing which looks at smears on glass slides for abnormal cell populations;

Immunohistochemistry (“IHC”) testing - the process of identifying cell proteins in a tissue section utilizing the principle of antibodies binding specifically to antigens. Specific surface cytoplasmic or nuclear markers are characteristic of cellular events such as proliferation or cell death (apoptosis). IHC is also widely used to understand the distribution and localization of differentially expressed proteins; and

Molecular testing - a rapidly emerging cancer diagnostic tool focusing on the analysis of DNA and RNA, as well as the structure and function of genes at a molecular level. Molecular testing employs multiple technologies including bi-directional sequencing analysis, DNA fragment length analysis, and real-time polymerase chain reaction (“RT-PCR”) RNA analysis.

All of these testing services are widely utilized to inform the diagnosis and prognosis of various types and subtypes of cancer and to help predict a patient’s potential response to specific therapies. NeoGenomics offers testing services on both a “tech-only” basis, where NeoGenomics performs the technical component of the testing (specimen set-up, staining, imaging, sorting and categorization of cells, chromosomes, genes, DNA or RNA) and the client physician performs the related professional interpretation component (analyzing the laboratory data, developing the diagnosis or prognosis as well as preparing and writing the final report), as well as on a full service or “global” basis where NeoGenomics performs both the technical component and the professional interpretation component.

Our Focus

Our primary focus is to provide high complexity, cancer-related laboratory testing services to hospitals, community-based pathology practices, and clinicians throughout the United States. We currently perform analyses for hematopoietic cancers such as leukemia and lymphoma (blood and lymphoid tumors) and solid tumor cancers such as breast, lung, colon, and bladder cancer. For hematopoietic cancers, we typically analyze bone marrow aspirate and peripheral blood specimens. For solid tumor cancers, we typically analyze formalin fixed, paraffin embedded tissue samples or urine.

The cancer testing services we offer to community-based pathologists are designed to be a natural extension of, and complementary to, the services that they perform within their own practices. We believe our relationship as a non-competitive partner to community-based pathology practices empowers them to expand their breadth of testing and provide a menu of services that matches or exceeds the level of service found in academic centers of excellence around the country. Community-based pathology practices typically order our services on a “tech-only” basis, which allows them to participate in the diagnostic process by performing the professional interpretation services without having to make the investment in laboratory personnel or equipment needed to perform the technical component of the tests.

In areas where we do not provide services to community-based pathology practices, we may directly serve oncology, dermatology, urology and other clinician practices that prefer to have a direct relationship with a laboratory for cancer-related genetic and molecular testing services. We typically service these types of clients with a “global” service offering where we perform both the technical and professional components of the tests ordered. Increasingly, however, larger clinician practices have begun to internalize pathology testing, and our “tech-only” service offering allows these larger clinician practices to also participate in the diagnostic process by performing the professional interpretation services.

We are also focused on innovation because we are committed to being a leader in oncology testing. With the recent advances in genomics, proteomics and digital pathology, frequently large amounts of data are generated and managing this data is difficult without the aid of computer-based algorithms and pattern recognition. We believe that the best system for pattern recognition and data analysis is a technology known as Support Vector Machine or “SVM”, especially when combined with a technology called Recursive Feature Elimination or “RFE”.

Health Discovery Corporation (“HDC”) has an extensive array of pending and issued patents surrounding SVM and RFE technology. In January 2012, we entered into a Master License Agreement (the “License Agreement”) with HDC, pursuant to which we were granted an exclusive worldwide license to utilize HDC’s intellectual property portfolio, including some 84 issued and pending patents related to SVM and RFE as well as certain patents relating to digital image analysis, biomarker discovery, and gene and protein-based diagnostic, prognostic, and predictive testing, to develop and commercialize laboratory developed tests (“LDTs”) and other products relating to hematopoietic and solid tumor cancers.

Under the terms of the License Agreement, we may, subject to certain limitations, use, develop, make, have made, modify, sell, and commercially exploit products and services in the fields of laboratory testing, molecular diagnostics, clinical pathology, anatomic pathology and digital image analysis relating to the development, marketing, production or sale of any LDTs or other products used for diagnosing, ruling out, predicting a response to treatment, and/or monitoring treatment of any hematopoietic and solid tumor cancers excluding cancers affecting the retina and breast cancer; provided, that the exclusion for breast cancer shall be in effect only so long as that certain license agreement between HDC and the licensee of the technology for breast cancer applications is in full force and effect and such licensee is not in material breach of any its obligations under that agreement.

By licensing this technology and combining the expertise that already existed at Health Discovery Corp with our expertise in genomics, proteomics and digital imaging, we believe we are well-positioned to begin developing innovative and proprietary new products.

We have greatly expanded our menu of molecular tests in the past nine months. Molecular testing is a rapidly growing part of oncology testing, allowing us to determine types of cancer, as well as predicted responses to certain therapeutics. We have combined several molecular tests into NeoType^TM panels, which will help pathologists and oncologists determine cancer types on difficult cases. We use bi-directional sanger sequencing analysis which we believe is superior to many of the molecular tests being offered by our competitor’s because we are able to pick up mutations that other methods would not detect. With our strong menu of molecular tests we are positioned to capitalize on this rapidly growing area.

Our goal is to develop new assays to help our physicians better manage their patients and to enable them to practice evidence-based medicine tailored specifically for each of their patients. High priority will be given to the development of better tests for the diagnosis and prediction of clinical behavior in prostate cancer, pancreatic cancer, breast cancer, leukemia/lymphoma and other solid tumors.

We intend to combine and analyze data from genomics, proteomics and digital imaging using SVM-RFE techniques to develop practical, cost-effective and reliable new assays. Using this technology, we believe we will be able to offer a whole line of advanced tests that will help physicians better manage the treatment options for cancer patients.

Competitive Strengths

Turnaround Times

We strive to provide industry leading turnaround times for test results to our clients nationwide. By providing information to physicians in a rapid manner, they can begin treating their patients as soon as possible. We believe our average 4-5

day turn-around time for our cytogenetics testing services, our average 3-4 day turn-around time for FISH testing services, and our average 1 day turn-around time for flow cytometry testing services are industry-leading benchmarks for national laboratories. Our consistent timeliness of results is a competitive strength and a driver of additional testing requests by our referring physicians. Quick turn-around times allow for the performance of other adjunctive tests within an acceptable diagnosis window in order to augment or confirm results and more fully inform treatment options. We believe that our rapid turnaround times are a key differentiator of NeoGenomics versus other national laboratories, and our clients often cite them as a key factor in their relationship with us.

Medical Team

Our team of medical professionals and Ph.Ds. are specialists in the field of genetics and oncology. Our medical team is led by our Chief Medical Officer, Dr. Maher Albitar, a renowned hematopathologist with extensive experience in molecular and genetic testing. Prior to joining NeoGenomics, Dr. Albitar was Medical Director for Hematopathology and Oncology at the Quest Nichols Institute and Chief R&D Director for Hematopathology and Oncology for Quest Diagnostics. He also served as Section Chief for Leukemia at the University of Texas M. D. Anderson Cancer Center. In addition to Dr. Albitar, we employ several other full-time M.D.s and Ph.Ds.

Extensive Tech-Only Service Offerings

We launched the first tech-only FISH testing services in the United States in 2006, and we currently have the most extensive menu of tech-only FISH services in the country. Indeed, we believe we are the only national laboratory offering tech-only FISH services for hematopoietic cancers in the U.S. We also offer tech-only flow cytometry and immunohistochemistry testing services. These types of testing services generally allow the professional interpretation component of a test to be billed separately from the technical component. Our NeoFISH^TM, NeoFLOW^TM and other tech-only service offerings allow properly trained and credentialed community-based pathologists to extend their own practices by performing professional interpretations services, which allows them to better service the needs of their local clientele without the need to invest in the lab equipment and personnel required to perform the technical component of genetic and molecular testing.

Our tech-only services are designed to give pathologists the option to choose, on a case by case basis, whether they want to order just the technical information and images relating to a specific test so they can perform the professional interpretation, or order “global” services and receive a comprehensive test report which includes a NeoGenomics Pathologist’s interpretation of the test results. Our clients appreciate the flexibility to access NeoGenomics’ medical staff for difficult or complex cases or when they are otherwise unavailable to perform professional interpretations. We believe this innovative approach to serving the needs of pathology client’s results in longer term, more committed client relationships that are more akin to strategic partnerships. Our extensive tech-only service offerings have differentiated NeoGenomics and allowed us to compete more effectively against larger, more entrenched competitors in our niche of the industry.

Global Service Offerings

We also offer a full set of global services to meet the needs of those clients who are not credentialed and trained in interpreting genetic tests and who are looking for specialists to interpret the testing results for them. In our global service offerings, our lab performs the technical component of the tests and our M.D.s and Ph.Ds. provide the interpretation services. Our professional staff is also available for post testing consultative services. These clients rely on the expertise of our medical team to give them the answers they need in a timely manner to help inform their diagnoses and treatment decisions. Many of our tech-only clients also rely on our medical team for difficult or challenging cases by ordering our global testing services on a case by case basis. Our Genetic Pathology Solutions (“GPS”) report summarizes all relevant case data from our global services on one summary report. When providing global services, NeoGenomics performs both the technical and professional component of the test, which results in a higher reimbursement level.

Superior Testing Platforms

We use some of the most advanced testing platforms in the laboratory industry. Our new 10 color flow cytometry platform was recently launched and we are the first national laboratory to offer this service on a tech-only basis. Most of our competitors only offer between 5 and 8 color Flow Cytometry testing. We believe that this allows us to provide more and

better data to our clients. The use of bi-directional sequencing in our molecular testing allows us to detect multiple mutations which can be missed with single point mutation analysis. Our automated FISH and Cytogenetics tools allow us to deliver the highest quality testing to our clients.

Client Education Programs

We believe we have one of the most extensive client education programs in the genetic and molecular testing industry. We train pathologists how to use and interpret genetic testing services so that they can then participate in our tech-only service offerings. Our educational programs include an extensive library of on-demand training modules, online courses, and custom tailored on-site training programs that are designed to prepare clients to utilize our tech-only services. Each year, we also regularly sponsor seminars and webinars on emerging topics of interest in our field. Our medical staff is involved in many aspects of our training programs.

Laboratory Information System (LIS)

We believe we have a state-of-the-art Laboratory Information System (“LIS”) that interconnects our locations and provides flexible reporting solutions to clients. This system allows us to standardize testing and deliver uniform test results and images throughout our network, regardless of the location that any specific portion of a test is performed within our network. This allows us to move specimens and image analysis work between locations to better balance our workload. Our LIS also allows us to offer highly specialized and customizable reporting solutions to our tech-only clients. For instance, our tech-only NeoFISH^TM and NeoFLOW^TM applications allow our community-based pathologist clients to tailor individual reports to their specifications and incorporate only the images they select and then issue and sign-out such reports from our system with their own logos at the top. Our customized reporting solution even allows our clients to incorporate test results performed on ancillary tests not performed at NeoGenomics into summary report templates. This feature has been well-received by clients.

National Direct Sales Force

Our direct sales force has been trained extensively in cancer genetic testing and consultative selling skills to service the needs of clients. Our sales representatives (“Territory Business Managers”) are organized into three regions (East, Central and West). These sales representatives all utilize Salesforce.com to manage their territories, and we have integrated all of the important customer care functionality within our LIS into Salesforce.com so that our Territory Business Managers can stay informed of emerging issues and opportunities within their regions.

Geographic Locations

Many high complexity laboratories within the cancer testing niche have frequently operated a core facility on either the West Coast or the East Coast to service the needs of their customers around the country. We believe our clients and prospects desire to do business with a laboratory with national breadth and a local presence. We have four facilities, two large laboratory locations in Fort Myers, Florida and Irvine, California and two smaller laboratory locations in Nashville, Tennessee and Tampa, Florida. Our objective is to “operate one lab with four locations” in order to deliver standardized test results. We intend to continue to develop and open new laboratories or expand our current facilities as market situations dictate and business opportunities arise.

Scientific Pipeline

In the past few years our field has experienced a rapid increase in tests that are tied to specific “genomic pathways”. These predictive tests are typically individualized for a small sub-set of patients with a specific subtype of cancer. The therapeutic target in the genomic pathways is typically a small molecule found at the level of the cell surface, within the cytoplasm and/or within the nucleus. These genomic pathways, known as the “Hallmarks of Cancer”, contain a target-rich environment for small-molecule “anti-therapies”. These anti-therapies target specific mutations in the major cancer pathways such as the Proliferation Pathway, the Apoptotic Pathway, the Angiogenic Pathway, the Metastasis Pathway, and the Signaling Pathways and Anti-Signaling Pathways.

As an example, recently the FDA approved a small molecule anti-therapy drug (Xalkori) that targets a mutation in the ALK gene for a small sub-set of patients with Non-Small Cell Lung Cancer (NSCLC). Approximately 50-61% of patients with an

ALK gene rearrangement will respond to this therapy. To identify patients eligible for this specific small-molecule therapy, an FDA-approved FISH test that NeoGenomics and certain other laboratories offer, must be performed. This ALK FISH test is considered a companion diagnostic test and it is critical that this test be performed and the patient found to have an ALK mutation before therapy can be administered. Tests such as the ALK FISH test allow our clients to direct individualized treatments to each cancer patient in a timely manner. We are increasingly focused on attempting to develop new predictive tests such as this in our new product development pipeline. We have already added over 30 molecular tests in fiscal year 2012 and anticipate at least a dozen more by year-end. We have also greatly expanded our IHC menu and our digital pathology platform, areas we believe will help to drive future growth.

We are working with the technology we licensed from HDC to develop new proprietary cancer tests. We are working on technology we believe could streamline our workflow and reduce our costs along with providing a revenue stream by selling it to other laboratories around the world.

Seasonality

The majority of our testing volume is dependent on patients being treated by hematology/oncology professionals and other healthcare providers. Volume of testing generally declines during the vacation seasons, year-end holiday periods and other major holidays, particularly when those holidays fall during the middle of the week. In addition, volume of testing tends to decline due to adverse weather conditions, such as heavy snow, excessively hot or cold spells or hurricanes, tornados in certain regions, consequently reducing revenues and cash flows in any affected period. Therefore, comparison of the results of successive periods may not accurately reflect trends for future periods.

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions and select accounting policies that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

While many operational aspects of our business are subject to complex federal, state and local regulations, the accounting for our business is generally straightforward with net revenues primarily recognized upon completion of the testing process. Our revenues are primarily comprised of laboratory tests, and approximately one-half of total operating costs and expenses consist of employee compensation and benefits. Due to the nature of our business, several of our accounting policies involve significant estimates and judgments. These accounting policies have been described in our Annual Report on Form 10-K for the year ended December 31, 2011.

Intangible Assets

On January 6, 2012 we acquired approximately $3.0 million of intangible assets related to our Master License Agreement (“the License Agreement”) with HDC pursuant to which we were granted an exclusive worldwide license to utilize 84 issued and pending patents to develop and commercialize laboratory developed tests (“LDTs”) and other products relating to hematopoietic and solid tumor cancers. The licensed intellectual property and know-how relates to support vector machine (“SVM”), recursive feature elimination (“SVM-RFE”), fractal genomic modeling (“FGM”) and other pattern recognition technology as well as certain patents relating to digital image analysis, biomarker discovery, and gene and protein-based diagnostic, prognostic, and predictive testing.

The License Agreement allows us to develop and sell any gene, gene-product or protein-based LDTs based on HDC’s technology in the Field and provides for sublicensing rights and the assignment of the License Agreement, in whole or in part, in our discretion. The License Agreement further provides us with access to certain HDC personnel and consulting

resources in the fields of mathematics and in genetic and molecular test development. The licensed technology also includes, among other things, certain tests, algorithms and computer software which have already been developed by HDC. Initially, we intend to focus on developing prostate, pancreatic, and colon cancer LDTs. In addition, we plan to develop interpretation software that will help to automate the analysis of cytogenetics and flow cytometry tests.

The intangible assets were valued at fair value based on cost of the assets as we acquired the assets in an arms-length transaction. We present intangible assets net of accumulated amortization in our financial statements. We have three classes of intangible assets and each class of intangible assets is amortized over its estimated service period from service date through the weighted average patent expiration date of each class of patents or the period of economic benefit.

Technical Component Grandfather Clause Expiration

On February 22, 2012, the Middle Class Tax Relief Act (“MCTRA”) was enacted. The MCTRA included a provision that specified that the Centers for Medicare and Medicaid Services (“CMS”) Technical Component Grandfather (“TC Grandfather”) clause would expire on June 30, 2012. The TC Grandfather clause had allowed independent laboratories like us to bill Medicare directly for the technical component of certain hospital in-patient and out-patient laboratory tests reimbursable off of the Medicare Physician Fee Schedule for hospitals that had a relationship with an independent pathology lab prior to July 22, 1999. As a result of this regulatory change, effective July 1, 2012, we are required to bill hospitals directly for these technical component services. Our hospital clients, however, receive no incremental reimbursement for in-patient tests and only limited incremental reimbursement for out-patient tests. Thus, the expiration of the TC Grandfather clause created price competition in approximately 18% of our revenue base, where previously there had been none. This resulted in a decline of approximately $1.3 million of revenue for the three months ended September 30, 2012 versus the three months ended June 30, 2012. This decline in revenue also directly impacted gross margin and net income. We believe that we can return to the gross margins we experienced before the TC Grandfather expiration as we continue to grow our business and improve the efficiencies of our laboratory operations. The requirement to submit claims to our clients directly, instead of Medicare, has also had an impact on the time it takes for us to collect on the receivables for the tests in question. Medicare typically pays each claim filed within 3 to 4 weeks of filing, however, clients typically get billed only once a month for all claims, and the collection cycle time from clients is generally 30-60 days from the time they receive a bill.

Overview of Financial Results

The following table presents the consolidated statements of operations as a percentage of revenue:


	For the three months ended September 30,						For the nine months ended September 30,
	2012			2011			2012			2011
NET REVENUE		100.0	%		100.0	%		100.0	%		100.0	%
COST OF REVENUE		58.5	%		55.2	%		54.6	%		55.6	%

GROSS PROFIT		41.5	%		44.8	%		45.4	%		44.4	%

OPERATING EXPENSES:
General and administrative		27.6	%		28.1	%		26.1	%		28.8	%
Research and development		5.7	%		1.1	%		4.1	%		1.3	%
Sales and marketing		13.0	%		15.2	%		12.9	%		16.9	%

TOTAL OPERATING EXPENSES		46.3	%		44.4	%		43.1	%		47.0	%

INCOME (LOSS) FROM OPERATIONS		(4.8	)%		0.4	%		2.3	%		(2.6	)%

INTEREST AND OTHER INCOME (EXPENSE) - NET		(2.1	)%		(1.7	)%		(1.9	)%		(1.7	)%
NET INCOME (LOSS)		(6.9	)%		(1.3	)%		0.4	%		(4.3	)%

Results of Operations for the Three and Nine Months Ended September 30, 2012 as Compared to the Three and Nine Months Ended September 30, 2011

Revenue

Supplemental Information on Customer Requisitions Received and Tests Performed

(in thousands, except test and requisition amount)


	For the three months ended September 30,							For the nine months ended September 30,
	2012		2011		% Inc (Dec)			2012		2011		% Inc (Dec)
Requisitions Rec’d (cases)		18,307		12,857		42.4	%		53,802		34,995		53.7	%
Number of Tests Performed		28,315		19,977		41.7	%		84,093		53,731		56.5	%
Avg. # of Tests / Requisition		1.55		1.55		0.0	%		1.56		1.54		1.8	%

Total Testing Revenue	$	14,202	$	11,320		25.5	%	$	44,973	$	30,591		47.0	%
Avg Revenue/Requisition	$	775.77	$	880.47		(11.9	)%	$	835.90	$	874.15		(4.4	)%
Avg Revenue/Test	$	501.58	$	566.66		(11.5	)%	$	534.80	$	569.33		(6.1	)%

Our increase in test counts and revenue for the three and nine months ended September 30, 2012 when compared to the three and nine months ended September 30, 2011 was primarily the result of adding new client accounts and expanding our test service offerings. Over the last year, we have expanded our relationship with a large oncology practice with multiple office locations. For the three months ended September 30, 2012, all of the affiliated locations from this oncology practice combined represented approximately 12.9% of our revenue compared to 13.5% of revenue for the quarter ended September 30, 2011 and for the nine months ended September 30, 2012 represented approximately 15.4% of our revenue compared to 8.8% of revenue for the nine months ended September 30, 2011. The decrease in average revenue per test and requisition for the three and nine months ended September 30, 2012 as compared to the prior year was primarily attributable to the expiration of the previously discussed TC Grandfather clause. As a result of this regulatory change, effective July 1, 2012, we no longer are able to bill Medicare directly for the technical component of certain hospital in-patient and out-patient laboratory tests and now must bill our hospital clients directly for such services, often at a lower rate than what we were previously billing to Medicare. Average revenue per test and per requisition was also modestly impacted by an increasing proportion of lower average revenue molecular and immunohistochemistry tests in our test mix.

Cost of Revenue and Gross Profit

Cost of revenue includes payroll and payroll related costs for performing tests, depreciation of laboratory equipment, rent for laboratory facilities, laboratory reagents, probes and supplies, and delivery and courier costs relating to the transportation of specimens to be tested.


	For the three months ended September 30,									For the nine months ended September 30,
	2012			2011			Change			2012			2011			Change
Cost of revenue	$	8,310,000		$	6,246,000		$	2,064,000		$	24,571,000		$	16,996,000		$	7,575,000
Cost of revenue as a % of revenue		58.5	%		55.2	%					54.6	%		55.6	%
Gross Profit	$	5,892,000		$	5,074,000		$	818,000		$	20,402,000		$	13,595,000		$	6,807,000
Gross Profit as a % of revenue		41.5	%		44.8	%					45.4	%		44.4	%
Cost of Revenue per Test	$	293.49		$	312.68		$	(19.19	)	$	292.19		$	316.32		$	(24.13	)
Gross Profit per Test	$	208.08		$	253.98		$	(45.90	)	$	242.62		$	253.01		$	(10.39	)

For the three and nine months ended September 30, 2012 the overall cost of revenue increased due to the large increases in our testing volumes. The declines in cost of revenue per test for these periods are a result of improved productivity in our laboratory, as we experienced an increase in the amount of tests processed per laboratory FTE (full time equivalent personnel). This was driven by improved capacity planning and utilization along with several process improvements in the laboratory. We also experienced a reduction in test send-outs to other laboratories as a result of our expanded Molecular test services menu and a reduction in our contract labor due to our expanded medical staff. We continue to focus on improving our laboratory operations in order to continue to drive further improvements in our costs per test. We believe that we will continue to see a reduction in average cost per test in future periods based on the activities of our best practices teams.

Our cost of revenue as a percentage of revenue increased for the three months ended September 30, 2012 as compared to the prior year primarily as a result of the decrease in revenue which resulted from the Medicare TC Grandfather expiration on July 1, 2012. These impacts were partially offset by the benefits of the decline in average cost of revenue per test mentioned above. Our cost of revenue as a percentage of revenue declined by 1% for the nine month period ended September 30, 2012 as compared to the nine months ended September 30, 2011 as reductions in average cost of revenue per test fully offset the impact of the Medicare TC grandfather expiration, which did not occur until July 1, 2012.

Sales and Marketing

Sales and marketing expenses relate primarily to the employee related costs of our sales, marketing, and customer service personnel and costs from marketing and advertising efforts.


	For the three months ended September 30,								For the nine months ended September 30,
	2012			2011			Change		2012			2011			Change
Sales and marketing	$	1,839,000		$	1,725,000		$	114,000	$	5,809,000		$	5,162,000		$	647,000
As a % of revenue		13.0	%		15.2	%				12.9	%		16.9	%

These increases were the result of increased sales commissions related to the increase in revenue. Our sales and marketing costs as a percentage of revenue declined for the three and nine months ended September 30, 2012 as compared to the three and nine months ended September 30, 2011 as a result of operating leverage on our increased revenues.

We expect our overall sales and marketing expenses to increase modestly with increased test volumes but to decline slightly as a percentage of revenue.

General and Administrative Expenses

General and administrative expenses relate to billing, bad debts, finance, human resources, information technology and other administrative functions. They primarily consist of employee related costs (such as salaries, fringe benefits, and stock-based compensation expense), professional services, facilities expense, and depreciation and administrative-related costs allocated to general and administrative expenses.


	For the three months ended September 30,								For the nine months ended September 30,
	2012			2011			Change		2012			2011			Change
General and administrative	$	3,929,000		$	3,182,000		$	747,000	$	11,745,000		$	8,801,000		$	2,944,000
As a % of revenue		27.6	%		28.1	%				26.1	%		28.8	%

For the three and nine months ended September 30, 2012 as compared to the same periods in the previous year, the increases in general and administrative expenses are primarily a result of adding information technology and billing personnel to support the increase in our testing volumes as well as health insurance costs, technology costs related to the co-location of mission critical information technology applications to a secure facility in Tampa, Florida, recruiting expenses to hire new employees across the organization and an increase in corporate performance based bonuses. During the three months ended September 30, 2012 we had approximately $170,000 of moving related expenses related to our move into our new California facility that we do not expect to occur on a going forward basis. General and administrative expenses as a percentage of revenue declined in the three and nine months ended September 30, 2012 as compared to the three and nine months ended September 30, 2011 as we continue to gain economies of scale as our business grows.

Bad debt expense increased by approximately 11%, or approximately $68,000 to $699,000 for the three months ended September 30, 2012 as compared to approximately $631,000 for the three months ended September 30, 2011. This increase was primarily a result of the 25% increase in revenue and partially offset by a 0.7% decrease in bad debt as a percentage of revenue. For the three months ended September 30, 2012 bad debt expense as a percentage of revenue was 4.9% as compared to 5.6% for the comparable period in 2011. Bad debt expense increased by approximately 40%, or approximately $694,000 to $2,434,000 for the nine months ended September 30, 2012 as compared to approximately $1,740,000 for the nine months ended September 30, 2011. This increase was primarily a result of the 47% increase in revenue partially offset by a 0.3% decline in bad debt as a percentage of revenue.

We expect our overall general and administrative expenses to increase as we add personnel, increase our billing and collections activities; incur additional expenses associated with the expansion of our facilities and backup systems; incur additional bad debt expense related to increasing sales, and as we continue to build our physical infrastructure to support our anticipated growth. However, we expect general and administrative expenses to continue to decline as a percentage of our revenue as our case volumes increase and as we continue to develop more operating leverage in our business.

Research and Development Expenses

Research and development expenses relate to cost of developing new proprietary and non-proprietary genetic tests, stock compensation expense, as well as cost related to our licensing agreement with Health Discovery Corporation, including amortization of the licensed technology.


	For the three months ended September 30,								For the nine months ended September 30,
	2012			2011			Change		2012			2011			Change
Research and development	$	808,000		$	125,000		$	683,000	$	1,833,000		$	416,000		$	1,417,000
As a % of revenue		5.7	%		1.1	%				4.1	%		1.3	%

The increases in research and development expenses is primarily a result of increased personnel costs, stock compensation expense and supply costs to develop and launch new molecular tests as well as to develop proprietary testing products and services including those related to our license with HDC. R&D expenses for the three and nine months ended September 30, 2012, also included $214,000 and $286,000 of stock based compensation expenses for non-employee options and warrants. This included $177,000 of incremental stock based compensation expenses for non-employee options and warrants that were due solely to the rise in our stock price from June 30, 2012 to September 30, 2012.

Other (Income) Expense

Other income and expense primarily consists of the interest expense we incur on our borrowing arrangements (primarily comprised of interest payable on advances under our revolving credit facility with Capital Source and interest paid on capital lease obligations) offset by the interest income we earn on cash deposits. Interest expense increased from approximately $185,000 for the three months ended September 30, 2011 to $291,000 for the three months ended September 30, 2012. Interest expense increased from approximately $545,000 for the nine months ended September 30, 2011 to $837,000 for the nine months ended September 30, 2012. This reflects higher borrowings, particularly related to our revolving credit facility and capital lease obligations as we acquired additional equipment to support our increasing testing volumes.

Net Income (Loss)

As a result of the foregoing, we reported a net loss of $(975,000), or $(0.02)/share, for the three months ended September 30, 2012 as compared to a net loss of $(143,000), or ($0.00)/share, for the three months ended September 30, 2011. For the nine months ended September 30, 2012 we reported net income of $178,000, or $0.00/share, as compared to a net loss of $(1,329,000) or ($0.03)/share, for the nine months ended September 30, 2011.

Non-GAAP Measures

“Adjusted EBITDA” is defined by NeoGenomics as net income (loss) from continuing operations before (i) interest expense, (ii) tax expense and therapeutic discovery tax grants, (iii) depreciation and amortization expense, (iv) non-cash stock-based compensation and warrant amortization expense and (v) other extraordinary or non-recurring charges, such as the costs related to moving our California facility. NeoGenomics believes that Adjusted EBITDA provides a more consistent measurement of operating performance and trends across reporting periods by excluding these cash and non-cash items of expense not directly related to ongoing operations from income. Adjusted EBITDA also assists investors in performing analysis that is consistent with financial models developed by research analysts.

Adjusted EBITDA as defined by NeoGenomics is not a measurement under generally accepted accounting principles (“GAAP”) and may differ from non-GAAP measures used by other companies. There are limitations inherent in non-GAAP financial measures such as Adjusted EBITDA because they exclude a variety of charges and credits that are required to be included in a GAAP presentation, and do not therefore present the full measure of NeoGenomics recorded costs against its net revenue. Accordingly, investors should consider non-GAAP results together with GAAP results in analyzing NeoGenomics financial performance.

The following is a reconciliation of GAAP net income (loss) to Non-GAAP EBITDA and Adjusted EBITDA for the three and nine months ending September 30, 2012 and 2011:


	For the three months ended September 30,						For the nine months ended September 30,
	2012			2011			2012		2011
*Net income (loss) (Per GAAP)*	$	(975	)	$	(143	)	$	178	$	(1,329	)

Adjustments to Net Income (Loss):
Interest expense (income), net		291			185			837		545
Income taxes		—			—			—		—
Depreciation and amortization		1,000			521			2,675		1,484

EBITDA		316			563			3,690		700

Further Adjustments to EBITDA:
Other non-recurring items		170			—			170		—
Non-cash stock-based compensation		356			130			699		379

Adjusted EBITDA (non-GAAP)	$	842		$	693		$	4,559	$	1,079

Allowance for Doubtful Accounts

We have established a reserve for uncollectible amounts which is estimated based on the aging of accounts receivable within each payer category and our historical data on bad debts in these aging categories. In addition, the allowance is adjusted periodically for other relevant factors, including regularly assessing the state of our billing operations in order to identify issues which may impact the collectability of receivables or allowance estimates. Revisions to the allowance are recorded as an adjustment to bad debt expense within general and administrative expenses. After appropriate collection efforts have been exhausted, specific receivables deemed to be uncollectible are charged against the allowance in the period they are deemed uncollectible. Recoveries of receivables previously written-off are recorded as credits to the allowance. Total adjustments for incremental revenue from tests in which we underestimated the revenue in previous years from collections we received in the current year are not material to the Company’s results of operations in any period presented. Our estimates of net revenue are subject to change based on the contractual status and payment policies of the third party payers with whom we deal. We regularly refine our estimates in order to make our estimated revenue as accurate as possible based on our most recent collection experience with each third party payer.


	September 30,
	2012			2011			Change		% Change
Allowance for doubtful accounts	$	2,551,000		$	2,046,000		$	505,000		24.7	%
As a % of gross accounts receivable		17.5	%		21.7	%

The $505,000 increase in the allowance for doubtful accounts is the result of increased revenue causing our receivable balance to increase. However, our allowance as a percentage of gross accounts receivable has declined as a result of our being on contract with more managed care payers and an improvement in our receivable aging.

Bad debt expense as a percentage of revenue was 4.9% for the three month period ended September 30, 2012 as compared to 5.7% of revenue for the three months ended September 30, 2011. For the nine month period ended September 30, 2012 bad debt expense as a percentage of revenue was 5.4% as compared to 5.7% of revenue for the nine month period ended September 30, 2011.

Liquidity and Capital Resources

The following table presents a summary of our cash flows provided by (used in) operating, investing and financing activities for the nine months ended September 30, 2012 and 2011 as well as the period ending cash and cash equivalents and working capital.


	For the nine months ended September 30,
	2012			2011
Net cash provided by (used in):
Operating activities	$	(493	)	$	(1,170	)
Investing activities		(3,300	)		(338	)
Financing activities		3,203			3,060

Net increase (decrease) in cash and cash equivalents		(590	)		1,552
Cash and cash equivalents, beginning of period		2,628			1,097

Cash and cash equivalents, end of period (1)	$	2,038		$	2,649

Working Capital (2), end of period	$	451		$	1,774

(1)	excludes restricted cash of $0.3M in 2012 and $0.5 M in 2011.

(2)	Defined as current assets minus current liabilities.

Our net cash used from operating activities is driven by increases in our accounts receivable. Our accounts receivable balance has increased as a result of our 47% revenue growth during the nine months ended September 30, 2012. Aside from our growth, two other factors have contributed to the increase in our accounts receivable balance. First, the American Medical Association introduced new Molecular billing codes that went into effect on January 1, 2012. Only some payers have adopted these new codes, which has complicated billing. Complications from the different billing formats have increased our “re-bill rate” for molecular testing and have increased balances in accounts receivable. Second, the expiration of the TC Grandfather clause on June 30, 2012 which now requires us to bill clients for the technical component of our certain testing services, whereas previously we were able to bill Medicare directly for such services. Historically, Medicare is a much faster payer, and this change has contributed to increase in our receivables. Historically, Medicare is a much faster payer, and this change has contributed to increase in our receivables. We expect that the policy changes made by the Blue Cross and Blue Shield Association (“BCBSA”) to the Blue Card program in the fourth quarter of 2012 will also increase our accounts receivable as it will make it more complicated to receive payment from each of the various Blue Cross plans in each state and to get out of network payments from patients.

On January 6, 2012, we entered into a Master License Agreement (the “License Agreement”) with HDC (See Note D to the Notes to Unaudited Consolidated Financial Statements). Upon the execution of the License Agreement, we paid HDC $1,000,000 million in cash and issued to HDC 1,360,000 shares of our common stock which had a market value of $1,945,000 using the closing price of $1.43 per share for the Company’s common stock on the OTCQB Market on January 6, 2012. We have recorded this transaction as a purchase of intangible assets.

We have also used approximately $2,300,000 in cash to purchase or develop property and equipment. Approximately half of this was related to our new facility in Irvine, California and the remaining amounts were for internally developed software and externally developed software interfaces.

I.)

II.)	Extended the term of the Amended and Restated Credit Agreement to March 26, 2015;

III.)

Revised the definition of “Minimum Termination Fee” to be:

2.5% of the Facility Cap if the “Revolver Termination” (as defined in the Agreement) is at any time before March 26, 2013;

1.5% of the Facility Cap if the Revolver Termination is after March 26, 2013 but before March 26, 2014;

0.5% of the Facility Cap if the Revolver Termination is on or after March 26, 2014; and

That there shall be no Minimum Termination Fee if the Revolver Termination occurs within five (5) days of the end of the term.

IV.)	Modified the definition of “Permitted Indebtedness” and “Fixed Charge Coverage Ratio”; and

V.)	Amended Section 3.1 of the Amended and Restated Credit Agreement by deleting “the LIBOR shall be not less than 2.0%” and replacing it with “the LIBOR shall be not less than 1.0%”.

We paid Capital Source a commitment fee of $80,000 in connection with the Amendment.

On July 27, 2012 the Facility Cap was increased from $8.0 million to $9.0 million.

Interest on outstanding advances under the Credit Facility are payable monthly in arrears on the first day of each calendar month and has an effective rate of interest of 5.25%.

On September 30, 2012 the available credit under the Credit Facility was approximately $0.3 million and the outstanding borrowing was $8.0 million after netting compensating cash on hand.

We had unrestricted cash on hand of $2.0 million as of September 30, 2012, along with the unused portion of our credit line. As such, we believe we have adequate resources to meet our operating commitments. In the event operating cash flows are not sufficient to fully fund our growth, we would look to secure additional borrowing lines or expand our current line. There can be no guarantee that we will be successful securing additional debt facilities. In the event we are unable to fund our operations by positive operating cash flows or additional borrowings, we may be forced to reduce our expenses, slow down our growth rate or raise equity capital.

Capital Expenditures

We currently forecast capital expenditures in order to execute on our business plan. The amount and timing of such capital expenditures will be determined by the volume of business, but we currently anticipate that we will need to purchase approximately $5.5 - $6.5 million of additional capital equipment during the next year. We plan to fund these purchases primarily through capital lease financing arrangements. If we are unable to obtain such funding, we will need to pay cash for these items or we will be required to curtail our equipment purchases, which may have an impact on our ability to continue to grow our revenues.

Related Party Transactions

Consulting Agreements

ITEM 3 — Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide information under this item.

ITEM 4 — Controls and Procedures

Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer, principal financial officer, and principal accounting officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

As required by SEC Rule 15d-15, our management carried out an evaluation, under the supervision and with the participation of our principal executive officer, principal financial officer, and principal accounting officer, of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our principal executive officer, principal financial officer, and principal accounting officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of the end of the period covered by this report.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the three months ended September 30, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

ITEM 1 — LEGAL PROCEEDINGS

From time to time the Company is engaged in legal proceedings in the ordinary course of business. We do not believe any current legal proceedings are material to our business.

ITEM 1A — RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide information under this item. However current and prospective investors are encouraged to review the risks set forth in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 12, 2012.

ITEM 2 — UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

ITEM 3 — DEFAULTS UPON SENIOR SECURITIES

Not Applicable

ITEM 4 — MINE SAFETY DISCLOSURES

Not Applicable

ITEM 5 — OTHER INFORMATION

None

ITEM 6 — EXHIBITS


EXHIBIT NO.		DESCRIPTION

31.1**		Certification by Principal Executive Officer pursuant to Rule 13a-14(a)/ 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2**		Certification by Principal Financial Officer pursuant to Rule 13a-14(a)/ 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.3**		Certification by Principal Accounting Officer pursuant to Rule 13a-14(a)/ 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1**		Certification by Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101**		The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Cash Flows and (iv) related notes.

**		Provided herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: November 5, 2012	NEOGENOMICS, INC.

	By:	/s/ Douglas M. VanOort
	Name:	Douglas M. VanOort
	Title:	Chairman and Chief Executive Officer

	By:	/s/ George Cardoza
	Name:	George Cardoza
	Title:	Chief Financial Officer

	By:	/s/ Edwin F. Weidig III
	Name:	Edwin F. Weidig III
	Title:	Director of Finance and Principal Accounting Officer

EX-31.1 2 d398503dex311.htm EX-31.1 EX-31.1

EXHIBIT 31.1

CERTIFICATIONS

I, Douglas M. VanOort, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the three months ended September 30, 2012 of NeoGenomics, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.2 3 d398503dex312.htm EX-31.2 EX-31.2

EXHIBIT 31.2

CERTIFICATIONS

I, George Cardoza, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the three months ended September 30, 2012 of NeoGenomics, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.3 4 d398503dex313.htm EX-31.3 EX-31.3

EXHIBIT 31.3

CERTIFICATIONS

I, Edwin F. Weidig III, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the three months ended September 30, 2012 of NeoGenomics, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-32.1 5 d398503dex321.htm EX-32.1 EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of NeoGenomics, Inc. (the “Company”) on Form 10-Q for the three months ended September 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: November 5, 2012						/s/ Douglas M. VanOort
						Douglas M. VanOort
						Chairman and Chief Executive Officer

Date: November 5, 2012						/s/ George Cardoza
						George Cardoza
						Chief Financial Officer

Date: November 5, 2012						/s/ Edwin F. Weidig III
						Edwin F. Weidig III
						Director of Finance and Principal Accounting Officer

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 6 ngnm-20120930.xml XBRL INSTANCE DOCUMENT 0001077183 us-gaap:ScenarioPreviouslyReportedMember 2012-03-12 0001077183 us-gaap:WarrantMember 2012-09-30 0001077183 us-gaap:WarrantMember 2011-12-31 0001077183 ngnm:PlasmaProstateCancerTestLicensedFromHealthDiscoveryCorpHdcMember 2012-01-01 2012-09-30 0001077183 ngnm:PancreaticCancerTestLicensedFromHdcMember 2012-01-01 2012-09-30 0001077183 ngnm:CytometryAutomatedImageAnalysisTechnologyLicensesFromHdcMember 2012-01-01 2012-09-30 0001077183 ngnm:CytogeneticsAutomatedImageAnalysisTechnologyLicensesFromHdcMember 2012-01-01 2012-09-30 0001077183 ngnm:ColonCancerTestLicensedFromHdcMember 2012-01-01 2012-09-30 0001077183 us-gaap:WarrantMember ngnm:ExpiredUnexercisedMember 2012-01-01 2012-09-30 0001077183 us-gaap:ExecutiveVicePresidentMember 2012-07-01 2012-09-30 0001077183 us-gaap:ExecutiveVicePresidentMember 2012-01-01 2012-09-30 0001077183 us-gaap:ExecutiveVicePresidentMember 2011-07-01 2011-09-30 0001077183 us-gaap:ExecutiveVicePresidentMember 2011-01-01 2011-09-30 0001077183 ngnm:DueBeforeMarchTwentySixTwoThousandAndThirteenMember 2012-01-01 2012-09-30 0001077183 ngnm:DueBeforeMarchTwentySixTwoThousandAndFourteenMember 2012-01-01 2012-09-30 0001077183 ngnm:DueAfterMarchTwentySixTwoThousandAndFourteenMember 2012-01-01 2012-09-30 0001077183 ngnm:AmendedAndRestatedCreditAgreementMember 2012-09-30 0001077183 us-gaap:WarrantMember 2012-09-30 0001077183 2011-09-30 0001077183 2010-12-31 0001077183 us-gaap:ChiefExecutiveOfficerMember 2012-07-01 2012-09-30 0001077183 ngnm:ChiefMedicalOfficerMember 2012-07-01 2012-09-30 0001077183 us-gaap:DevelopedTechnologyRightsMember 2012-01-01 2012-09-30 0001077183 ngnm:LaboratoryDevelopedTestTechnologyMember 2012-01-01 2012-09-30 0001077183 ngnm:FlowCytometryAndCytogeneticsTechnologyMember 2012-01-01 2012-09-30 0001077183 us-gaap:DevelopedTechnologyRightsMember 2012-09-30 0001077183 ngnm:LaboratoryDevelopedTestTechnologyMember 2012-09-30 0001077183 ngnm:FlowCytometryAndCytogeneticsTechnologyMember 2012-09-30 0001077183 2011-12-31 0001077183 2007-06-01 2007-06-30 0001077183 us-gaap:MaximumMember 2012-01-01 2012-09-30 0001077183 us-gaap:ChiefExecutiveOfficerMember 2012-01-01 2012-09-30 0001077183 ngnm:ChiefMedicalOfficerMember 2012-01-01 2012-09-30 0001077183 us-gaap:WarrantMember 2012-01-01 2012-09-30 0001077183 2012-07-01 2012-09-30 0001077183 2011-07-01 2011-09-30 0001077183 2011-01-01 2011-09-30 0001077183 us-gaap:MinimumMember 2012-01-01 2012-09-30 0001077183 2012-09-30 0001077183 us-gaap:MinimumMember 2012-09-30 0001077183 us-gaap:MaximumMember 2012-09-30 0001077183 us-gaap:WarrantMember ngnm:ExpiredUnexercisedMember 2012-09-30 0001077183 us-gaap:WarrantMember ngnm:CashlessNetExerciseMember 2012-09-30 0001077183 us-gaap:WarrantMember ngnm:CashExerciseMember 2012-09-30 0001077183 us-gaap:WarrantMember ngnm:CashlessNetExerciseMember 2012-01-01 2012-09-30 0001077183 us-gaap:WarrantMember ngnm:CashExerciseMember 2012-01-01 2012-09-30 0001077183 ngnm:EquipmentFacilityOneMember 2012-09-30 0001077183 2012-10-30 0001077183 2012-01-01 2012-09-30 iso4217:USD ngnm:Other iso4217:USD xbrli:shares xbrli:pure xbrli:shares iso4217:USD

NOTE A — NATURE OF BUSINESS AND BASIS OF FINANCIAL STATEMENT PRESENTATION Nature of Business NeoGenomics, Inc., a Nevada corporation (the “Parent” or the “Parent Company”), and its subsidiary, NeoGenomics Laboratories, Inc., a Florida corporation (“NeoGenomics Laboratories” or the “Subsidiary”) (collectively referred to as “we”, “us”, “our”, “NeoGenomics”, or the “Company”), operates as a certified “high complexity” clinical laboratory in accordance with the federal government’s Clinical Laboratory Improvement Act, as amended (“CLIA”), and is dedicated to the delivery of clinical diagnostic services to pathologists, oncologists, urologists, hospitals, and other laboratories throughout the United States. Basis of Presentation The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. These financial statements include the accounts of the Parent and the Subsidiary. All intercompany transactions and balances have been eliminated in the accompanying financial statements. Certain information and footnote disclosures normally included in the Company’s annual audited consolidated financial statements and accompanying notes have been condensed or omitted in these interim financial statements. Accordingly, the unaudited consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company’s annual report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission on March 12, 2012. The results of operations presented in this quarterly report on Form 10-Q are not necessarily indicative of the results of operations that may be expected for any future periods. In the opinion of management, these unaudited consolidated financial statements include all adjustments and accruals, consisting only of normal recurring adjustments that are necessary for a fair statement of the results of all interim periods reported herein. Certain amounts in the prior year’s consolidated financial statements have been reclassified to conform to the current year presentation.

NOTE B — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America. These principles require management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the consolidated financial statements. Actual results and outcomes may differ from management’s estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these consolidated financial statements include, but are not limited to, those related to revenues, accounts receivable and related reserves, contingencies, useful lives and recovery of long-term and intangible assets, income taxes, and the fair value of stock-based compensation. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected in the consolidated financial statements prospectively from the date of the change in estimate. Research and Development Research and development costs are expensed as incurred. Research and development expenses consist of cash and equity compensation and benefits for research and development personnel, amortization of intangibles, related supplies, inventory and payment for samples to complete validation studies. These expenses were incurred to develop new genetic tests. Intangible Assets Intangible assets with finite useful lives are recorded at fair value which is our cost, less accumulated amortization. Amortization is recognized over the estimated useful lives of the assets. The Company’s intangible assets are related to our license agreement with Health Discovery Corporation. Concentrations of Credit Risk Concentrations of credit risk with respect to revenue and accounts receivable are primarily limited to certain clients to whom the Company provides a significant volume of its services, and to specific payers of our services such as Medicare and individual insurance companies. The Company’s client base consists of a large number of geographically dispersed clients diversified across various customer types. Over the last year, we have expanded our relationship with a large oncology practice with multiple office locations. For the three months ended September 30, 2012, all of the affiliated locations from this oncology practice combined represented approximately 12.9% of our revenue compared to 13.5% of revenue for the quarter ended September 30, 2011 and for the nine months ended September 30, 2012 represented approximately 15.4% of our revenue compared to 8.8% of revenue for the nine months ended September 30, 2011. All other clients were less than 5% of total revenue individually. Income Taxes We compute income taxes in accordance with applicable accounting standards. Deferred taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities. Also, the effect on deferred taxes of a change in tax rates is recognized in income in the period that included the enactment date. Temporary differences between financial and tax reporting arise primarily from the use of different depreciation methods for property and equipment, stock based compensation expense and the timing of recognition of bad debts. We evaluate tax positions that have been taken or are expected to be taken in our tax returns, and record a liability for uncertain tax positions. As of September 30, 2012 we had no provision for related income taxes because we have large Net Operating Loss positions to offset our current net income.

NOTE C — REVOLVING CREDIT AND SECURITY AGREEMENT On March 26, 2012, the Parent Company, NeoGenomics Laboratories (“Borrower”), and CapitalSource Finance LLC (“Capital Source”) entered into a First Amendment (the “Amendment”) to the Amended and Restated Revolving Credit and Security Agreement, dated April 26, 2010 (the “Amended and Restated Credit Agreement” or the “Credit Facility”). The Amended and Restated Credit Agreement amended and restated the original Revolving Credit and Security Agreement dated February 1, 2008, as amended, among the Parent Company, Borrower and CapitalSource (the “Original Credit Agreement”). The terms of the Amendment and the Amended and Restated Credit Agreement are substantially similar except that the Amendment, among other things:   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">I.)</td> <td align="left" valign="top">Increased the maximum principal amount of the revolving credit facility (the “Facility Cap”) to $8.0 million from $5.0 million; provided, that the Borrower may request to increase the Facility Cap twice during the term of the Amended and Restated Credit Agreement in increments of $1.0 million to a maximum of $10,000,000; </td> </tr> </table>   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">II.)</td> <td align="left" valign="top">Extended the term of the Amended and Restated Credit Agreement to March 26, 2015; </td> </tr> </table>   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">III.)</td> <td align="left" valign="top">Revised the definition of “Minimum Termination Fee” to be: </td> </tr> </table>   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%"> </td> <td width="4%" valign="top" align="left">a.</td> <td align="left" valign="top">2.5% of the Facility Cap if the “Revolver Termination” (as defined in the Agreement) is at any time before March 26, 2013; </td> </tr> </table>   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%"> </td> <td width="4%" valign="top" align="left">b.</td> <td align="left" valign="top">1.5% of the Facility Cap if the Revolver Termination is after March 26, 2013 but before March 26, 2014; </td> </tr> </table>   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%"> </td> <td width="4%" valign="top" align="left">c.</td> <td align="left" valign="top">0.5% of the Facility Cap if the Revolver Termination is on or after March 26, 2014; and </td> </tr> </table> <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%"> </td> <td width="4%" valign="top" align="left">d.</td> <td align="left" valign="top">That there shall be no Minimum Termination Fee if the Revolver Termination occurs within five (5) days of the end of the term. </td> </tr> </table>   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">IV.)</td> <td align="left" valign="top">Modified the definition of “Permitted Indebtedness” and “Fixed Charge Coverage Ratio”; and </td> </tr> </table>   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">V.)</td> <td align="left" valign="top">Amended Section 3.1 of the Amended and Restated Credit Agreement by deleting “the LIBOR shall be not less than 2.0%” and replacing it with “the LIBOR shall be not less than 1.0%”. </td> </tr> </table> We paid Capital Source a commitment fee of $80,000 in connection with the Amendment. On July 27, 2012 the Facility Cap was increased from $8.0 million to $9.0 million. Interest on outstanding advances under the Credit Facility are payable monthly in arrears on the first day of each calendar month and has an effective rate of interest of 5.25%. On September 30, 2012 the available credit under the Credit Facility was approximately $0.3 million and the outstanding borrowing was $8.0 million after netting compensating cash on hand.

NOTE D — INTANGIBLE ASSETS On January 6, 2012, we entered into a Master License Agreement (the “License Agreement”) with Health Discovery Corporation, a Georgia corporation (“HDC”). We were granted an exclusive worldwide license to certain of HDC’s “Licensed Patents” and “Licensed Know-How” (as defined in the License Agreement) to, among other things, use, develop, make, have made, sell, offer to sell, modify, and commercially exploit “Licensed Uses” (as defined in the License Agreement) and “Licensed Products” (as defined in the License Agreement), in the fields of laboratory testing, molecular diagnostics, clinical pathology, anatomic pathology and digital image analysis (excluding non-pathology-related radiologic and photographic image analysis) relating to the development, marketing production or sale of any “Laboratory Developed Tests” or LDTs (as defined in the License Agreement) or other products used for diagnosing, ruling out, predicting a response to treatment, and/or monitoring treatment of any or all hematopoietic and solid tumor cancers excluding cancers affecting the retina and breast cancer (collectively with certain other qualifications as defined in the License Agreement, the “Field” or “Field of Use”); provided, that the exclusion for breast cancer shall be in effect only so long as that certain license agreement between HDC and the licensee of the technology for breast cancer applications is in full force and effect and such licensee is not in material breach of any its obligations under that agreement. The License Agreement allows us, among other things, to develop and sell, without limitation, any gene, gene-product or protein-based LDTs using HDC’s technology in the Field and provides for sublicensing rights and the assignment of the License Agreement, in whole or in part, in our sole discretion. The License Agreement further provides us with access to certain HDC personnel and consulting resources in the fields of mathematics and in genetic and molecular test development. The Licensed Know-How also includes, among other things, certain tests, algorithms and computer software which have already been developed by HDC. We have agreed to use our best efforts to commercialize certain products within one year of the date of the License Agreement, subject to two one-year extensions per product if needed, including LDTs for prostate, colon and pancreatic cancer and software to automate the interpretation of cytogenetics and flow cytometry (collectively, the “Initial Licensed Products”). If we have not generated $5.0 million of net revenue from products, services and sublicensing arrangements pursuant to the License Agreement within five years of the effective date, HDC may, at its option, revoke the exclusivity with respect to any one or more of the Initial Licensed Products, subject to certain conditions.   We had no intangible assets on December 31, 2011 and at September 30, 2012 intangible assets consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="64%"> </td> <td valign="bottom" width="4%"> </td> <td width="9%"> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="center" style="border-bottom:1px solid #000000"> Weighted Average Amortization Period </td> <td valign="bottom"> </td> <td valign="bottom" colspan="10" align="center" style="border-bottom:1px solid #000000">September 30, 2012</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">COST</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Net</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Support Vector Machine (SVM) technology </td> <td valign="bottom"> </td> <td valign="bottom" align="center">108 months</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">500</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">42</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">458</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Laboratory developed test (LDT) technology </td> <td valign="bottom"> </td> <td valign="bottom" align="center">164 months</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,482</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">54</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,428</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Flow Cytometry and Cytogenetics technology </td> <td valign="bottom"> </td> <td valign="bottom" align="center">202 months</td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">30</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">970</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Total </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,982</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">126</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,856</td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table> We recorded approximately $56,000 and $126,000 in straight-line amortization expense of intangibles for the three and nine months ended September 30, 2012 as a research and development expense in the consolidated statement of operations. We will record all amortization of intangibles in that category until the time that we have products, services or cost savings directly attributable to these intangible assets that would require that it be recorded in cost of goods sold. We continually review the estimated pattern in which the economic benefits will be consumed and adjust the amortization period and our pattern to match our estimate. The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of September 30, 2012 is as follows (in thousands):   <table cellspacing="0" cellpadding="0" width="68%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="89%"> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom" colspan="4" nowrap="nowrap"> Year Ending December 31, </td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Remainder of 2012 </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">56</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> 2013 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">223</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> 2014 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">223</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> 2015 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">223</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> 2016 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">223</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> 2017 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">223</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Thereafter </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,685</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Total </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,856</td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table>

NOTE E — NET INCOME (LOSS) PER SHARE Basic net income (loss) per share is computed using the weighted average number of common shares outstanding during the applicable period. Diluted net income per share is computed using the weighted average number of common shares outstanding during the applicable period, plus the dilutive effect of potential common stock. Potential common stock consists of shares issuable pursuant to stock options and warrants. Diluted net (loss) per share is computed using the weighted average number of common shares outstanding during the applicable period. Potential common stock is excluded from diluted net (loss) per share as such amounts are anti-dilutive. Calculations of net income (loss) per share are done using the treasury stock method. The following table provides the computation of basic and diluted net income (loss) per share for the three and nine month periods ending September 30, 2012 and 2011: (in thousands, except per share amounts)   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="68%"> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Net income (loss) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(975</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(143</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">178</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,329</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Basic weighted average shares outstanding </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45,175</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43,104</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44,944</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">42,570</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Effect of potentially dilutive securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,282</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Diluted weighted average shares outstanding </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45,175</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43,104</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">48,226</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">42,570</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Basic net income (loss) per share </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.02</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.00</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.00</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.03</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Diluted net income (loss) per share </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.02</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.00</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.00</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.03</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>   For the nine months ended September 30, 2012 there were no outstanding options or warrants excluded from the calculation of diluted earnings per share due to anti-diluted affects, as all options and warrants were less than the average market price of the Company’s common stock for the nine months ended September 30, 2012.

NOTE F — STOCK OPTIONS On January 9, 2012, Dr. Maher Albitar, our Chief Medical Officer was granted stock options to purchase 250,000 shares of the Company’s common stock at an exercise price per share of $1.43, which was the closing price per share on the last trading day prior to his start date. The stock options have a five year term and become 25% vested on each of the first four anniversaries of his start date. The stock options also fully vest upon a change of control of the Company. Dr. Albitar works in our California laboratory location, and the State of California has certain regulations that prohibit the corporate practice of medicine. As a result of this regulation, Dr. Albitar is not an employee, but rather is a full-time consulting physician to NeoGenomics. Thus, these stock options are non-employee consultant options and as such are being revalued at the end of every reporting period using a trinomial lattice model. At September 30, 2012 these stock options were valued at $428,000 and we recorded $118,400 and $158,000 of stock compensation expense related to the stock options in the three and nine months ended September 30, 2012, respectively. On February 14, 2012, Mr. VanOort, our Chief Executive Officer was granted supplemental non-qualified stock options to purchase 800,000 shares of common stock at an exercise price of $1.71 per share which have a five year term so long as Mr. VanOort remains an employee of the Company (the “Supplemental Options”). The Supplemental Options are scheduled to vest according to the passage of time with 200,000 shares vesting each year on the anniversary of the grant date for the first four years after the grant. The Supplemental Options are valued at $505,000 based on a trinomial lattice model and we recorded $60,225 and $149,999 of stock compensation expense related to the Supplemental Options in the three and nine months ended September 30, 2012. In the event of a change of control of the Company in which the consideration payable to common stockholders of the Company has a deemed value of at least $4.00 per share, any unvested portion of the Supplemental Options will immediately vest in full. As of September 30, 2012, stock options to purchase 5,826,135 shares of our common stock were outstanding. The exercise prices of these options range from $0.25 to $1.71 per share and have a weighted average exercise price $1.02 per share.   NOTE G — COMMON STOCK WARRANTS Albitar Warrant On January 9, 2012 Dr. Maher Albitar was granted performance incentive warrants to purchase 200,000 shares of the Company’s common stock (the “Albitar Warrants”) at an exercise price per share of $1.43, which was the closing price per share on the last trading day prior to his start date. These warrants are being treated as non-employee consultant warrants and as such are being revalued, with assumptions for meeting performance, at the end of every reporting period using a trinomial lattice model. The Albitar Warrants have a five year term and vest in accordance with the performance criteria as follows:   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%"> </td> <td width="4%" valign="top" align="left">(i)</td> <td align="left" valign="top">80,000 will vest upon the commercial launch of the Company’s gene-based plasma prostate cancer test licensed from Health Discovery Corp (“HDC”) or similar test based on our mutual agreement. </td> </tr> </table>   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%"> </td> <td width="4%" valign="top" align="left">(ii)</td> <td align="left" valign="top">40,000 will vest upon the commercial launch of the Company’s gene-based colon cancer test licensed from HDC or similar test based on our mutual agreement. </td> </tr> </table>   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%"> </td> <td width="4%" valign="top" align="left">(iii)</td> <td align="left" valign="top">40,000 will vest upon the commercial launch of the Company’s gene-based pancreatic cancer test licensed from HDC or similar test based on our mutual agreement. </td> </tr> </table> <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%"> </td> <td width="4%" valign="top" align="left">(iv)</td> <td align="left" valign="top">20,000 will vest upon successful consummation of a sublicensing agreement with an instrument manufacturer to commercialize the cytogenetics automated image analysis technology licenses from HDC. </td> </tr> </table>   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%"> </td> <td width="4%" valign="top" align="left">(v)</td> <td align="left" valign="top">20,000 will vest upon successful consummation of a sublicensing agreement with an instrument manufacturer to commercialize the flow cytometry automated image analysis technology licenses from HDC. </td> </tr> </table> In the event of a change of control of the Company in which the consideration payable to common stockholders of the Company has a deemed value of at least $4.00 per share, any unvested portion of the Albitar Warrants will immediately vest in full. On September 30, 2012 the Albitar Warrants were valued at $342,500 and we recorded approximately $95,800 and $128,000 of stock compensation expense related to the Albitar Warrants for the three and nine months ended September 30, 2012. Warrant exercises For the nine months ended September 30, 2012, 650,000 warrants previously issued to members of our board of directors and 348,417 warrants issued in June 2007 as part of a common stock offering were exercised or expired as follows:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="55%"> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> Type of Exercise </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Warrant Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Exercise Price /Share</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Cash Received</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Common Stock Shares Issued</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> For cash </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">175,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.50</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">262,500</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">175,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Cashless net exercise </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">725,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.50</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75,066</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Expired unexercised </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">98,417</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.50</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right"> —  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table> Warrant activity for the nine months ended September 30, 2012 is summarized as follows:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="72%"> </td> <td valign="bottom" width="8%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="8%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Shares</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Weighted Average Exercise Price</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Warrants outstanding, December 31, 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,156,750</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.34</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Granted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">200,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.43</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Exercised </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(900,000</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.50</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Expired </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(98,417</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.50</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Cancelled </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Warrants outstanding, September 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,358,333</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.24</td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table>   NOTE H — CAPITAL LEASES On September 9, 2011, we entered into a master lease agreement for an equipment lease line of credit with Garic, Inc. The facility had a 12 month draw down period and each schedule has a thirty six month term. The lease had a fair market value option at the end of the term at a price not to exceed fifteen percent of the equipment cost or the right to return the equipment. The facility expired and we had borrowed $658,000 over the life of the line at an interest rate of 16.12%.   In June 2012, we entered into a five year, $1 buyout equipment lease of approximately $495,000 for the purchase of laboratory equipment with Wells Fargo Lease Equipment Financing. The lease has an interest rate of approximately 6%. During the nine months ended September 30, 2012, we entered into several vendor lease arrangements for approximately $1,555,000, primarily for the acquisition of lab equipment and to a lesser extent computer hardware. These capital leases are for 36 to 60 month terms, have either $1 purchase options or were fair market value at the end of the term, and had approximate interest rates between 8% and 16%.

NOTE I — OTHER RELATED PARTY TRANSACTIONS During the three months ended September 30, 2012 and 2011, Steven C. Jones, a director of the Company, earned approximately $52,500 and $50,000, respectively, for various consulting work performed in connection with his duties as Executive Vice President of Finance. During the nine months ended September 30, 2012 and 2011, he earned approximately $155,000 and $148,500, respectively, for various consulting work performed in connection with his duties as Executive Vice President of Finance. Mr. Jones also received $55,000 and $2,500 for the nine months ended September 30, 2012 and 2011 as payment of his annual bonus compensation for the previous fiscal year.

NOTE J — INCOME TAXES On July 17, 2012 the Internal Revenue Service completed its audit of our fiscal year 2009 and 2010 tax returns. The audit resulted in a small proposed adjustment to our Net Operating Loss carry forward which resulted from the Therapeutic Discovery Grant being considered as a reduction of expenses for tax purposes. As a result of the audit our net operating loss tax carry forward of federal and state income taxes changed to $16,249,164 at December 31, 2011 from $16,683,683 as previously disclosed in our Annual Report on Form 10K as filed with the Securities and Exchange Commission on March 12, 2012. Since we did not meet the standard established by ASC Topic 740 at December 31, 2011 we had a valuation allowance to fully reserve our deferred tax asset and that reserve will also change to $16,249,164 as well. END OF FINANCIAL STATEMENTS.

Use of Estimates The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America. These principles require management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the consolidated financial statements. Actual results and outcomes may differ from management’s estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these consolidated financial statements include, but are not limited to, those related to revenues, accounts receivable and related reserves, contingencies, useful lives and recovery of long-term and intangible assets, income taxes, and the fair value of stock-based compensation. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected in the consolidated financial statements prospectively from the date of the change in estimate.

Concentrations of Credit Risk Concentrations of credit risk with respect to revenue and accounts receivable are primarily limited to certain clients to whom the Company provides a significant volume of its services, and to specific payers of our services such as Medicare and individual insurance companies. The Company’s client base consists of a large number of geographically dispersed clients diversified across various customer types. Over the last year, we have expanded our relationship with a large oncology practice with multiple office locations. For the three months ended September 30, 2012, all of the affiliated locations from this oncology practice combined represented approximately 12.9% of our revenue compared to 13.5% of revenue for the quarter ended September 30, 2011 and for the nine months ended September 30, 2012 represented approximately 15.4% of our revenue compared to 8.8% of revenue for the nine months ended September 30, 2011. All other clients were less than 5% of total revenue individually.

Income Taxes We compute income taxes in accordance with applicable accounting standards. Deferred taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities. Also, the effect on deferred taxes of a change in tax rates is recognized in income in the period that included the enactment date. Temporary differences between financial and tax reporting arise primarily from the use of different depreciation methods for property and equipment, stock based compensation expense and the timing of recognition of bad debts. We evaluate tax positions that have been taken or are expected to be taken in our tax returns, and record a liability for uncertain tax positions. As of September 30, 2012 we had no provision for related income taxes because we have large Net Operating Loss positions to offset our current net income.

The following table provides the computation of basic and diluted net income (loss) per share for the three and nine month periods ending September 30, 2012 and 2011: (in thousands, except per share amounts)   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="68%"> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Net income (loss) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(975</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(143</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">178</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,329</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Basic weighted average shares outstanding </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45,175</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43,104</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44,944</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">42,570</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Effect of potentially dilutive securities </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,282</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Diluted weighted average shares outstanding </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45,175</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43,104</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">48,226</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">42,570</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Basic net income (loss) per share </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.02</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.00</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.00</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.03</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Diluted net income (loss) per share </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.02</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.00</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.00</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.03</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> </table>

false --12-31 Q3 2012 2012-09-30 10-Q 0001077183 45270280 Smaller Reporting Company NEOGENOMICS INC P5Y 0.1612 P12M 1 262500 175000 75066 4.00 1.50 1.50 1.50 9000000 8000000 less than 5% 1555000 495000 658000 P5Y P5Y 0.15 P5D 0.088 0.135 0.154 0.129 2500 55000 1.50 1.34 1.24 428000 505000 0.25 1.50 1.43 1.43 P60M P36M 342500 348417

2529000

3238000

7894000

12013000

773000

690000

6653000

9202000

2982000

1000000

1482000

500000

P202M

P164M

P108M

28490000

31635000

158000

149999

118400

60225

2150000

2551000

30000

29000

126000

56000

19949000

29302000

13178000

17121000

2107000

2513000

1255000

2845000

2608000

3410000

1097000

2649000

2628000

2038000

1552000

-590000

0.001

100000000

43416200

45268905

650000

43416200

45268905

43000

45000

16996000

6246000

24571000

8310000

0.020

0.010

The libor shall be not less than 2.0% and replacing it with the libor shall be not less than 1.0%

0.06

0.08

0.16

16249164

1484000

2549000

-0.03

0.00

-0.02

-0.03

0.00

-0.02

128000

95800

2137000

2194000

126000

30000

54000

42000

1685000

223000

56000

223000

2856000

970000

1428000

458000

8801000

3182000

11745000

3929000

13595000

5074000

20402000

5892000

-1329000

-143000

178000

-975000

356000

649000

3870000

6552000

208000

704000

37000

-38000

-286000

-61000

3282000

2856000

545000

185000

837000

291000

519000

809000

1202000

1906000

14052000

20080000

19949000

29302000

11444000

16670000

8000000

80000

0.005

0.015

0.025

8000000

5000000

2015-03-26

10000000

1000000

0.0525

300000

3898000

8035000

3060000

3203000

-338000

-3300000

-1170000

-493000

-1329000

-143000

178000

-975000

1945000

14379000

5032000

19387000

6576000

-784000

42000

1015000

-684000

129000

91000

148500

50000

155000

52500

1037000

338000

2263000

954000

864000

3176000

503000

1030000

4137000

200000

6642000

9234000

1740000

2434000

1146000

1637000

416000

125000

1833000

808000

500000

300000

121000

211000

-22636000

-22458000

5000000

30591000

11320000

44973000

14202000

5162000

1725000

5809000

1839000

P5Y

175000

725000

98417

900000

98417

200000

40000

20000

40000

80000

200000

2156750

1358333

250000

800000

5826135

1.02

1.71

0.25

200000

1.43

1.71

5897000

9222000

257000

488000

16249164

16683683

42570000

43104000

48226000

45175000

42570000

43104000

44944000

45175000

EX-101.SCH 7 ngnm-20120930.xsd XBRL TAXONOMY EXTENSION SCHEMA 06051 - Disclosure - Net Income (Loss) Per Share (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0505 - Disclosure - Net Income (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0610 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0210 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0606 - Disclosure - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 0605 - Disclosure - Net Income (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0608 - Disclosure - Capital Leases (Details Textual) link:presentationLink link:calculationLink link:definitionLink 06071 - Disclosure - Common Stock Warrant (Details 1) link:presentationLink link:calculationLink link:definitionLink 0208 - Disclosure - Capital Leases link:presentationLink link:calculationLink link:definitionLink 0206 - Disclosure - Stock Options link:presentationLink link:calculationLink link:definitionLink 0205 - Disclosure - Net Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 06072 - Disclosure - Common Stock Warrants (Details Textual) link:presentationLink link:calculationLink link:definitionLink 06041 - Disclosure - Intangible Assets (Details1) link:presentationLink link:calculationLink link:definitionLink 0507 - Disclosure - Common Stock Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 0130 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0609 - Disclosure - Other Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 0607 - Disclosure - Common Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 06042 - Disclosure - Intangible Assets (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0604 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0603 - Disclosure - Revolving Credit and Security Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 0602 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 0504 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 0402 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0209 - Disclosure - Other Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0207 - Disclosure - Common Stock Warrants link:presentationLink link:calculationLink link:definitionLink 0204 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0203 - Disclosure - Revolving Credit and Security Agreement link:presentationLink link:calculationLink link:definitionLink 0202 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0201 - Disclosure - Nature of Business and Basis of Financial Statement Presentation link:presentationLink link:calculationLink link:definitionLink 0120 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0111 - Statement - Consolidated Balance Sheets (Parenthetical) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0110 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 ngnm-20120930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 ngnm-20120930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 ngnm-20120930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and entity information. Document Type Amendment Flag Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Consolidated Balance Sheets [Abstract] Cash and Cash Equivalents, at Carrying Value CASH AND CASH EQUIVALENTS, END OF PERIOD CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD Cash and cash equivalents Restricted cash Restricted cash Accounts Receivable, Net, Current Accounts receivable (net of allowance for doubtful accounts of $2,551 and $2,150, respectively) Prepaid Expense and Other Assets, Current Other current assets Assets, Current Total current assets Property, Plant and Equipment, Net PROPERTY AND EQUIPMENT (net of accumulated depreciation of $9,202 and $6,653 respectively) INTANGIBLE ASSETS (net of accumulated amortization of $126 and $0 , respectively) Intangible Assets, Net (Excluding Goodwill) Intangible assets held TOTAL ASSETS TOTAL ASSETS Capital Lease Obligations, Current Short-term portion of equipment capital leases Line of Credit, Current Revolving credit line Liabilities, Current Total current liabilities Capital Lease Obligations, Noncurrent Long-term portion of equipment capital leases Liabilities TOTAL LIABILITIES Commitments and Contingencies Commitments and contingencies Common stock, $.001 par value, (100,000,000 shares authorized; 45,268,905 and 43,416,200 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively) Common Stock, Value, Issued Liabilities and Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Property and equipment accumulated depreciation Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Amortization Intangible assets, accumulated amortization Common Stock, Par or Stated Value Per Share Common stock, par value Common stock, shares authorized Common stock, shares authorized Common Stock, Shares, Outstanding Common stock, shares outstanding Consolidated Statements of Operations [Abstract] Sales Revenue, Services, Net NET REVENUE Gross Profit GROSS PROFIT Operating Expense Total operating expenses Operating Income (Loss) INCOME (LOSS) FROM OPERATIONS Interest Expense INTEREST AND OTHER INCOME (EXPENSE) - NET Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest NET INCOME (LOSS) BEFORE TAXES Income Tax Expense (Benefit) INCOME TAXES Net Income (Loss) Per Share [Abstract] NET INCOME (LOSS) PER SHARE Earnings Per Share, Basic Basic net income (loss) per share Basic Earnings Per Share, Diluted Diluted net income (loss) per share Diluted Weighted Average Number of Shares Outstanding, Diluted [Abstract] WEIGHTED AVG NUMBER OF SHARES OUTSTANDING Weighted Average Number of Shares Outstanding, Basic Basic weighted average shares outstanding Basic Weighted Average Number of Shares Outstanding, Diluted Diluted weighted average shares outstanding Diluted Consolidated Statements of Cash Flows [Abstract] Provision for Doubtful Accounts Provision for bad debts Amortization of Intangible Assets Amortization expense of intangibles Amortization of intangibles Amortization of Financing Costs Amortization of debt issue costs Stock or Unit Option Plan Expense Stock-based compensation - options Restricted Stock or Unit Expense Stock-based compensation - warrants and restricted stock Increase (Decrease) in Accounts Receivable (Increase) decrease in accounts receivable, net of write-offs Increase (Decrease) in Inventories (Increase) decrease in inventories Increase (Decrease) in Prepaid Expense (Increase) decrease in other current assets Net Cash Provided by (Used in) Operating Activities NET CASH (USED) IN OPERATING ACTIVITIES Payments to Acquire Intangible Assets Purchase of intangible assets Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Net Cash Provided by (Used in) Investing Activities NET CASH (USED) IN INVESTING ACTIVITIES Net Cash Provided by Used in Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from (Repayments of) Lines of Credit Advances (payments) on credit facility, net Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities Repayment of capital leases Cash and Cash Equivalents, Period Increase (Decrease) NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Income Taxes Paid Income taxes paid Other Noncash Investing and Financing Items [Abstract] NON-CASH INVESTING AND FINANCING ACTIVITIES Capital Lease Obligations Incurred Equipment leased under capital leases Common stock issued for intangible asset purchase Non Cash Intangible Asset Purchase Nature of Business and Basis of Financial Statement Presentation [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] NATURE OF BUSINESS AND BASIS OF FINANCIAL STATEMENT PRESENTATION Summary of Significant Accounting Policies [Abstract] Revolving Credit and Security Agreement [Abstract] Schedule of Line of Credit Facilities [Table Text Block] REVOLVING CREDIT AND SECURITY AGREEMENT Intangible Assets [Abstract] Intangible Assets Disclosure [Text Block] INTANGIBLE ASSETS Earnings Per Share [Text Block] NET INCOME (LOSS) PER SHARE Common Stock Warrants [Abstract] Common stock warrants. Common Stock Warrants [Text Block] Common stock warrants. COMMON STOCK WARRANTS Other Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] OTHER RELATED PARTY TRANSACTIONS Use of Estimates, Policy [Policy Text Block] Use of Estimates Intangible Assets, Finite-Lived, Policy [Policy Text Block] Intangible Assets Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations of Credit Risk Regulatory Income Taxes, Policy [Policy Text Block] Income Taxes Schedule of Intangible Assets and Goodwill [Table Text Block] Classes of intangible assets Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Computation of basic and diluted earnings (loss) per share Summary of Significant Accounting Policies (Textual) [Abstract] Summary of significant accounting policies. Summary of significant accounting policies (Textual) [Abstract] Oncology Practice Combined Represented Revenue Oncology practice combined represented revenue. Oncology practice combined represented revenue Individual Clients Revenue Revenue of all other clients individually Individual clients revenue. Revolving Credit and Security Agreement (Textual) [Abstract] Revolving credit and security agreement (Textual) [Abstract] Revolving credit and security agreement. Line of Credit Facility, Interest Rate During Period Effective rate of interest Line of Credit Facility, Current Borrowing Capacity Current maximum principal amount of credit facility Line of Credit Facility, Amount Outstanding Outstanding borrowing Laboratory Developed Test Technology [Member] Laboratory developed test technology. Laboratory developed test (LDT) technology [Member] Flow Cytometry and Cytogenetics Technology [Member] Flow Cytometry and Cytogenetics technology [Member] Flow Cytometry and Cytogenetics technology. Classes of Intangible Assets [Abstract] Classes of intangible assets. Classes of intangible assets Incremental Common Shares Attributable to Share-based Payment Arrangements Effect of potentially dilutive securities Intangible Assets (Textual) [Abstract] Intangible assets. Intangible Assets (Textual) [Abstract] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Finite Lived Intangible Assets Net Net Common Stock Warrants (Textual) [Abstract] Common stock warrants (Textual) [Abstract] Common stock warrants. Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table] Warrant [Member] Warrant [Member] Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items] Other Related Party Transactions (Textual) [Abstract] Other Related Party Transactions (Textual) [Abstract] Other related party transactions. Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Domain] Executive Vice President [Member] Executive Vice President [Member] Related Party Transaction [Line Items] Commitments (Textual) [Abstract] Commitments (Textual) [Abstract] Commitments. Lease Agreement Amount Lease agreement amount Lease agreement amount. Lease Term Period Lease term period. Lease term period Annual Interest Rate Interest Rate Annual interest rate. Increase (Decrease) in Accounts Payable and Other Operating Liabilities Increase (decrease) in accounts payable and other liabilities Net Cash Provided by (Used in) Financing Activities NET CASH PROVIDED BY FINANCING ACTIVITIES Earnings Per Share, Basic and Diluted [Abstract] Computation of Basic and diluted earnings (loss) per share Inventory, Net Inventories Other Assets, Noncurrent OTHER ASSETS Accounts Payable, Current Accounts payable Employee-related Liabilities, Current Accrued compensation Accrued Liabilities, Current Accrued expenses and other liabilities Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total stockholders' equity Allowance for Doubtful Accounts Receivable, Current Accounts receivable, allowance for doubtful accounts Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Common Stock, Shares, Issued Common stock, shares issued Cost of Services COST OF REVENUE General and Administrative Expense General and administrative Selling and Marketing Expense Sales and marketing Net Income (Loss) Attributable to Parent NET INCOME (LOSS) Net income (loss) Depreciation Depreciation of property and equipment Proceeds from (Repayments of) Restricted Cash, Financing Activities Restricted cash Proceeds from Issuance or Sale of Equity Issuance of common stock and warrants for cash , net of transaction expenses Interest Paid Interest paid Significant Accounting Policies [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Assets [Abstract] ASSETS Liabilities and Stockholders' Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities Noncurrent [Abstract] LONG TERM LIABILITIES Stockholders' Equity [Abstract] STOCKHOLDERS' EQUITY Operating Expenses [Abstract] OPERATING EXPENSES Net Cash Provided by Used in Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Increase Decrease in Operating Capital [Abstract] Changes in assets and liabilities, net: Net Cash Provided by Used in Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES Supplemental Cash Flow Elements [Abstract] SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Research and Development Expense Research and development Research and Development Expense, Policy [Policy Text Block] Research and Development Assets, Current [Abstract] CURRENT ASSETS Liabilities, Current [Abstract] CURRENT LIABILITIES Term of Capital Leases Period Term of capital leases period Term of capital leases period. Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum Lease fair market value purchase option maximum Debt Instrument, Interest Rate, Effective Percentage Rate Range, Minimum Lease fair market value purchase option minimum Schedule of Expected Amortization Expense [Table Text Block] Estimated amortization expense Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Weighted Average Amortization Period Warrants Issued [Table Text Block] Warrants issued to members of board of directors Warrants issued to the members of the board of directors. Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Remainder of 2012 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2013 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2014 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2015 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2016 Finite-Lived Intangible Assets, Amortization Expense, Year Five 2017 Finite-Lived Intangible Assets, Amortization Expense, after Year Five Thereafter Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Estimated amortization expense Cash Exercise [Member] Cash Exercise [Member] Cash exercise. Cashless Net Exercise [Member] Cashless Net Exercise [Member] Cashless net exercise. Cash Received on Common Stock Warrants Cash Received Cash received on common stock warrants. Common Stock Shares Issued on Common Stock Warrants Common Stock Shares Issued Common stock shares issued on common stock warrants. Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Warrants issued to members of board of directors Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) Warrant Shares Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Schedule of Investment Income, Reported Amounts, by Category [Axis] Investment Income, Categories [Domain] Equipment Facility One [Member] Garic, Inc. [Member] Equipment facility one. Lease Outstanding Amount Amount borrowed Lease outstanding amount. Capital Leases [Abstract] Capital Leases Agreement Price Capital leases agreement price Capital leases agreement price. Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Line of Credit Facility, Remaining Borrowing Capacity Available credit under credit facility Developed Technology Rights [Member] Support Vector Machine (SVM) technology [Member] Other Cost and Expense, Operating Fees for consulting work performed Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Exercise Price Per Share on Common Stock Warrants Exercise Price / Share Exercise price per share on common stock warrants. Acquired Finite-lived Intangible Asset, Amount COST Adjustments to Reconcile Net Income Loss to Cash Provided by Used in Operating Activities [Abstract] Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Commitments [Table] Commitments. Commitments [Line Items] Commitments. Commitments (Additional Textual) [Abstract] Commitments (Additional Textual) [Abstract] Commitments. Range [Axis] Range [Domain] EX-101.PRE 11 ngnm-20120930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R33.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) (USD $)	Dec. 31, 2011	Mar. 12, 2012 Scenario Previously Reported [Member]
Income Taxes (Textual) [Abstract]
Federal and state income tax	$ 16,249,164	$ 16,683,683
Valuation allowance for deferred tax asset	$ 16,249,164

- Definition

Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.

+ References+ Details

- Definition

The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.

+ References+ Details

XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT

Net Income (Loss) Per Share (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Computation of Basic and diluted earnings (loss) per share
Net income (loss)	$ (975)	$ (143)	$ 178	$ (1,329)
Basic weighted average shares outstanding	45,175	43,104	44,944	42,570
Effect of potentially dilutive securities			3,282
Diluted weighted average shares outstanding	45,175	43,104	48,226	42,570
Basic net income (loss) per share	$ (0.02)	$ 0.00	$ 0.00	$ (0.03)
Diluted net income (loss) per share	$ (0.02)	$ 0.00	$ 0.00	$ (0.03)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 36, 37, 38

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References+ Details

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

XML 15 R9.htm IDEA: XBRL DOCUMENT

Intangible Assets

9 Months Ended

Sep. 30, 2012

Intangible Assets [Abstract]

INTANGIBLE ASSETS

NOTE D — INTANGIBLE ASSETS

We had no intangible assets on December 31, 2011 and at September 30, 2012 intangible assets consisted of the following (in thousands):


	Weighted Average Amortization Period	September 30, 2012
		COST		Accumulated Amortization		Net
Support Vector Machine (SVM) technology	108 months	$	500	$	42	$	458
Laboratory developed test (LDT) technology	164 months	$	1,482	$	54	$	1,428
Flow Cytometry and Cytogenetics technology	202 months	$	1,000	$	30	$	970

Total		$	2,982	$	126	$	2,856

The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of September 30, 2012 is as follows (in thousands):


Year Ending December 31,
Remainder of 2012	$	56
2013		223
2014		223
2015		223
2016		223
2017		223
Thereafter		1,685

Total	$	2,856

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References+ Details

EXCEL 16 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]C-64V-69B85\P-68S7S1D,C9?.#1A,%\R-V,R M9#`Y,#(W86$B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O M=6YT/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I% M>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;6UO;E]3=&]C:U]787)R86YT#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D-A<&ET86Q?3&5A#I%>&-E;%=O5]4#I%>&-E;%=O&5S/"]X.DYA;64^#0H@("`@/'@Z M5V]R:W-H965T4V]U#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]! M8V-O=6YT,3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DEN=&%N9VEB;&5?07-S971S7U1A8FQE#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/DYE=%]);F-O;65?3&]S#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O M;6UO;E]3=&]C:U]787)R86YT#I7 M;W)K#I%>&-E;%=O M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DEN=&%N9VEB;&5?07-S971S7T1E M=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/DEN=&%N9VEB;&5?07-S971S7T1E=&%I;'-? M5&5X=#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYE M=%]);F-O;65?3&]S#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/DYE=%]);F-O;65?3&]S#I7;W)K#I7;W)K M#I%>&-E;%=O#I.86UE/D-O;6UO M;E]3=&]C:U]787)R86YT7T1E=&%I;'-?,3PO>#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/D-O;6UO;E]3=&]C:U]787)R86YT#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-A M<&ET86Q?3&5A#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D]T:&5R7U)E;&%T961?4&%R='E?5')A M;G-A8W1I;S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I!8W1I=F53:&5E=#X- M"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM M/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@ M8F4@;W!E;F5D('=I=&@@36EC'1087)T7V,U M938U9F)A7S`U9C-?-&0R-E\X-&$P7S(W8S)D,#DP,C=A80T*0V]N=&5N="U, M;V-A=&EO;CH@9FEL93HO+R]#.B]C-64V-69B85\P-68S7S1D,C9?.#1A,%\R M-V,R9#`Y,#(W86$O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^3D5/1T5.3TU)0U,@24Y#/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^4V5P(#,P+`T*"0DR M,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^9F%L'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^+2TQ,BTS,3QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1087)T7V,U938U9F)A7S`U9C-?-&0R-E\X-&$P7S(W8S)D,#DP,C=A80T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C-64V-69B85\P-68S7S1D M,C9?.#1A,%\R-V,R9#`Y,#(W86$O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2D\+W1D/@T*("`@("`@("`\=&0@8VQA6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]C-64V-69B85\P-68S7S1D,C9?.#1A,%\R M-V,R9#`Y,#(W86$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S5E M-C5F8F%?,#5F,U\T9#(V7S@T83!?,C=C,F0P.3`R-V%A+U=O'0O:'1M;#L@8VAA2!A;F0@97%U:7!M96YT(&%C8W5M=6QA=&5D(&1E M<')E8VEA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]C-64V-69B85\P-68S7S1D,C9?.#1A,%\R-V,R9#`Y,#(W86$- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S5E-C5F8F%?,#5F,U\T M9#(V7S@T83!?,C=C,F0P.3`R-V%A+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$F%T:6]N(&]F M(&EN=&%N9VEB;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ M,C8\2!A;F0@97%U:7!M96YT/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#4T.3QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6%B;&4@86YD(&]T:&5R(&QI86)I M;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-#D\2!A;F0@97%U M:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#(V,RD\ M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M6UE;G1S*2!O;B!C&5S('!A:60\+W1D M/@T*("`@("`@("`\=&0@8VQA'1087)T7V,U M938U9F)A7S`U9C-?-&0R-E\X-&$P7S(W8S)D,#DP,C=A80T*0V]N=&5N="U, M;V-A=&EO;CH@9FEL93HO+R]#.B]C-64V-69B85\P-68S7S1D,C9?.#1A,%\R M-V,R9#`Y,#(W86$O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N0V]N M&)R;"QN&)R;"QN>"`M+3X-"B`@(#QF;VYT('-T>6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/CQB/DY/5$4@02`F M(S@R,3([($Y!5%5212!/1B!"55-)3D534R!!3D0@0D%325,@3T8@1DE.04Y# M24%,(%-4051%345.5"!04D5314Y4051)3TX@/"]B/CPO9F]N=#X\+W`^#0H@ M("`\<"!S='EL93TS1&UA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M#MM87)G:6XM8F]T=&]M M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/DYE;T=E;F]M:6-S+"!);F,N+"!A($YE=F%D82!C;W)P M;W)A=&EO;B`H=&AE("8C.#(R,#M087)E;G0F(S@R,C$[(&]R('1H92`F(S@R M,C`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`@ M=&AE(')E#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A M;6EL>3IT:6UEF4],T0R/D-E65A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]C-64V-69B85\P-68S7S1D,C9?.#1A,%\R-V,R9#`Y,#(W86$- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S5E-C5F8F%?,#5F,U\T M9#(V7S@T83!?,C=C,F0P.3`R-V%A+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/"$M+41/0U194$4@:'1M;"!0 M54),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A M;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E M9"!.;W1E(#(@+2!U#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3IT:6UEF4],T0R/CQB/DY/5$4@0B`F(S@R,3([ M(%-534U!4ED@3T8@4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4R`\ M+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HV<'@[ M;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3IT:6UEF4],T0R/@T*("`@5&AE($-O;7!A;GD@ M<')E<&%R97,@:71S(&-O;G-O;&ED871E9"!F:6YA;F-I86P@2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E2!O9B!L;VYG+71E2!A;F0@=&AE(&5F9F5C=',@;V8-"B`@(&UA=&5R M:6%L(')E=FES:6]N#MM M87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT M:6UEF4],T0R/CQU/E)E6QE/3-$;6%R9VEN M+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@6UE;G0@9F]R('-A;7!L97,@=&\@8V]M M<&QE=&4@=F%L:61A=&EO;B!S='5D:65S+B!4:&5S92!E>'!E;G-E#MM87)G:6XM M8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CQU/DEN=&%N9VEB;&4@07-S971S(#PO=3X\ M+V9O;G0^/"]P/@T*("`@/'`@#MM87)G M:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE MF4],T0R/@T*("`@26YT86YG:6)L92!AF%T:6]N(&ES(')E8V]G;FEZ960@;W9E6QE/3-$;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O M;3HP<'@^/&9O;G0@65A'!A;F1E9`T*("`@;W5R(')E;&%T:6]N2`Q,BXY)2!O9B!O=7(@ M2`Q-2XT)2!O9B!O=7(@ M6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2!D:69F97)E;F-E2!A<'!L>6EN9R!E;F%C=&5D M('-T871U=&]R>2!R871E65A M"!R97!O'!E;G-E(&%N9"!T:&4@=&EM M:6YG(&]F(')E8V]G;FET:6]N(&]F(&)A9"!D96)T3IT:6UEF4],T0R/E=E(&5V86QU871E('1A>"!P;W-I=&EO;G,@=&AA M="!H879E(&)E96X@=&%K96X@;W(@87)E(&5X<&5C=&5D('1O(&)E('1A:V5N M(&EN(&]U2!F M;W(@=6YC97)T86EN('1A>`T*("`@<&]S:71I;VYS+B!!7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA2!!9W)E96UE;G0\ M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L M2!!9W)E96UE;G0@6T%B M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'1";&]C:RTM/@T*("`@/'`@6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O3IT:6UEF4],T0R/DDN M*3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$ M=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@2!#87`@ M='=I8V4@9'5R:6YG('1H92!T97)M(&]F('1H92!!;65N9&5D(&%N9"!297-T M871E9"!#6QE/3-$9F]N M="US:7IE.C9P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF M(S$V,#L\+W`^#0H@("`\=&%B;&4@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$9F]N="US:7IE.C9P M>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^ M#0H@("`\=&%B;&4@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/E)E=FES960@=&AE(&1E9FEN:71I;VX@ M;V8@)B,X,C(P.TUI;FEM=6T@5&5R;6EN871I;VX@1F5E)B,X,C(Q.R!T;R!B M93H@/"]F;VYT/CPO=&0^#0H@("`\+W1R/@T*("`@/"]T86)L93X-"B`@(#QP M('-T>6QE/3-$9F]N="US:7IE.C9P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM M8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4] M,T0R/C(N-24@;V8@=&AE($9A8VEL:71Y($-A<"!I9B!T:&4@)B,X,C(P.U)E M=F]L=F5R(%1E6QE/3-$9F]N="US:7IE.C9P>#MM87)G:6XM=&]P.C!P>#MM M87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C$N-24@;V8@=&AE($9A8VEL:71Y($-A<"!I9B!T:&4@4F5V M;VQV97(@5&5R;6EN871I;VX@:7,@869T97(@36%R8V@F(S$V,#LR-BP@,C`Q M,R!B=70@8F5F;W)E($UA6QE/3-$)V)O3IT:6UE MF4],T0R/F,N/"]F;VYT/CPO=&0^(`T*("`@/'1D M(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`^/&9O;G0@'0M86QI9VXZ(&QE M9G0G(&)OF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!W M:61T:#TS1#0E('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@7,@;V8@=&AE(&5N9"!O9B!T M:&4@=&5R;2X@/"]F;VYT/CPO=&0^#0H@("`\+W1R/@T*("`@/"]T86)L93X- M"B`@(#QP('-T>6QE/3-$9F]N="US:7IE.C9P>#MM87)G:6XM=&]P.C!P>#MM M87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O3IT:6UEF4],T0R/E8N*3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!A;&EG;CTS1&QE9G0@ M=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@2!A2!O9B!E86-H(&-A;&5N9&%R M(&UO;G1H(&%N9"!H87,@86X@969F96-T:79E#0H@("!R871E(&]F(&EN=&5R M97-T(&]F(#4N,C4E+B`\+V9O;G0^/"]P/@T*("`@/'`@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@28C,38P.S8L(#(P M,3(L('=E(&5N=&5R960@:6YT;R!A($UA2`F(S@R,C`[3&%B;W)A=&]R>2!$979E;&]P M960@5&5S=',F(S@R,C$[(&]R($Q$5',@*&%S(&1E9FEN960@:6X@=&AE($QI M8V5N&-L=61I;F<@8V%N8V5R2!S;R!L;VYG(&%S('1H870@8V5R=&%I;B!L:6-E;G-E(&%G M6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2!G96YE+"!G96YE+7!R;V1U8W0@;W(-"B`@('!R;W1E M:6XM8F%S960@3$140T*("`@ M8F5E;B!D979E;&]P960@8GD@2$1#+B`\+V9O;G0^/"]P/@T*("`@/'`@71O;65T2P@=&AE("8C.#(R,#M);FET:6%L M($QI8V5N65AF4Z,7!X.VUA#MM87)G:6XM M8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\<"!S='EL93TS1&UA6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$9F]N="US:7IE.C$R<'@[ M;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T* M("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED M=&@],T0Y,B4@8F]R9&5R/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T* M("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@/'1R/B`-"B`@(#QT M9"!W:61T:#TS1#8T)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0T)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!W:61T:#TS M1#DE/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@ M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/B8C,38P.SPO=&0^(`T*("`@ M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#0E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D M/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`- M"B`@(#QTF4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX-"B`@(#QP('-T>6QE/3-$ M;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@@86QI9VX],T1C96YT M97(^/&9O;G0@#MM87)G:6XM8F]T=&]M.C!P>"!A;&EG M;CTS1&-E;G1E3IT:6UEF4],T0Q/CQB/D%V97)A9V4\8G(@+SY!;6]R=&EZ871I M;VX\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HP M<'@[;6%R9VEN+6)O='1O;3HQ<'@@86QI9VX],T1C96YT97(^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/D-/4U0\+V(^/"]F M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT M:6UEF4],T0Q/CQB/DYE=#PO8CX\+V9O;G0^/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUAF4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^ M/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ MF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUAF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/C$L-#@R/"]F;VYT/CPO M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D9L M;W<@0WET;VUE=')Y(&%N9"!#>71O9V5N971I8W,@=&5C:&YO;&]G>3PO9F]N M=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@3IT:6UEF4],T0R/C(P,B!M;VYT:',\ M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/CDW,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@"!S;VQI9"`C,#`P,#`P)SXF(S$V M,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*("`@/'`@6QE M/3-$)V)O6QE/3-$)V)O3IT:6UEF4],T0R/E1O=&%L/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C(L.3@R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M2`D-38L,#`P(&%N M9"`D,3(V+#`P,"!I;B!S=')A:6=H="UL:6YE(&%M;W)T:7IA=&EO;B!E>'!E M;G-E(&]F(&EN=&%N9VEB;&5S(&9O2!U;G1I;"!T:&4@=&EM92!T:&%T('=E(&AA=F4@<')O9'5C=',L('-E M0T*("`@871T3IT:6UEF4],T0Q/CQB M/EEE87(@16YD:6YG($1E8V5M8F5R)B,Q-C`[,S$L/"]B/CPO9F]N=#X\+W`^ M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@2`M M+3X-"B`@(#QT3IT:6UEF4],T0R/E)E;6%I;F1E6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C4V/"]F M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@'0M:6YD96YT.BTQ+C`P96TG/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C(R,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C(P,30\ M+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T M6QE/3-$)VUA6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/C(R,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C(P,3<\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$ M)VUA6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/@T*("`@/"]TF4Z,7!X/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O3IT:6UEF4],T0R/E1O=&%L/"]F M;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C(L.#4V/"]F M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@'1087)T7V,U938U9F)A M7S`U9C-?-&0R-E\X-&$P7S(W8S)D,#DP,C=A80T*0V]N=&5N="U,;V-A=&EO M;CH@9FEL93HO+R]#.B]C-64V-69B85\P-68S7S1D,C9?.#1A,%\R-V,R9#`Y M,#(W86$O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'1";&]C:RTM/@T*("`@/'`@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@&-L=61E9"!F6QE/3-$9F]N="US:7IE.C$R<'@[;6%R9VEN+71O<#HP<'@[;6%R M9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E;&QS<&%C M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@8F]R9&5R/3-$ M,"!S='EL93TS1"=B;W)D97(M8V]L;&%P'0M86QI M9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I;B!486)L M92!(96%D("TM/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#8X)3XF(S$V M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3XF M(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V M,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0T)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V M,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3XF(S$V M,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\ M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0T)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\ M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D M/@T*("`@/"]TF4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L MF4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/@T*("`@/"]TF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L M6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UE MF4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^ M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@8V]L2`M+3X-"B`@(#QT3IT:6UEF4],T0R/DYE="!I;F-O M;64@*&QO6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4] M,T0R/B@Y-S4\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W3IT M:6UEF4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$3IT:6UE MF4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X-"B`@ M(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG M;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*("`@/'`@"!D;W5B;&4@(S`P,#`P M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*("`@/'`@3IT:6UEF4],T0R/D)A M6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3IT:6UEF4],T0R/C0T+#DT-#PO9F]N M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ XML 17 R29.htm IDEA: XBRL DOCUMENT

Common Stock Warrant (Details 1)	9 Months Ended
Common Stock Warrant (Details 1)	Sep. 30, 2012
Warrant Activity
Warrants Granted	200,000
Weighted Average Exercise Price Granted	1.43
Warrant [Member]
Warrant Activity
Warrants outstanding, December 31, 2011	2,156,750
Warrants Granted	200,000
Warrants Exercised	(900,000)
Warrants Expired	(98,417)
Warrants Cancelled
Warrants outstanding, September 30, 2012	1,358,333
Weighted Average Exercise Price Warrants, Warrants outstanding, December 31, 2011	1.34
Weighted Average Exercise Price Granted	1.43
Weighted Average Exercise Price Exercised	1.50
Weighted Average Exercise Price Expired	1.50
Weighted Average Exercise Price Cancelled
Weighted Average Exercise Price Warrants, Warrants outstanding, September 30, 2012	1.24

XML 18 R28.htm IDEA: XBRL DOCUMENT

Common Stock Warrants (Details) (Warrant [Member], USD $)	9 Months Ended
	Sep. 30, 2012
Cash Exercise [Member]
Warrants issued to members of board of directors
Warrant Shares	175,000
Exercise Price / Share	$ 1.50
Cash Received	$ 262,500
Common Stock Shares Issued	175,000
Cashless Net Exercise [Member]
Warrants issued to members of board of directors
Warrant Shares	725,000
Exercise Price / Share	$ 1.50
Common Stock Shares Issued	75,066
Expired Unexercised [Member]
Warrants issued to members of board of directors
Warrant Shares	98,417
Exercise Price / Share	$ 1.50

XML 19 R30.htm IDEA: XBRL DOCUMENT

Common Stock Warrants (Details Textual) (USD $)	1 Months Ended	3 Months Ended	9 Months Ended
Common Stock Warrants (Details Textual) (USD $)	Jun. 30, 2007	Sep. 30, 2012	Sep. 30, 2012	Dec. 31, 2011
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Common stock, shares issued		45,268,905	45,268,905	43,416,200
Common stock, shares outstanding		45,268,905	45,268,905	43,416,200
Warrants Granted			200,000
Common stock warrants (Textual) [Abstract]
Exercise price per share			1.43
Albitar Warrant period			5 years
Value of warrant		$ 342,500	$ 342,500
Stock compensation expense		$ 95,800	$ 128,000
Warrants Issued	348,417
Deemed value per share			$ 4.00
Warrant [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Common stock, shares issued		650,000	650,000
Plasma Prostate Cancer Test Licensed From Health Discovery Corp HDC [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Warrants Granted			80,000
Colon Cancer Test Licensed From HDC [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Warrants Granted			40,000
Pancreatic Cancer Test Licensed From HDC [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Warrants Granted			40,000
Cytogenetics Automated Image Analysis Technology Licenses From HDC [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Warrants Granted			20,000
Cytometry Automated Image Analysis Technology Licenses From HDC [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Warrants Granted			20,000

XML 20 R31.htm IDEA: XBRL DOCUMENT

Capital Leases (Details Textual) (USD $)	9 Months Ended
Capital Leases (Details Textual) (USD $)	Sep. 30, 2012
Commitments (Textual) [Abstract]
Lease fair market value purchase option minimum	6.00%
Amount borrowed	$ 495,000
Commitments (Additional Textual) [Abstract]
Lease agreement amount	1,555,000
Lease term period	5 years
Capital leases agreement price	1
Maximum Fair value at the end of the term of the equipment cost	15.00%
Facility draw down period	12 months
Garic, Inc. [Member]
Commitments (Textual) [Abstract]
Interest Rate	16.12%
Amount borrowed	$ 658,000
Maximum [Member]
Commitments (Textual) [Abstract]
Term of capital leases period	60 months
Lease fair market value purchase option maximum	16.00%
Minimum [Member]
Commitments (Textual) [Abstract]
Term of capital leases period	36 months
Lease fair market value purchase option minimum	8.00%

XML 21 R8.htm IDEA: XBRL DOCUMENT

Revolving Credit and Security Agreement

9 Months Ended

Sep. 30, 2012

Revolving Credit and Security Agreement [Abstract]

REVOLVING CREDIT AND SECURITY AGREEMENT

NOTE C — REVOLVING CREDIT AND SECURITY AGREEMENT

I.)

II.)	Extended the term of the Amended and Restated Credit Agreement to March 26, 2015;

III.)

Revised the definition of “Minimum Termination Fee” to be:

2.5% of the Facility Cap if the “Revolver Termination” (as defined in the Agreement) is at any time before March 26, 2013;

1.5% of the Facility Cap if the Revolver Termination is after March 26, 2013 but before March 26, 2014;

0.5% of the Facility Cap if the Revolver Termination is on or after March 26, 2014; and

That there shall be no Minimum Termination Fee if the Revolver Termination occurs within five (5) days of the end of the term.

IV.)	Modified the definition of “Permitted Indebtedness” and “Fixed Charge Coverage Ratio”; and

V.)	Amended Section 3.1 of the Amended and Restated Credit Agreement by deleting “the LIBOR shall be not less than 2.0%” and replacing it with “the LIBOR shall be not less than 1.0%”.

We paid Capital Source a commitment fee of $80,000 in connection with the Amendment.

On July 27, 2012 the Facility Cap was increased from $8.0 million to $9.0 million.

Interest on outstanding advances under the Credit Facility are payable monthly in arrears on the first day of each calendar month and has an effective rate of interest of 5.25%.

On September 30, 2012 the available credit under the Credit Facility was approximately $0.3 million and the outstanding borrowing was $8.0 million after netting compensating cash on hand.

XML 22 R32.htm IDEA: XBRL DOCUMENT

Other Related Party Transactions (Details) (USD $)	3 Months Ended		9 Months Ended
Other Related Party Transactions (Details) (USD $)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Other Related Party Transactions (Textual) [Abstract]
Payment of Annual Bonus Compensation			$ 55,000	$ 2,500
Executive Vice President [Member]
Other Related Party Transactions (Textual) [Abstract]
Fees for consulting work performed	$ 52,500	$ 50,000	$ 155,000	$ 148,500

XML 23 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
CURRENT ASSETS
Cash and cash equivalents	$ 2,038	$ 2,628
Restricted cash	300	500
Accounts receivable (net of allowance for doubtful accounts of $2,551 and $2,150, respectively)	12,013	7,894
Inventories	1,906	1,202
Other current assets	864	954
Total current assets	17,121	13,178
PROPERTY AND EQUIPMENT (net of accumulated depreciation of $9,202 and $6,653 respectively)	9,234	6,642
INTANGIBLE ASSETS (net of accumulated amortization of $126 and $0 , respectively)	2,856	0
OTHER ASSETS	91	129
TOTAL ASSETS	29,302	19,949
CURRENT LIABILITIES
Accounts payable	3,238	2,529
Accrued compensation	2,194	2,137
Accrued expenses and other liabilities	690	773
Short-term portion of equipment capital leases	2,513	2,107
Revolving credit line	8,035	3,898
Total current liabilities	16,670	11,444
LONG TERM LIABILITIES
Long-term portion of equipment capital leases	3,410	2,608
TOTAL LIABILITIES	20,080	14,052
Commitments and contingencies
STOCKHOLDERS' EQUITY
Common stock, $.001 par value, (100,000,000 shares authorized; 45,268,905 and 43,416,200 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively)	45	43
Additional paid-in capital	31,635	28,490
Accumulated deficit	(22,458)	(22,636)
Total stockholders' equity	9,222	5,897
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 29,302	$ 19,949

XML 24 R6.htm IDEA: XBRL DOCUMENT

Nature of Business and Basis of Financial Statement Presentation

9 Months Ended

Sep. 30, 2012

Nature of Business and Basis of Financial Statement Presentation [Abstract]

NATURE OF BUSINESS AND BASIS OF FINANCIAL STATEMENT PRESENTATION

NOTE A — NATURE OF BUSINESS AND BASIS OF FINANCIAL STATEMENT PRESENTATION

Nature of Business

Basis of Presentation

Certain amounts in the prior year’s consolidated financial statements have been reclassified to conform to the current year presentation.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

+ Details

XML 25 R22.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details) (USD $) In Thousands, unless otherwise specified			9 Months Ended
	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2012 Support Vector Machine (SVM) technology [Member]	Sep. 30, 2012 Laboratory developed test (LDT) technology [Member]	Sep. 30, 2012 Flow Cytometry and Cytogenetics technology [Member]
Classes of intangible assets
Weighted Average Amortization Period			108 months	164 months	202 months
COST	$ 2,982		$ 500	$ 1,482	$ 1,000
Accumulated Amortization	126	0	42	54	30
Net	$ 2,856		$ 458	$ 1,428	$ 970

XML 26 R24.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details Textual) (USD $)	3 Months Ended	9 Months Ended
Intangible Assets (Details Textual) (USD $)	Sep. 30, 2012	Sep. 30, 2012	Dec. 31, 2011
Intangible Assets (Textual) [Abstract]
Intangible assets held	$ 2,856,000	$ 2,856,000	$ 0
Amortization expense of intangibles	56,000	126,000
Sales Revenue, Goods, Net		$ 5,000,000
License Agreement Expiry Period		5 years

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References+ Details

XML 27 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 28 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2012

Summary of Significant Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE B — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

Research and Development

Intangible Assets

Concentrations of Credit Risk

Income Taxes

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

XML 29 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Consolidated Balance Sheets [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 2,551	$ 2,150
Property and equipment accumulated depreciation	9,202	6,653
Intangible assets, accumulated amortization	$ 126	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	45,268,905	43,416,200
Common stock, shares outstanding	45,268,905	43,416,200

- Definition

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References+ Details

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References+ Details

XML 30 R17.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2012

Intangible Assets [Abstract]

Classes of intangible assets

We had no intangible assets on December 31, 2011 and at September 30, 2012 intangible assets consisted of the following (in thousands):


	Weighted Average Amortization Period	September 30, 2012
		COST		Accumulated Amortization		Net
Support Vector Machine (SVM) technology	108 months	$	500	$	42	$	458
Laboratory developed test (LDT) technology	164 months	$	1,482	$	54	$	1,428
Flow Cytometry and Cytogenetics technology	202 months	$	1,000	$	30	$	970

Total		$	2,982	$	126	$	2,856

Estimated amortization expense

The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of September 30, 2012 is as follows (in thousands):


Year Ending December 31,
Remainder of 2012	$	56
2013		223
2014		223
2015		223
2016		223
2017		223
Thereafter		1,685

Total	$	2,856

XML 31 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2012	Oct. 30, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	NEOGENOMICS INC
Entity Central Index Key	0001077183
Document Type	10-Q
Document Period End Date	Sep. 30, 2012
Amendment Flag	false
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		45,270,280

XML 32 R18.htm IDEA: XBRL DOCUMENT

Net Income (Loss) Per Share (Tables)

9 Months Ended

Sep. 30, 2012

Net Income (Loss) Per Share [Abstract]

Computation of basic and diluted earnings (loss) per share


	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012		2011
Net income (loss)	$	(975	)	$	(143	)	$	178	$	(1,329	)

Basic weighted average shares outstanding		45,175			43,104			44,944		42,570
Effect of potentially dilutive securities		—			—			3,282		—

Diluted weighted average shares outstanding		45,175			43,104			48,226		42,570

Basic net income (loss) per share	$	(0.02	)	$	(0.00	)	$	0.00	$	(0.03	)

Diluted net income (loss) per share	$	(0.02	)	$	(0.00	)	$	0.00	$	(0.03	)

XML 33 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Consolidated Statements of Operations [Abstract]
NET REVENUE	$ 14,202	$ 11,320	$ 44,973	$ 30,591
COST OF REVENUE	8,310	6,246	24,571	16,996
GROSS PROFIT	5,892	5,074	20,402	13,595
OPERATING EXPENSES
General and administrative	3,929	3,182	11,745	8,801
Research and development	808	125	1,833	416
Sales and marketing	1,839	1,725	5,809	5,162
Total operating expenses	6,576	5,032	19,387	14,379
INCOME (LOSS) FROM OPERATIONS	(684)	42	1,015	(784)
INTEREST AND OTHER INCOME (EXPENSE) - NET	(291)	(185)	(837)	(545)
NET INCOME (LOSS) BEFORE TAXES	(975)	(143)	178	(1,329)
INCOME TAXES
NET INCOME (LOSS)	$ (975)	$ (143)	$ 178	$ (1,329)
NET INCOME (LOSS) PER SHARE
Basic	$ (0.02)	$ 0.00	$ 0.00	$ (0.03)
Diluted	$ (0.02)	$ 0.00	$ 0.00	$ (0.03)
WEIGHTED AVG NUMBER OF SHARES OUTSTANDING
Basic	45,175	43,104	44,944	42,570
Diluted	45,175	43,104	48,226	42,570

XML 34 R12.htm IDEA: XBRL DOCUMENT

Common Stock Warrants

9 Months Ended

Sep. 30, 2012

Common Stock Warrants [Abstract]

COMMON STOCK WARRANTS

NOTE G — COMMON STOCK WARRANTS

Albitar Warrant

(i)

80,000 will vest upon the commercial launch of the Company’s gene-based plasma prostate cancer test licensed from Health Discovery Corp (“HDC”) or similar test based on our mutual agreement.

(ii)

40,000 will vest upon the commercial launch of the Company’s gene-based colon cancer test licensed from HDC or similar test based on our mutual agreement.

(iii)

40,000 will vest upon the commercial launch of the Company’s gene-based pancreatic cancer test licensed from HDC or similar test based on our mutual agreement.

(iv)

20,000 will vest upon successful consummation of a sublicensing agreement with an instrument manufacturer to commercialize the cytogenetics automated image analysis technology licenses from HDC.

(v)

20,000 will vest upon successful consummation of a sublicensing agreement with an instrument manufacturer to commercialize the flow cytometry automated image analysis technology licenses from HDC.

Warrant exercises


Type of Exercise	Warrant Shares		Exercise Price /Share		Cash Received		Common Stock Shares Issued
For cash		175,000	$	1.50	$	262,500		175,000
Cashless net exercise		725,000	$	1.50	$	—		75,066
Expired unexercised		98,417	$	1.50	$	—		—

Warrant activity for the nine months ended September 30, 2012 is summarized as follows:


	Shares			Weighted Average Exercise Price
Warrants outstanding, December 31, 2011		2,156,750		$	1.34
Granted		200,000			1.43
Exercised		(900,000	)		1.50
Expired		(98,417	)		1.50
Cancelled		—			—

Warrants outstanding, September 30, 2012		1,358,333		$	1.24

XML 35 R11.htm IDEA: XBRL DOCUMENT

Stock Options

9 Months Ended

Sep. 30, 2012

Stock Options [Abstract]

STOCK OPTIONS

NOTE F — STOCK OPTIONS

XML 36 R23.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details1) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012
Estimated amortization expense
Remainder of 2012	$ 56
2013	223
2014	223
2015	223
2016	223
2017	223
Thereafter	1,685
Net	$ 2,856

XML 37 R19.htm IDEA: XBRL DOCUMENT

Common Stock Warrants (Tables)

9 Months Ended

Sep. 30, 2012

Common Stock Warrants [Abstract]

Warrants issued to members of board of directors


Type of Exercise	Warrant Shares		Exercise Price /Share		Cash Received		Common Stock Shares Issued
For cash		175,000	$	1.50	$	262,500		175,000
Cashless net exercise		725,000	$	1.50	$	—		75,066
Expired unexercised		98,417	$	1.50	$	—		—

Warrant Activity

Warrant activity for the nine months ended September 30, 2012 is summarized as follows:


	Shares			Weighted Average Exercise Price
Warrants outstanding, December 31, 2011		2,156,750		$	1.34
Granted		200,000			1.43
Exercised		(900,000	)		1.50
Expired		(98,417	)		1.50
Cancelled		—			—

Warrants outstanding, September 30, 2012		1,358,333		$	1.24

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References+ Details

XML 38 R15.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2012

Income Taxes [Abstract]

INCOME TAXES

NOTE J — INCOME TAXES

END OF FINANCIAL STATEMENTS.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 136, 172

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 43, 44, 45, 46, 47, 48, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

ZIP 39 0001193125-12-451638-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-12-451638-xbrl.zip M4$L#!!0````(`(U[94'`Z9P<)%HA=*E,R' M."*6F5Z^Z>D-P/&_IQ./W8A(R.E*5_O_O? M_SG^U_X^^^.D<\[>"U]$/!8NNY7QF(Y=\.@C:P;A+)*C<-']D@QGK=-AI MX/O"\\2,[>_;04ZX@GL#7X]6+]?,N>D@\AC0XZNWI7$5RNWM;1D/EX-H M5*E7JP<5Z:N8^XXHZ2L//>E_O.-R/#V`^>SETX7K;P_HZMJ;-V\J=-9>ZH_\ M2>%*7P0CX0<3Z2@S0:U>?7-0M3=(%?Q4K[VZBWA]A;T!Y#OB/$QO&'(UH(O- M"9IAOUK;/ZBE],-X\A/$@V?=[(;\Q3]7],GT4B67"0:NK%7^N#CO.F,QX?OS M$[AB;G0EG/(HN*G`B3S]H&#&CE&^AXI&ZH@A(WD?QK-0O"TI.0D]'):.C2,Q M?%M"%>Q;,9>GRBVQBAX(<=0,_%A,8]853@SPU2B",X_6[CO!Y)(/^=21N9)`H;];OB#"(`-;]"S$9B$B3#.,)/Y;QS/R" MW]+%(T,I(D:LB(+8+/_-]G]*[ZH@O.JK5[77!\>5[+9L*"5&$SB:'H!#6BF' M8AIZTI&QIH6Y$J[3B]2`X[`;PQK$NRTOC:E4I7?I:7,T8]#RIX<\KBR=*:.M M4B3NN%*0PW$H8'`W)Q4"1OQ.Z_Q@OU8_KMAC=H3>3V`-I%M1@V'D(';_8/JE]%![53X<"0M3D=[#1PIP9J ML`3`\GVN!BZE+R[@]UBU?!>,4K82KCVN)APL5Z#0!/2;J*FHWQ,J[I]+6/:P MO?;/HF#2_T5P+Q[W3Z5R`MCD9_UF$(7]7USGB6CP@O\51*A!@.&I&,0-WVW] MG0"E8/*32,92**U;W"@.M5RL6+144"A6)B@2+9%4("@/$,=FL`!D1/$ID/+. M[H-50$-V-+U0^&[N,KUL[;&O!AH01R1X+)V[\/)S,E%6#"&?N!%XQF%AGJ>2,CE4DJ$I*(%4@F#RN. M;PLN$.\(6#5JAY@"8JQ8=J!9``WP[7^#.PSQ_2UO+G/A66L:R@@N^."+J8@< MJ9Y,6+VVWC\KGOBD`!^DX":>N!JV_1L`%;+4]AW8KVPDWY@$B1^KDUD35#D* M8!?+$&DTD%/`LT%A;QR)%3!L34%+L;P1_=]@"6)V1Q%`G@CX.L+#[>0:A#?K M`:H4I]06:#A_IHB_E&7D.&7X893]ZC%-SD[7#ZKKQUS8M9VR'U#9M?46=FTS M"WNGZP?6]3H+>T.ZKO=/$]$_$<,@$GVJSO1[MT#]K-^54_@SZ/?&0:*X[T+$ MZ<(/"6Z/\+<<".1_=<1-X-U@.!!-I,\1`3GO#-C67!/3FF=@&3BV#`._EMUG M8]^_$@S.@N1;@H%E]QN!06,80P#YC:&`F/ZF0+"\RML`HA$2J.".H$*.VV]" M'"OC?F,$WN'DZ?@!FNPS[DA/QOG0W#`)/%H6]:4I@T^J.KPB!;3MVMELGF>[ M=%/;N#(^J2[^U3L3JMO$7_7+ZOYW)+>:8RF&N>CH:CB4F&=_&@ON5`Q%!':N M&4Q".*2/=A'NMJ>,EV(78'?-(4,?@-9_A=0H6ZG6@ MXDC$,J([3X0OAA+3H#T9ZW2I'::X@DE^J?B,])Y-HNQ>X%S`'N-P;P>;-6&C M"SLH.B.YYX:8._QP<2.\((1CN?IN!WM[U1.!S9GT92S.89V[;1_,\$@./-@T ME$"%T][?]+B:V^)3MC.N-=//QNM>K?)S/@@B'@?1K*!]%>'.^:9WN+/2C6N@-/UVQ33F,+WQVX6K>Q_@U\46]6GWUZ#SF=UD,L7Z^ M?Y?5EVW"X[K@4SE))D]DL78PY"[NF8:!9^,0W='7NDN]/=74VQ;@9I=Y>TJ9 MMRWJH]YVB#S&(Y;;U)>X^:>0MS!MO+I+<[ND\Q@^*C2WP6\6].?M7M$[YMY1.^!@=7D:NP)I?J7(L:4 M";&V@]:#0LOJ`%1@-?!LL+7#U.-AZJF`:>T'U7?&:CN`]2#&:HLS?3O+]JPM MV[8$^'W43T@/T=@'4_I7_E/!VW44`._Q[!HXLV`C9DYF61):N];VC.422]); MOF<5%7;EQ-N7D:E5OX"_7[F/P-?O7Q4AC+2_%1P^T-K\U_[^!U^FKZNU;ZM- M\!B*YT/W]/I#*@PJB.7FQLLNDXF@MJ;\XID(KI)(O#/O%CZ$88XK]F`&ZN7W MT["G]%)C?]7`M)ZNXC$NG>7C+@YP7,G1KR]:Y+9UW=U"=ND-RX<*JYCJ:S)\ M#<.D[!8G"^'/XE1+1Z#*JEHQQC*"5PE^88B5PLR/@*]<;GE4P%UXY3*]UEN, MI,].O,#YR'I\-!(NNPQBD5YCC?A5-.*^_(?*R@/3U8&'IR3\W:3E?8KE=\/FI7*:>^4_?%+[^*)8-;S9_+D?Y^XLN[%;`AG\,(J/2.J&D)7BJK%]MBE1+2$#T;/GJV44 MZE/3^5-#$#=3\XQ_[P_Y1'JSPQCV:\5\<UVOU(W;9Z'WHM-C5&3OYT&U?MKI=UK@\92>- M;KN+1\_:EXW+9KMQSKJ]1J]UT;KLL>M.JPO_;_3:5Y>KF*0?X;WL_KP9;A/B MEL<`:Q8,V4FB(,!22A.;;!&QER)X;[X6L,<@%"GO,7/)&K5F2")5IW*\5"X9)'NI<+%\`/LJT(B05`0BZ"CZ6IL M9?>.Y6@,8L0/&DS!\T2G?MM`097-\W9C"6P4$2[P.@R#VT8UU4^\3QL!+0-56Q*F:YVPLF37N M^PDP;7!&C*V!39BZ(#VD(2]P&,*E-_*BI0?S'V>B!SPL@B8O\P8!&D;U8"M% MLK-5<#]E*8`)`7L>)Q)@C+\27\=3UO9K.*P]R0KV/T'<$65) M\:-,9Z`L5JON_X>6$]XV$SQB>@\Y%0YER_00M9^K1P>U/89]8WM`F6<_"45K M)$T!$WFMJ3/&?@HD8B(5YO5P-GKE439:K4ZCUC"3A./&T0M!-` MRSO4QMZ*&':`OQ,>`9C(IYD7Z?^3#07=P$1@#Q2/)"T*VG)AE[769OE<\9C' MQ/J$SQ`_8AJ"_X20`#VAX1DFY!7K#!3@MJVU'H2P:Z.TAW"GSW7S]IY!_F=` MF<%29MS]*]%9]A1]44+;.8X#>SRB,/`]\AOT^@>V`!$1GLC?C6QIN1B9S#1# M;,AEE$T/XQ#S<_+AUOK"ZC6,&\&G2V[[C";7I0B[+&%7!(9QE156YOT*2^ROQ!WEMB*EDDF8[9F,#X>P49J=PVP-U@3C%D+/&^\Q3_(!E@HI+Q*) M&^$GQG?!G18_XP&;9C`2%*IJYLT@QM?-N(ST>WZ-&V8-\'WR14\SULZ8WM\H M,DYBK&(KW/6);U<".Q$;@GYSHBGL'.N(ILQRUF(]828J[S.O[2_LL4$2IYX/ M!CXZO8`N"`@M%1:(R4I]+PO`8%<3\H8//('TF(U.WX#;3G0CM,^!$!2^0\H# M0H>)QS!QH;F`00*;Q/`"?[0/#L-$ISS2Q\Y3'$AJ&V`QGPJ3G:!D#'HC-]Q+ M:)&K&`WI@#YDZN0>C[,P7B;/O06!HDSPZXSB%H;1W@NF5W#9F%D%05=9YP>' MC"0AY$8J&@/TD4YF!AQZVB\T8+Q?46$4J##-Q1&R*/4#%UB7U#CON=D^SZVJ M;M``=T#R&$Z0],R+'\AL;*75-UH[97UP MRMEQI2\4U)A30*O.3IB',A4]"G?/;1Z46Q<00O,;!F1[=3K4R5A MZ-&"E#ZL:TI0XKBA?BZ4)E1\0L:>_%7\$R`'J\PXER!8B$XPWV>6E67P%CS[ M5")XLZ&5!&[>!\%@17QVRF23J<+L51=,O^MB2P':GK>->M<;TDL[YHPL&1Y, MDR!8X[RUO!U+P!/F1I.(H`T[+19LP,(GDT0C)0\IV`7S`).T!02P5?V#R1NP MXMHP&BOD%NDPUDJ32Z@A3I8E/A8LOV$BW8R07D]_QXEQ^V9>+0+]%4F6?D:2 M-;.2R18"#@(V8".VB000DG[?,.M(]7%+P;=(LZ-ICI!FT@(8JY`53B[L@776J0DPUQS3 MAKH4E$1Z=:$^QS(T+K0ASA2*4-B8.K>U`S`0,48#0#6^``"<-X<;]_7,9"=C M?!J93:C%UF0INQARS*4IJSJQN$<9(VLF8%#P^A$*Z<#6_4&#M4`3:&$@?7(] ML\P?#P$@4[)&(,Q:O?SF>ZMH`TN3Q)[H$@E@HW90?DD76=S:5*O)'M[+1\TD MV_5=/M"TM@3NHOUE^:=YV@MTORZ_7DKVN@20()!\73;153\+.MK3:6N`J,UG M6D!Q$&MWE^;+EH8WVT([JQN.60\CARTUJ[]KA2:Q*,0Y2^MVZ+TYVGQF43XV M?KH\POSR:5JTIR&L#V"V:HL-.$GF"/Q/054PU*J8X'89S4PTJT\,9C0G%3"$ MSRF&P2@E(<_1U-U3HG0V.+!9;[0\9+X+(XKX%JL_%,`M1C[@'$<1361MW M(=$#6]$54Y//MGX"7)1+%B"65;"7B]G-3H.-4-<9*%1FBZ&R=>8SF6-)=*3-"PG$!!AP M+\8B`W#HMJHJ!$M)H(N+43)*,PQT$M=DG;+:8\P_PK]8TXAR51N`ZD"8)T M\.>9BG3.,`R$PQ$$=D_7V_6EB-F5+DV!RL[10KGLC901TD=)SF%;NQH6/N/QC"L)!_E*PKHRV(IB0K-03.BT?KLZ_PV+ M!LU.Z[3=HZ[';JOYH=/N_NX=96$JX5R>/UGZ[7FFE",[[^ZJZ_0 M)',21%%P*_(-<:;;J\FI`ZL+BQ2V?%VV$^S\O$E\%[K%])5,7UIHN4$W4O?] M8.<>C!)!%$#?MZ%]:;ZY,3U3&,0DR,UG<8@X^V$MJE,L=ZD=^#"#)9; M'7-`?.>/U.'ZO@0M8ERL^85_3T([%?Z2@6/RJ\W@`\R;1?O8$>`BAT3`N,7WMVU*UQ!SA>2%WL3,I_:U"@*+Y?2O=>/RV5*M6OR>" M6#9[-/?;M1?_]'V)\J\C_VT)V"LQ\S=-_D76K5W^<5':L;M`2'["`BE?-KOO M1()\4$3%1+_&Q58;T26F`"!KP+&KS22=AF:!+]@1N_)QDPV8.I'GD M8*%'_=W+[,B1S2NY>QE<[;I+^WRP"`K+`(>3A@6Z,#\OBV\Q.>$FU%L3FT56 M6&/WKB@=>$2F(`2W?E?+$4^VW0J-3E;WJE7Z[VC)&M):S9QU#;?<;P3_;IUM M:)T][D)K36.-M\_#(2!MN0_T<@>TK0/:XR*M@S5P`S174%7*)`QR]MF\+HWE M/KP)WE'>A]6!^#)78(>N==!5U"'II[:,H?M`LG&\\O(C@K5N$OX+>[<4)GT,`>@#9^'7A%3;U8&=3GSWJ!X^) M^MH]J%\&=4(P?@UY%6BIG>Q.7/^TP_6SQ[7SF+BN?B:N`UT&N`/=`%UTD+\` MOFP'LZ\(,_,;HK\+I&\-%3EFT?B[?" MQ=Y=JG)9\&,WS=@:":=@Z9.,!Y^^2JD[?"<:Y5J5ZN?C^/[$B$'NF+2=,T M6AR1Y'+GJ+7BJ%_9#&^^.2+D,JT=F=(A]L#@X[^Z:64HJ+?DN]>42#9/%_FB M^"1T5L'9KNZ/*Y_]FGBY"EO]E6FO6'`*;W7WOJD_Z$+`ZV)V_;LWV>_M>5ZU M3<5=1?U,01)3ZY=^?/=&O]`@@46EN[SF"J&ZX9;/R!128Z"G7W,21=2G%=B> M+"P7@^]!;5;<&3.'>P+[R_1-YBT3V')E6JO`<='/`)EG4V1*XI"]+-=??K\] MT@.$W-6%0PVH-UQZ)"-39UHM4`11L5OSNVKY(,60J9^:3MM,50,J*.%?.$`! M=CH,\45,]BYKS<(?^-`(7`)FR%VO6V?=?I%--.S,?SKT^;\C[J=M/#<+[91I/TXMV*^]>6"J_^V]Z7- MC1M)HG\%X;5?=$=0,@'>[9V)D'6T-=,Z5I+M-Y\4$%@4,08!#@ZIN;]^,[,* M)T$2!`$2H+"Q8UL26957969EY8'GZ9NH&`F]BN23\=(G8N_&J?4EHB(BJ#'! M5F)?&YM:^QI[O8KMOP_P77,&`=5HI'.8E@"![1!-`VF M>9@A$_;NPL)9OZ.7W[J+*`'?G>E:^#M>#:B_DB<'YN<5DW958X'YT9^8/_@1 MW%?S)/C.25"EJXYUZONE\>*_J>7ZU2>)M3Z+^A!,8O";CP45B,A/^R\F*LV) M8#H/ISDJU8<0ZOCN$25Q2(E@$+B$D\"3/>N^73PY&;F(_8,HATA`(>JB,8%6 MD)8(;GL&93-[`/D+W!X=L_B0!OX?*7D< M$,/0(5P4I@P<`&MNZ53DB#2E\E[)]686/P\:>F?@986L\7_#2^']-!&'![F^A^S4P&PK62SUQ7*+,)-B3_C)C#68OJ ML=2T&:''1!YS#!6R/S^)'O1@D*LF/L7" M8)D_?WP9#+]P@=-+IX*+B0=`P2\3RE)>NUHF6^1"32WRB+I^KP%)6V`'%I(WSOT):`SZ[8RY M8.5CAFO)Y%QCI!H;I@HI)/Q3O*_/U9&*ZTE0>8,V@#?60;B;X@\9H[_]7(C\^0I+5( MP\Q4]"==;J#F7#EC;NU?+&JVWX)N0I&*;G)X3-*(,\L.)#?)PH!],>D-JKHM M<^S7167F:/@>(,??`];Q=]V#P)[ZH/P9E'4MMS8`&5G=NI%7S;OKHE6))A_^ MLJ+,G`7OA1,+33B*UBDWQ!2;ZPB$>2D?)3["$F MQS..>-?0*#[PPXJ8SA,!]1NV`$U$9U8_X/3]A_,XMBD/+?[;"B?3#\F']XW? M]XFQI_WV_*$&W*(_E'R!6OL4-AXMX#K'@$^X[D`]+,M_,1[`] MP7A/!?W983Z@J(.1`XMI8IK!+G*_NP"L<4S6$;)4RGTO94.I50XKM.=W MCT\'D\Z/3/BSL+'<&OK[EJ2`_3+:HH3>:/A=$+]OF5L9*Q"[Z6&&P^I[7O(N M^*LU7BS?!:675PR?P67TOS2-LXW7DJD6^GNX/7TBWS:;K.9N+?J.!3# M_7+"?[E;^.'1F].\@S^8YEJ8WJY-L2O8I\<_;CY'0ND5]G<*\?E$X4M[&`+# M&Z-5Z.CNA-J/N]"6'D=VV[_7;F>"P+3>;77^MQ_XOW\HE`:55,BUYFI7:9AZ M?$SM#6O`U5PWN0,;VTAB2_BB24^NG[Y=/'U`>]OO2HV9+?+LRJWNL-')Q\?7 M7K=AZM$Q%0ZK4G=36Y^;[A7FG)P'.2?4(B^:E_+1C*_25AKC6_!Y;C>WW"/D M:Z=AZO$Q=32H`U?7FMZTS+?5YC<*\+;)*S7XTK)7(=XQ*`<5%-=AS^_S#;F/G[;:8V:P-@1\E56^@U7CXZK M2FO8JP-?,R:2I"6)I+7^VV/16CCV,]Z=I->GKCX8'?L1SI;?XL=Q;179>F)@ M=DALEJP_$(JW=?'GR8:#Q&C0'ZZW-&Z.\%[7;`6;IZP>;NMOG#8P.1P6AG/Q M^,@CJB?"=@JZ800SF@PC.1DWA@6MC27&L-PKOMOA1"/#'WS%^!_]4J^4VBV+ M#T^5'!7G$N"(1MC8-7AIH^JZMO[B\4H77KY%Z"3K=?@FEF>,@^GJ?+(8%CB' MG*3**=Y3Y]7"^5Y`CO$IGQV'W-1&,N=?QOS^$%W3%*BAEH?!JZ'6PA*EIA7ZR$AC_L-IFZK#+G MD#:IPAX9..O_'1FVS#L\!ECT34CXY598;N=X&"^GXLN)[F`S!UZ7)RJ0;<8; M_:@;YX+I5,C/2[B`:[EI0U3^.DI\P=;3[0]+NKKUZKLHD_87H M\V6DS'.["XFDTG]AW?,E[Z&56CE)J+\$9^%@=[Z,CL-'R$!]8#-5I]87H.B" MXI#JWL;KZE/7TJ&N0U87=K<_4IDMYK6ZB`NADD+B6DEO?10R]K-OY+F1Y]IJ MXUXCO8WT'I$V3G'<&GENY+DFVGC02&\CO<>BC9^"R&PCU64GT_:'*8Y2Z M!AEZ39Y2DZ=T8)USZ,CH1\LV"`>`9)A"4<;HCTO5-O$Y_)[9CU/U>`=^]"(# M/U;B7(DQ'Y>Q,1^WET_2]>WYW/C9^G^\D%Z_.WLX9)+4Z87M#T- M_/A5=72-&NGJIF;-F/0))-CY3#V/':0TOI"+=M-CT3,<7^'?14,]215#ZTP/ MGPNI7[$UFUDF_[83&\PS]FS_^Z(U/)P=PIBG.YQ*%[I!&T4`VA\D`HJ6-#<\ MA_>/1G`PW\!OH#^1YA8._,!VO/[J+HCAJ72?^GN_6RSE(0@X=,?Q0L0C#8CY M-WC/8)[*\$[-BETG3IB]LRA@SPHD=7_L@C_J:[P.6M4AS*G?OSJS/.S#3+^' ME4]\BI]*YZJ!7=4Y,42SYU4RBO\;8^?D$'N<)`&J>"%`G#%W:JV;ZW2`+)FP M<3#/]@C:V/.$+&1HD%;U0N>4SR1)'A$"?HDFZU+(!$,IDPSW7YM&!M_$CLE? MXMDQ+60Y?"W*!<[,SW5)FZETW^-ATX>X`?<(P=TEAVHOUZ\2F@7V#]LL\(DL MP(U%N<.7F#M,?Q+-(--U_SI'M2+WY.-CU"T:Z)KPZ2.>XP,W_3QH[^3^(R1VH^0WGV;#'HLTZQYQ"C@$>/3:'#XY]+/E=1)]>:KW#U\ M>D?#U^+S&P9U:/W7<'7;T]KJ**.#,S;#>3WJO)4..)5CRT/_::^)*P7MVU"R MH61#R0]'R1+STDJ[WO'LBZ6'^N5W^2.]]E4F7[;;:\D5N`$>GTM9'0YW6G*[ MZ0-_S!SNMD;=AL/'S&&EU:M_X^':!)\OEY,>C468$^DPS;-U5VMI1FH,=1<_@H`N!UOQ@>:P9%0\F& MD@TECY62Q_$FN;%?S9%>%`^>FMT^;1_^,:*II"B%L8?W*!O&%L[82O"U86L9 MY[46)6W-%;"&3F)#R8:2#26/E9+EO!&FM^L#A?Z+M-=7Q.92V%P*&R>SN10V MC&TNA1^,K;6]%#9WPLKLVU"RH61#R0]'R94:>W: MN7-C_BO1-C]LED]=\MF8`%G7*-_%Z6;2._[#M&)#%?R1#K"T/]$A,3"!.OZ' M`P^PYM+O\\_$Z)-(H_VQQW!>1#@P`5-GJ5C3:4FJ`XZ%D3I&@@-G,`='#*@F MG_(@4FZ!C'_!!7INZQK#[?%OY]9LKIJ+_^?7J0Q^X:,;8L,?)JL(MHY8:P8Q MA/-U5@Y]*7*JCOEJSKX\(B9WG&+'.DZG+YU(JY&MQ!R=J]@GN_-_2G?W M3]=WMX]<7EX"85D3S-G3Y)P[4P*A\%1[$8KWB$MW2[JP3\/?WJB@&:0SXT5W M5;L%FL&6SJHP2>FU M6V`&@B1Y.JN$?E]JFM3@HTOM)>F,.D@2V8RJ`);331+=AWPF0DY!731,6 ML1W5UCE5-F^N&HXE33RL:LUQ2PA6]51&2Z<&!C M-"Z6=,NLK\RT9KKF(/D]L$[P=6>)#60QS1-_*W\]'(L4-6-`%CXT"#[_PG`W MFX$[Y:'U`/APPFG@C!@2I(*XZ`@:'#^A`1)M98V8` MN=Q-1GX)?K*J`2#2CUUE2`>43"\#TY\9PMN1AJRO^\*/QP"R5C#HX#'!UC49WQ2*!< MK]B+'=>NIB*A60B)0K]Y\;K`9,UT0`12^ M_WAX`/6UFG?83FK>S=J5Z]2!'%&;7+FF:SY02(:%$NJD(@GLFH%:<*(G,Z&= MI$_X@V\#E/8OCQ%4B0;"]@IRW/\K5.;S7'`_0P":9G,T6%5'GIX);-?!RX?[+*3A7%W0#!29PLD@>\%O8"L9 M]:[#!4N?H8T%IOK>`^"`)K$Z?#@CZJS5_D1*`BQ-W_5:0Z7?DCN]B,;#TQ?3 M>F3](K==?@KC6M!G$_SL[V.31-#E]\?V*1PFV#BI*/$,"#6Y5"*:4+/PU;82 M?G7M_7+U+:CPB^4Y48KV^E-3.AJ=']FC'FWZ)\IK20)!LO7(3XQDL76HPD]=>$ M!GQSRYU0DA""FOS0B-AHM@[?@1NUZHAAJ\Z7[-8YC&#W"YQ-&H_P9QHR&AE1 MFIQDFIQT*N8]RNWV3\FGTY6C1OWAD`6\J8WAVX]90)."B#1 M#9RY]BJBOWR[.8QK+XG$Q1P?$ M5+%F<-E!-V[FN7#IE=17FY&'F^8T;7@D"I^`FO-3C_-ST`/4+?P`8=FBN>[8 M7)SCL]L6AR"4[>8@'/5!.+*3`'_3T`W4M4H=!ZD1VT+%]NV04JND2BU<)33F M.!//X!>.V2Q(8E#ACR]*`PZ=:CSS`@I)JJL7!T'N9WF38UP32\+OP#X`0'H'%S MCO^8?.13,H%[+AV5&7/AGE"5D!/ MP2_Q@M[!1ETY<`\9\:@S+5ZL50;(Y6$VE@'H7(MF\=#.]UAJRL/PO7$(G#"_N&9%&`>8!!QCK%8KERB M@61K,F$V:FZ28Y_*8_2T0?!@I_&N$%?J7X@F7WK=>6X?G-\)GA9S]9[YD+'0+W3F^Z MN\C7:$\2B;Z4;VS#\K5,11OTJYN*-E!V3$4;5B?[J&;@[I(LM1>E?S2)`DU& MTIY2P42;FQ"+,][O!E?T\S#\M"6)9ROMEWI-&D720CO1[D\FFG6P.VEOA4VRE+>WWE?98:[52R=N*] MJ6H@Q`V+G:U/BDD8FJZ8;N+@CUJ3J& M362%9U1*8UM]E\;6N^D/C,3V@#2OSI^!)SI]NE/==A>`VG?Q39Q.PM?GD/"% M)ZIN^[.5WWA74!JKDAB>0CTG:;R)*ZEB4`P.X`0*L.\:P_;=^L1EC,#21(M3 M^GZ`OV8YKB121$F#XI=MYGJV&?\D`4FX^X0(NQ3R?IL(.OBEMO5.P^[\095O M8MB>H4^"H8-$;SX;1R>^.30DE/XN]T]EY:WY+T8FO)>(O3[HA/*?23?X.91_#1R <"&2^#\Q MK5:Z`BPMB526=!E\X$HW55,+!K7YPNJDLC`.37\;9I:<'GWA4CSC3PM.*J=5&D*%-M%`UH#BW.X)7 M$2;1]%^4#*R59]@EU.5'>#;W4-E-57O\3F/L^,@GC5L?#AL?_(1[=?JX2K\= MT4!.B\]-8CH-Z@51"R4F,H4>^Y0NJZ9TG=02<_AB[7?CHN)(+\Q]1_4T_(EC M#]^0UXJ+[[*DVM4BG15_FOP#;_U[KX+:)F\"$^N!'CA1Q[`<+S)?_LBGOXE/3VG5=T2GQ$3?&> MTID+-_`(<9_HT<6NYM+YJ?0/RV1PPM6@?7&B"WD+7!7;3#;*)IQ_[(4MM7_D M[9/CPY];I%+>0)-9GA,=Z8USS?VQ:KPG,OS19"0WW-S@G+JQY^+<=;`CX?#E M/]"-N8=-]+%P6;CQ`;V65WU'R(*:*@5;G*S=\^=O<]3E[A!Q/R2^L6'.Q$8^ M?=X6O0Z!)P'0TH^<5?D*?GP"\7[5"[0W1`6`!N%631,'O+Q8)F$=Z9$>N!BB MES:X+8X&'T6G9:TBSZ%;RE#PX-];,_:D?C]^C2ZW(RI]'=Z5T.'_B.GPZ]OS MNYM+Z>GL_^]\/2UI\OP_/",Z=7X0F5QPC5X/<$QZ0)4,+M,CL]_PU.-),AA- MV<`9FQY>/D7?^<@QPD;R(_^$MB57_2YN:`YWQNE[A#(H$5!'7/VHDC-3#0.G M!,XM["NOCO_M.2YYDN#_X1ZWX,/=S6EZ!6BP;Y8#9QM<6'))W['M/1]T$:Q* M,SX0(=C55N?,P[%1X6Q!R@T6DT']P1B\YKNU8JZ"&)P`Z("WB3`" M/F?\P[BA;Z4$60!>;`]E!?`:""]\FS"/PPW?G+`Q^>=(-CXE42>)QV_`SGS, MQYC/C^ZWE.ZH)?>[Z,OZE1@1)2E*,L3<:?AX?]C!_Y&R#&<(C/E)XN1'>,^X MUGR@Z:8X*^L*C`,3-T;HC]F$V2@!R&(5 MKBSB"C.%C?S/T8P2LFD"WR1#<,Q'E::57-Y>2'=7TM7U[=GM^?79-^GQ"=S* MF\O;I\=,YFZ=WMW1OIUIFN69=#;N+4/7%E\H"DEFJCWJM)]!)ICRK`8?>Y[3 MQYXI*"PG+>/O#KN;7#HN>4C.\=C"'I+MY0(7[U.A@8_213[D*>3F' MJX&F@SGE\PU!]X,Z@K^CTTL:&17A[Z:./SVZ1"$@U]F,V;JF^B&3R"(V!EYL MAJ.S5![2H>DPZE\\4L-\.K>D?WOC5PXAGY(=#L$F5:=.)G`-X!%6L@1H$V<( M-D%`BA%6,73U!>.J.BYI!K^B;RY:$@^PH0L.1%XO$[`[?AL\K0D%V_*E% M&^D+QE>C,8[<_/*]+<]%?>4`XOQ&.-9Q;`TWA2%I`E<-QTMF(V]X8]:27CR7@E]H$@U]IO-13D#-J14?[N13O>7+E2-N M6O2>YE\,_2$$P:?1M4((L@`!/P1`,5Y;0;QGPQ3J-G:XF@2!/T7A@&[/G# M!;"#CHW8E9'H.O[X(US2UDE"WG2'U@!^!)N)!2<&?"<4QLV,PCG6P04[=#+' M(II,BW#G(+);)F,;5]!KS&M!IK,4BZ,LQR0=AG[@F3F^`(DU+`H/7W(MP3=H MK+6@72R(N9%L&4QX"0]!@0GW(:3S%X&QHJ8\!NXX`BX^*G)M($P770)!L7EX M'3A=_<7@8DC71X>N@#AR@)M!L,?N(AY]PM^_@+6?Z.+!Q5ZU-.@W!P-R1@OM MINWJ_^L/TB1<0D5,UI=K>,>;SPU2Z;J)$R+QS0S7%0$RVM!19^0N$F/=)NG M=)`Q7]YQX?;*G$`Q^PC26XI/$?RR@)4(+J;5TJ!E)V,0;:-LEZ;]E%*U7V.`(<0@KJO.NDPX;=\4G M1,^$YV='9Y"Z41>.Q]5TA$DJ"U;]*:+;J,_$T.'/Z-J0;\*PP'GEOV MW+(%_)DB(QMDM#0-UBE5@W63&NS<,C$9AY/F07?^.J>T(_RO1G<)FD5TUQIR M'5IKQ4"CD\9ADXB7U=1@RS"+K#<;8::C+!X\(U=B?G=,NQ3;+)+*$MZN)8W9 MKHH1&W"@\#OPJ_>IN-F%\1_K31^CJ@0PPVC`FV5X,[KZH5?G\+<2_RYL20@; M?I2P`5`T8Q^#=R(U5\TN5/M)[-533R`K(!@H2^D)'=PWR+]RI:DJ<0*[E\D`.[1<>#6.1R5BO4ENJ6:ZMQQF M>457#"Y]P9L-L;!41X)F<(%*%#[\&N!SNCX2+K'UM1Y'U29'LY M),Q?\W$[_XG##T@CT&"'=8>G$8`EID^)NPI\*/**@JK0H3"_'\C&%_1QG#AD MQL/H,N56$$+Q.Y9N^FP146V1YT\//.*A81QD\1*1")$Q1:J?TLDJB!`2@+"D M[`Y$B+,;-V).EA!<-SCKWW^>K`3&A]8A2Z(,^9.K3&/B&'^!\.B`S^&1J&A M%G]#D);?$/P854AS<.H`%+).1!`_C>-%Q1#;"UPJP_JB"KS0PU%B/$>!R\O< MXHI1/,>1`_5"TJ?^!?_$+&T1J=2$[_K"Q-]$'DJ^=(,?R]+8A\5O:4MVUV1W_`H2G/N)LG( MPYDY_FI98\Q-H56/-2%P(\DBYCT'M0[SFO)G<(J6HUEPH-9D.-$=UUUW1!-/ M!?ZRXE+(@@((WBD?I?T3V0NXW\'BSN?:M,X?*=5MG=_O[M@Z/_/W?6+L:;\] M?Z@!MYDLL&M#A1Q=[G/8@Q1=DL,\R/$D\Z!IOK%+,OD>`4[IZ1]]%2H:#[E@ M/(+M"<9[NC]EA[D*PQWD]D&F.P0T6^.8K"/D7@<['*_*J]>RAQY)$@CM^=WC MT\&D\R,3_BS,)5A#?]^2%+!?1EN4T!L-OPOB]RUS*V,%8C>]CS7>Y]&;4[77 M'[S2^D;5IOB&]^GQCYO/L)LV->GIL\+^3B$^GVBHU1Z&P/!GS`H=W9U0.W2O MLEX%>NQ74B'7FJO=E/Z-#5/KSM3>L`9/J`]K;?E1HS6VR[U^ZPT'1J]-DS=^K`J=3>U];GI7AG6NW2^P*1E M5Q3&X4^B>,WY<,97:2N-\2WX/%=ADERCIXOF:Z=AZO$Q=32H`U?7FMX:3*#9 MWY>6O8IFUDU#QX:.>Z1CB2&YT@8!/F%=674=_OPRVYC[^&VG-6H"8T?(5UGI M-UP].JXJK6&O#GS-F$B28;35#G4KF]JP9JXTVJ7V9JGK6XC(I2A5BV9I/YE9B1!CS^W_$4+!M2K/\A>CS9:3,<]O21,;EO[`W_R5-8DTO*R347X*S M<+`+44:K^A'2,Q_83,7UJ%W/$<_+/;3#64MOLPXI3R"S*:.'CT)FBWG*+>*V MI-1ANO-Q9!&`/*>DXC3RW,AS3;1QKY'>1GJ/2!NG.&Z-/#?R7!-M/&BDMY'> M8]'&3T%DMI'JLC--^\,41ZY>BV`&? MY,,6GOQI.9A5P6<:8JMN-6R$##CPB6,#$47/X2?XIO2>P[#CZ-["@Z:7^NRQM]I3N0#IN. MH`VX1PCN+@D;>_'U2FC;U3]LVZXGL@`W%HUXN<01+_0GT98M7?<3CBOR2BKB ME!\?HV[10->$3Q_Q'!^X_=Y!N[!^<,++#>$;B?]0A#^^RB3G=7LMN0(WP.-S*:O#X4Y+;C<=F8^9 MP]W6J-MP^)@YK+1Z]6\!6IO@\^5DPC07L\_FE@NKZJIA+'C^&35\89IGZZ[. M4II1-]Y)D7+/`1DJLA*%:3OH&I77L+YA?9U8WVDI3?O+8V9P_<_V48?!C[-6 MK*%C0\>&CL='QSJ&OT5!5A,`/[POT@3`CY[#30#\V#D\;"E-:_VCYO!1!,#K M?C$\U@R*AI(-)1M*'BLEC^--DF=,F%`^>FMT^;1_^,:*II"B% ML8?W*!O&%L[82O"U86L9Y[46)6W-%;"&3F)#R8:2#26/E9+EO!&FM^L#A?Z+ MM-=7Q.92V%P*&R>SN10VC&TNA1^,K;6]%$9^]OMYKVCGO4U/Y]PMO9/=N'/U MIAXD%L%/?/E3M6W5=)UKQ_$^:M/N0=BT>R--,K3E[A??E?M*],P..V53BVS` M+.B^*?F-L5M2O]=N@8\NO0L\I+G-WG3+69TLOEFJ/ MX0=";:S;3',M,26[TQVVNO(@7$\L`E3^AP<`*>WV`$=CSU6;JK)4;!(.4`*: MR`-K,F$V=O-^9S:3V'=F:[H#7\>!W=_GL-,X,E>[-H.TJ]RDN]<[GD':#;@- MN+L%"GQT"IRDWNON.DG]:3%GJ"LOA3JL;B3@T+T_A34.D2`_*Z6VMR(N^M$0 M/A#-`(M[6]./?-AY07XX_4VQLN6AD>NLB9Y)_0JDS0N#WIX38XU!*`*O\S?\X M1'J@U$6DZ\;B0]NCQLTX2K9*'/[J66,F>U<_L?3W06NZ&-T9S^@,#@?-?=1D4ZD MG6F6(39LR?!<^&F3DNX0Y(XW`_A@^5IF)0[Z MU_1BBOZ*3E^ M!IO$$]?V2[TFHR9IH6.-9&.KEE16G*OWQHT08@C M#$+(IYTZ]-`M\=6^4Y;V^HJZJPE[EZZ=VNWFG?ZX62R?=@]?#5R=M[URU=9E M\UZW'ZG^-*J(YCK"OA2587)-WN[JZ%^)%(-&396MIJJ15]!HJ49+'86#=:Z: M^`K3:*ZRI;K^C^P-ZS\LZ]?JNKJW&S[.D875(7YQ7RKQ8K#G9Z/ECE>-_2W9 MJVQU>L-6IU.'V%W=F'SX=R.ECN]&*Q[3TQ[*PSQ&*;V%XY99;KLF.@8YBF.F M?SF;,7,,_W.O#/4U6\[A1#4<]M\_+WT[7/3YHJO$OIMH`Z(4*H&5: M_^1$5DXZ,M]AU5+A9A>6YLV"C]PS6[?&5_`[)]MN_]/A&ZU<9M5.",P6^^`_ MTW8*EEG>AP.Q%>WPGR?M$?PBOE=LJ>6=J!E8I@WD]LG_Q)?&[X8K7IHNR.\Y M_-Y6C6NPQ=__R1;9E@8W2FX/!O)0<"1UJ:6=J$4.G2">^707FNK8MK^J!EZ7 MSYR[R7.G?:>YM*GDF3K_.__V#]*8:?H,)/QO/US?7OWP]VY/&;2583L&TIH] MD_!=Z0:SSX'HKY:=D0Z/L#U\27I@<\MV$0_8<*Z:BR@,L763FSZP5]W!=%WW M5IUE9.SMY=W7R]N[F^OS1^GZ]CRZ5WRY2._6,^-%=U5;:"HN8]EVN^_]2Z1T MIZT1W<(T/>2^RX#.[D/R(,2Y"EO05JA$YRB;SU>JIAN`PO.=R9YOR&N+\/S> MLUF4XUT0PE.YCP=UQ>81R,[5.0!N?&.JP_QM+FSUW=R*#K)R(S;;L-Z*G9VS M5YLQ.N*88I9IUY``OS]>1/%OP_E.@2:Q1PP29^JW`[LS(^L9EG_WGPV6V):"F(&".?Y#-3SF=\"^FYQ;IJ.# M-Z5BL<*]NJ`Z$2NRD'"VKLW+-Y!J^,)4-5_9->P%QL8RMC]%E_>/4>S@9'=/ M`^Z5`F.$!C[=Z70&.VQDR@[1&?#`);.[S$&^;S[V&9 M])ZPNC8U&ZW$V#=:8#HRP'^C?M=GWFRC=C_I_?#W$0^R"2C3-BP`'MW,#,]P M.WC&^IL^!D?BW-#A)#L/#`ZTE]$MHVX]+AQ]J?=3L%_Z@I$]R6P'5OML9GEP M*=Y(@_6.0:\7,4AI&R3WCWC%NT/`G?%1$H2E/0H`(K/[F`9BOS?<%L0G9L_R M^,?;55DG?)8FSV@U*:`N@UH4/T88-(K#< MF?C0_+JXM[%R4&.@9U]@QS%<_,#_P5J6<9JN6`65O(9N':1:>S@40&;?>7=P MGZ8@-[G@E3N]`\"[O5!R8'O=*A%W,[S*:!=XP6.=D5O*[\B_6J;G8)@"-`4) M_=82NVQQ(A>Z3;OE!2S/#3EJ!K>`RQ_.P\;1#YRA._5*:O771?@1L>[9NVJ/ M;RWS;HZ?Y:'A:]-Q;0J\.5>6/6&Z"]QUSLPQJ65:%.X,7-?X-6JB,BWFWN6Z M[\4)<__[:E>R:NCNC1-K:?[=T;^8NO&W'^"+[(>"6/!SN;A%_)?]RU.G6YX\ M942L$M0%,F[EGVQ)9N7P9`XP+(+>Y`N*AS4.EB.*J#+2[WRJLPE0;ZQKJO%\ M-YD`A':V&T!7B=P`2L"@0O0!!FJ>J[^Q[2C4:_>J3R'FX-,+B"06E8.PWDW$ MZF*O:_-2U:9@]P%]VU$3CSL[2U;29\/WL5.EMS/1MD9K&V(ZVVL'7P?4PFW!B\95C5&.[WB4QQ9F9.#)S M\P-=ISOLRH/4YFOQ-F=GFH:A34<\9(FLG=7(RQ=,6Q\`..E@!$`9D:>P?IO= M0-G,!P2EHW2&N4'A;]'XL5OF%D2;P7#4304H;;,BP,I&)QD^TLD/%UR+Q]]T M]06C[CISBJ+58`FD](UVAB<;D?JC=DYXO)EGJ*""+S`VI^FDXN&_#4:ZWAR? MS3!EZ'_YH[)MS9GM+NX!/AP%7?B] MS<978']<]@US5Z[!13=?=3@R9X[#"GC'(Z4Z&B;1R;9Q6>`^7QG6^_/YPK5F MS+47ST`B^NF5F4!.S7E^8MK4I!#UYM=95$'^ZVQE$/RFOEBVZEJ`W`5[8P;( MPQBPM6C7=1?`)4>,)R)HQZ>^)5,B[[N\,FGO%-GV1UR[<7TK_?@^*X MV0:UU4#N'=UM1/;O]W*_6U=$,P@PX-<>EH/?>"P:ZMZK.BPBKA:1A)N=7>AA M-^EL;-RS.!@S^M9RO]/;#4;#L#2TQ^F7X,OO^)]9)6*'V*_<2UP2,L%5.BXY MX[1R=P3_MW=L5K]I[\0:>=@]`&LV(I.3-_VV@M'@7;%YQ[-Z9=D7EO?B@HI: MOJP5=967>^VEHY%Y]U(`S^@N]WIR88!';@5W$S`?L(QNOIY;3L;\ZPU$[B1( MO&:[G(!MG3#!;QR%@)6TL;L#)BO]-9`E]\L-6Z8DG33?>`?H3%*Q2Y5VP06.'[.;XK[OYG`*V*(40R*@"J!Z#*Y M33J)H0TC:@;]LIZ_^XDXPDK]RI(^3!,V3)=267;.6,X<"`K/3;)C]+K98'/ MWS,_@/GLR[!;/'BW%O]T`8+7;P^S@!?N6!B`&>]?7;F]&X#.],P.:>J[:]``5.KU8;J=C>%-4;)8]OAET+!33;85'Z"5.R?T"SRJ62E,L# M4733^6YW2@*4O][Z!3Q`-?IW(2JSUU,RP)P.0$&@YU*F)[U14AGD!MR:S727 M$@EP`8`,>,/`V6?.NDS83*+\<_%;K1+&E*U$$.I>M>_L1Q?OW;'JSFW1213E MB2*7=EN.<&'SK@6"F4Z*DL'D]X4+>SBG=I7D3FS;-Y-LE[RX;-'?=N\LCL-UUC MA<0+Y?YHU$]`$-TC\_Z9:OS2,DF4;B'[Y[LV=GL#N53L-P`P["3O76OVOV`O M;IB9^:OJZ,[C')RN\9WYAVKK&'/.UAUG8Y6H$H$HXZXE@?I,_<6`H/C:_L`< MS^$*K[O/03WRYN1YCI=<+%X7S-%L?^'5H M1[LA74XF#&>>LK">`'_]@!G'(HVVF'KO=G\5(EN"4Q9FF=.)-Z,ZW#.JW$5/ M6X?G8>?+VMYU*_\S`S6E&>!N\_VNWB+F`7#+!8([G? MC<*^<<\DD&'*8"%&O#N,)P)'-\BX=3[[V4L$NE9OG'S)02VCY4%^N7W-"1R9 M3@A#ZD[;`I/5G5F&IGT:)4@AP.3L/U4")%G]G'0F*3M!,[:6&;'7 M]@"5)3>Y`2I%=HHGSZ[RDP[1;&Y8"\9^92:;Z!073$^.V4T3\EA.(I*>>>\B M0,YS_2"H1YBM5AC0#XPRXHNOWE#DSB"5NBMW+`S`C.\3NLC<< M(U\2>:!G$[AA4>-Q^,+.Q[$_[&7&90,LNR!U"S@\O3/C3=C"G;6ZTMD!K20T MNV#VP&8JCC6Q,5O2[QF_*WJ][$HT(T2[H%B4,.[&M"+$D/?S]W;F3P&8`!2[ M8D*^Y>%1(3!VQN7=J@`F[U9F/&[9[J[I,/LYA^V*!:UH)X@2P`Z%2X$UG(G+ MXE[1V-EOZ>4'_BOPW58-+(\>S^![.%,"8]C;E#1MN-@,A^WXD]Z&/?,#F/?) MLR,G2GA+@S!?280\2#Q*[Y^"F])51XF"DNT@M"W'N;>MB>X6(7!RIS=*T"O< M(-O.>26IUQYT=]LY7]B_W4W4+Q2'\2:?=3C*N/.UJ8'1^09_Y54EF`_HZ>;K MW5Q,7'!^91/+9OQS3^IWYMSHIF53^R/^_`3B%%^%=T>Z8>X4$Q_?X".4;UB$ M%)W(G81,[Q&!:E`N[RDXD1,9/!^.E6B'"V(5?)Y MF@MO2JO>8HN,4KAJ`V&KQ=M#J;ADWRJ[3MI]K[W1+[O@+^\52_:_-A,]T$", M[]PILX7DFZ^1AX]"RIL3=]F=`"H+MUS:.%DRM!?,PF+U0I@S3-S.LVR\(ZCY M:)VLS"D"4%32I@M*O1A)5]I+UGGUAGEART6]0;M;'&0DPF%584I]=5YA'&P` M,G7GW<'-5W'5V<3L7-#>VVP.-KO`X,J),MRD@..;[@!B/DKVY5WA0S\K:#3$ M:W!:728HI]V@BN)YU*L%XW>;>(;9%]_[RW:7E8$`"YSN]P26\7 MC?[&WAQ)!9(!`+H9%<%\.>D$ANMGW#D?U=O9]^6F?;'VK2%C3Y)D5]7HXGFV MS9BM,&HGS_VJ;5=Y^'F0[;833N=*?SW3KEGKYLF-W')73/N+S)_EH8CB&^QL MVK$H^/(VY^1NM[L*HM0TPN(3&^5^?[!2@%;`8.)L8ZK0\H=G\K9- M>4M(DV!%QZ]NM>MF0,,F`E[#&-Q&7,S%IF%RWKW0+R?:#,`[$E MX"P?`_S87O@`*5L8:/L$A)KT;$> MC750[0>G+>1EJ3E^&1B%]9L7GLW'C66=.[U:ZW1)Z_0VJ9U5NV^&FR>UPA=R MG-GU1.]DH/GJW9S;%P)VSE!^\J@7#'7PWE@P_Z*< M?*[8%EEW+RPG*M?NA>05%8OWMKDYZW:W3`UDY9:KL/C, MCVPN\(986"+*GQ>4.$*!E(M@=3$=HKJ=05R0E[;9!HK\J:X=I3@HRPGSE[K)3G!DG-TGYP(#&['AI#Y^I`(29CLYD9$N?^@:>[Z'ZRBX M(RM&^B8;#'6'O26(5X"3$_#5)VTGR!--,$L`?'4$9">*)WK;[Y/BNT'>4W** MBD@1<9XLX4N4,%JEG7C+W[CG!A"SC??,>[%/W#6S[UX(U/GJ<)1^IQB@8SE1 M?F9IH0-(1HF6#AFV+!#&C-&G_LXP6AIC8TK@QXZ_","=_:@:[&Z2\DJ=5U3E MA`.X>=N=P,PEF[U$R&D7&!^`#5RP[R:Q@&`A]YMVHK-*IIUW!3873;O)-D@% M@HJ]56U=S\LTRPA8[&A9YNL3LV?8L)1F8M"< MG'"462$TE!,]L;^<#E8_&PTSD@W3:^'PYW`"YB=4H?O92<>K[E]B7!GK']0CFP4X9E M@2<\.7MH0\L+@J8#[V>YU&VL!=L(FNZ3N[-R=X@TRJP4V;%@=D MQGBFHB1;SFP+)%XSG`=0`*;'L))CJ5/.]CQ-2[Q*VV8U(/Z0AR0LN3,3>HE0 MYXK-MHV_6.3Q MIY@RE'X"II7;Y0(KMSP-$FY1P7#E"W0DBV?V1:S-CEI.N%([/D>*"7]=+)<: MOJOVF/[Q!T]JX1EW?#P@=]-)L@]SDSOT;`K#VI/[EM+ M;+,$AB^`V2ILMY_=.$IZ\26B4#JQKBQ[PG37L]=/O=V!>C_O$P?^CBU*1+(6 M0VPM``4=H!P8E4[+KTB)K4?"K"!4\@&G/'@/0I/?\VUC)+6_>CTC#:]OG,_$U(2\B%CG9K'K%71*5^-1+4*M#(YF M4_QU(E6.P[>9"KVATH?S5AP92CY8D>7_9#B4A(W/P/"#$^L'4>YM?=T0YZP# M1>78/-$]@5U16JWMB9%&NH'88`;+DX6_ M*D5[%>:4;@G[EA1SMC(=F05N9R=BQ>GM;N-Z%8=;/8B:P>$H0BF61M;"&S?V MAJ-X4N^F3HC%]V8<*8JR/0BY([G=#>-;LM3M0LD(-[3C%-&:J<$ZP>/)- MMSS'6#P_L+EENVGOJ&F@]X<=^/\HS(@$4OF293!A9+WP+; MIVO[/A'I4!2%P#Y.0[D8Y#X)W5&W`N#OXQ2LQ."_?_[^8N.,@/\#4$L#!!0` M```(`(U[94'>9$_]=PT``&ZU```5`!P`;F=N;2TR,#$R,#DS,%]C86PN>&UL M550)``-J(9A0:B&84'5X"P`!!"4.```$.0$``.U=6W/B.A)^WZK]#U[.R\P# MX9+K3$WV%+G,5*J20$%FS^S3*6,$J(ZQ6,DF87_]MHP-OLF6;"XV[--DB+KI MK[O5:K6DSK??/V:FMD"486+=UEIGS9J&+(.,L#6YK3FLKC,#X]KO__S[W[[] MHU[_===_UD;$<&;(LC6#(MU&(^T=VU/MGA+&QI@B;;C4^GB!;&U`QO:[#I]X M_+7+L]99Z^+FK*E-;7O^M=%X?W\_HWPL\X:>&616KWO?=JVSUJK MWYC8^FL(O])`=(O=U@*\/H;4/"-TTF@WF^<-?V!M-?+K!\.AT>_G_MA6X]?+ M\\"8HIE>QQ:S=;*R,N"BECU%-C9T,Z]0$2:%)1S8 M,`NY)5AWW)TCZEI`164B!H4E>]5MAZ+N^,YAV$*,@:O`G,;P-=^Q!0K!NKG^ M[AY%#/Y1]<+\7U%<[\YLIM-E=SS`$PN/P9HP&0R#.#`;K$F/F-C`2,D.D@P+ M2]Y'"V(N@.<]12/,9_``&0Z%.=R94.3J2D%L*6Z%97X"PUD3/#11AS&UD!`G M+2S-/9G-B#6PB?'7'SJE8"@5@1*I"\O4A9A"^\CD:S+$&'OY!IR9;JB&@PP^ M>YHW.YL_6YQ'4<=ZT^''(I[I,]B3CA^0K6-S^RI>\]U'I%('H<)TZSZB+JZ0 MPZYD>T,?MJ.4WV0QVD6\55=D&I/=1E]U6>78;35WO-?9]+M)WO.FC@'Z7=A; M.;BF\-C5S&D5GS.MGD,S7_#]/MP*MR>'T:D^UJ*K_'IW'9C:^KKP_I M;+;J^3FRQ"3JXC'W];[[\OC6^?4X4`FS0:HMQ'VN\S?](T_RG$2\&W]27BM3 MN>S4Y]7GIQ0W3V9#-PW'="L^SR!A2'88BJP1&OG2<^9%RYX>?VQS5LVF5M?\ M\<$?=6NDK8BUI*+I]H6.%$7#4K9:7,YU)@<_W\.\A:W[3:BEC[]-/2 M'=@UH='G524:!#:)$1+2Y#5P0L-NX8.[2P.9-O,_ M<1VHWFQY1>_?O(__?,;Z$)O8AETFW[?Q0#,EY@A1]O@?!Q3J?Z>I#Y'IGF!( MDC4."R9;[C^OSB^NV^WSZ\O6]47[LGUSU0Y('?"9#@T#T*GAW%R=E\>,B29)-6(:JFK8TBM? ML9Z^Y.M=NCV3!Y?:IFDRQDVK`+`:YGV$!(4L$?)J*=(S-Y/NB(R>#ZMG_XMR MVS^XF^L.33Q9G6ZF&S^=Z(@LGP.H9_:KK"G_6&AT?>D0FEH;G M&?:FW(:%!8HZ"G%<./Z(3*R&T;-SJUEN0PM"TRNQC#RQ>T-7:L-+9N#Y0%9C MQ9;>U,<'EMJTTGMD25S5L&:@X/\OW720:-9&AI7/DI)629BK,M"JL9GJ\RJK MA4:/.K6P-6&P\#@SQ]TT/*`Q-K`H*&<3'I'!0C!,O8#P3'E\[BP;D,NE2EX-=80 M?DT(4B'^#Y]2"]WDUX&LEQF%\9836RBB=K`0`(70(: M@6V#0X[#EIF(JE&4[5$TASSW\6..+(8@(KG7EV72,0G*X[!T7J`5J=;V*)DC M:B][IKZZ&P7+T9Q?)Q+/YC22LMH\V;**.*JQ]@;\,[/FGCBV2C:4!U"5Q33\ MN`!<\?'#,!W^KO\'(:-W;)K"13:;M$JFS8U'<>E=:^!;(W*!+94KGB%>GT-7/G=W1U7T"CV"I)UZ677#1"-C;6!1,O,N8P M8"@8S"D!*+L$D*]#`9G(1WM,#,,`D#CO"?%6M>=_>9NXTN7/;\ MT_47!,KWB2U9=W"V(-E9-8JQ'<7H,>)P`JRT#2\MUEYR^VBD&JY&H9Q'H:RY M:"LVKK%\1EJ\=>OV<<3[LD:%OH@*O2'1(KU8I?6J(3740E75)I+IL6Z MNVY?RHQNK5%YOT3E=>DUCX'F:E:*9N=%D=FI??)_VN61IJB]:QC( MI82;:Y]6M#L]@%7K[1H&<57,&A[77<)3Z?H:Q98W>.X%F+`_;!2%C)NMY3U` MA@D)`N1ISWB!1@F7-B*))LB127"(-#E%IL`[L,Z,4!O_-Y1:R0$3,CE(%BUC MA4U*G1=:=H4LG%:W#F/ZC@%[10@'8H@`RTFYN2Y+7@%3JX-2+(ZU]KYURFIR M'0NWL151'&\UC\LNUXFT]M=1V>72VKTL;W*=L*,`E//4F-\E85#VCUK^@H5X%%J/YR&O%, MK,D;HK,'-+3=:>9V$?#VF>*(HL+B!-REL#I4R_HE""HAS,$.(!M.8%`^#]I?-BRK MCKQ%E3T')6]JO!&O7"1\4BN*0M(,RNX-(^U.8;*3]!@)%60'H%(L6W%L?F\HE0@3 MH#E)?\C"G[V)+JDSQ)N^*:\Z&]*3=`U)-4CTVRJ%BVR*2.Z9?.;SG(3!)^`& M"L!]PY<\>PC\;56^G\]X@Y:R0Y`1\01F^[PDES_J4^P>>@*VS\?K& M+7EJ%]^KNF7/32/:U/@O37U&[3G!N?)^?F\/"Q(NYHM>"LK>R]_]:T'! M:XA6PCN(V$MQ\3N(UO\?GNWBX5D@0_(;T(]M1/^-=/H="-009G.KP/NDPABK M<=:D!G%K_G#DKA#S@I(G&#G0$8=NQPM<1L?K!2Z\:MQQ4$?W!E^_G6#@<3I: M/_#P5>..KAJ\/IKI&/)#RFNH#`S'\19V"@'7HW00`5;5O^Q3"6]Q)\,[V4[0 MX'R.TB/6Z#P?^'),+O`*&\JW=V0NT`NQ[&FT;J&NK3C#HW2*.$S?.R[+VA)! MW%)`V!7A.M85(;VUP#XZ(X0JB3U$!U.=HJCH[>9EK.,=LK45H?:)DW[6@%CS MJ'?81&!]MIW0X.LJUH;)U>MZ_.[:2ZR>4C[S8ER"7#B&M5 MU[%:59)W;IRSM=.&'4&-9LVK#/T>?CX)6W6H3*O#-JCZPXVZ:-19(*I/T*LS M&_*D[@&;#K]AQ`5D7<=F$.KY7Q=+6/B4.1SL/((_$%G_P7I7KHYM4SQT;%Y: M?B/N9W?@6B/O-4F'3XT)2OKC3ASY-I@>;-G/:7@_#]@&]FK4&P6*BFF(-X4U MY.>'B+ZJ#J$(<[U3+&L>&$Q)A'$^/3/93ZO$U_ONR^-;Y]?C():AM)KQ8RIW M#7+[A._T)&W=C5RDNW39]J*ZQ#5==$RIMJ3O_K`R+2$19E27\0[7$HE))+_Z MUN!V5!V7`.!Q<3``!:=P$`%0`<`&YG;FTM M,C`Q,C`Y,S!?9&5F+GAM;%54"0`#:B&84&HAF%!U>`L``00E#@``!#D!``#M M'=ERXS;R?:OV'[C.2_+@L3V3:[P[FY*/253E&;LTRO&V!9.0A`T%*`!H2_OU M"_"P*(D'(($"2+-2-9$E'-V-[D8WNM'XUT_+>>@]0/KA)&*G@/D(G?ST[[__[5__.#W]XVITYP7$C^80<\^G$'`8>(\K;S3R;@C& M,`SARAN#Z132;%3OXOR-_._MQ8__]*[)8D71=,:]KZ^_V>AU>IK.<068&%/T MBR=[^^8B^25$^,]+^<^C^-T34&-VN7RD8<`_G,PX7UR>GH=@:OM(7\ZS1K=BJ_.KUX M>_KNXLV2!2>"Q)Z7$)F2$([@Q(NAN.2K!?QPPM!\$4KHX^]F%$X^G.`IGHMA M+MZ>OW]W+@?Y:@2?2/@D6.>:P@#Q`0Z^0#^BB*\&4PJA9)H;R`$*V8DG9_EU M--S`"$,RA9C,D<]BL&6;,YU!SXR@,<2"":;H,80#QB!G^C"7CF`&P"^<^'_> M+R1'[`%<86\S@%V3^9S@>(+?`:4`[T.\JD&:`C.=X.(@,->#-$W-,5SR"(1& MB/HREB&@P0)Q$-Y!H60.`+=J%#.`WO,9I",8RBWL`5"^&@NJ,.#O*55JPYE2 M4#Z9PS%8PKUTTV[G/%B`^JJ0E6PUV=XK]YCO8H!G8@CJ1X_P-$!"84NSX,1+ M)\H#_3(*POQ,-#U+VYP5#M`TU"]3G09D#I`FR+N]CP@OG(`HY'L#G'5O'.*8 M,J=S.'^$5!/:S:Y-0PK"4`^^N$,*E;!JO5\R#O9NX`1A)/6"]_4=PM`;.: M)T+P",/8[:EK?Z:/PZX:E]_\)R$?I&-(YPC'5OY@B=@62-5--Z%9L\N`;L(E M>#,;-V73/35O,L:$DKD2M5(82!T>A`:0"B_T17#."OA_+5(WL0KP/L4J@'F] MS-CA-\/0W*2[I1(\-QM;JPF(;B)X!2>$PD]"`F;C9[$,JR]H.7XFXQF)F%@H ML?3C&:(<0OPIW7UV8=UKF"-C\9%$)K#8'L8H%H,)A_1@)+1':5*C[AJ&>76J M(J15FC23B&U=VA`NFU:8"B*;\OV"REX"TTDDMWDQ1?)MBY#4EK<4QW>*.W]O M3+]R8]H,#B.`I[#`^BGXO3TF=@'PVQJDMZNMB\_>K'=L&`OMJL(6UN#\!)9H M'LTK(=UJ8P]6(3VUL&ZVL6>+EC+KCIYQQB"KX-T\T%OLT!JP-SE#4Z_W5I-U MM=\%JVD3FHH]K*AA^^RH(BPTW97>H&H55UJ#NO#HL[JIN<.VP3QF-L$O(\BX M#&.G#)0MI-LH#I9Q MN8XH%92^(I229[FZ8"%^X2L-U,J'<`K3(98Y\`P.@B"6"Q"^0*RSD-7#.(6Q MS"-%7`K21P@?A"$@/H&ISF94.H(U/&_@(Q]B)A2OA.H*,,2^+,2"!/?X-T"1 MU-:R'KDVNZ9EBFO[-*@]:"KKKK6UVA84*Q1@BLQW M+4.F7G.FB'VO>BR9G9A(3UXF?/='DWT.9>.'<]G=@KQ`-)7TU@N`$PYOYY,= MCBHL>T?EE?-_>K$X"LOU(2M;HF,@"M3&5-72:^G;0O7MME"M>WI)5P?$1]9L M"*)06-`?)9G@'7J"P3:*5:$2G0&LB5L%:%>K3^"_A%Z'@+$*[:$U@A/Y&?HK MFQ=;+7Q=OG+6+7&URLANX+F&\3.8P\JM4WL4BZ?G3S`D"QB,H3_#)"33U4A6 M^&&5QG1M+W/^\1UX)%2V7N4F97P]<7EBBW)7<]!^#,GS]8J3.>1T)2QA^5FH M!LB%:E`!6:^__82D^1RN;EDTK]X!N:M)6E'K:B652P>KO,K56;*U+K*9D MO,U`=C_9GFWPR#@%/B^R(14Z65-'`_^O"%$85!#R=RB-(!@,GB`%4_@K@Y,H MO$.3,C5\V)`.4V(P)Q'>7F'][BYN/0/?C^917&U/@$DY^E\<"-27NM*!7,3Z M,RQ;S;I.[EK#E=OM8:+9!F?@0/0S&74F!VE?5/<146>RDAI`.I;:[4PEUP*W MK\:LZT^H39]06XG[VCYL;%&LN+!*^+98?[\MUG$O+^WF@$BOW75!44C%5GI- MY@O!*DEZF2R$/8W][M\1GPUQ@)Y0$('P=NF'D7P#X8U^4/ M:H]B\-QTAN#D$PR0#\+[R03YD);'W"L:VTO3E##=+J$?<6&O5J&@U,-^HH!M MH'HNS]^JZ6XVW#8NYJ]E: M4A:X&XJJ\Q??^BJ_?95?BY9>7^77G=S.;FCL]FSJO6GIT('@74W:WS$!L))/ M>WP*%V?ENLO\ZPP=R]G`QUNJ?L/I55-#>'03%:MTOYL?3N MBF+G]NF0='TD0\>O&$A4?/%Q3.17]Q%GPLZ5ILCGJ.*4[7C3&WSV5E:H2GA5 MR'$,WOWD6@"#A`<1PR\`E4[%F,B:I`3'_#PCH?A9RO>3P$%TF$D4AUATY,)> M+I*CAB9J+:\=BZG,<(]S-&O"CC(UN^437\O'(TU8_\Y3E. MGQ_PYGZVZTD>(4+LUW_^Y415M7KUU*=.O_HW0URZY)2SFW\'-#Y>*Y6#'[;E(.F&8LE.E';'5QOYE(4W&T]0FSEV;U^;#/,);B]?B MHF"=U*&]9;4?M8;X";+X/>0A]LD"5F9A""&3Y7W5 M0"EI;`ZBV^5"EIC^%<-TBJ`P.3_ILF[-Q@FG;I<2MU+GBDN4$[%;IYZ;[.N\0CZ4#ZO MH0RJ0B>#$*Z'CTG"AHQ%.L!J]6]3MJFNC7)TT7+&&VR"K-I"V\Y[9#K44-`+ M[;SWI44$+7WC^F-CG;2L^P2.AA(XK*17VLF*Z`6UC^]U);YG16QMA(ZZD5B= MBN5%@6!?J$CVBV![%RZ(]O[%'-0.]0\>WUZ1JA@(,4N%4MMJXUB*CJ&UW;AH MOHEPN[*?.R&Z![.E2\>:I0RXQ@`'#R'`M6_S-C-5GR&MDX]2R)IF*@=5+9(S MN1Q-LGO3V=4V4B0ZH8][4ZK!\-;.09^I@-6=Y70(7Y4%)ASOANM!<(':6T%=HZ\8B# MDM[7*!)N'9HCTK34`ZE1_OL\8N,$1&[3-@/6*?)J`N6T1BC=%QHC^-%A;`O] MW:)TBVFJN*_VNQQ8KD<.]CL./(H[ZTR><6N(N%V]WGY2&865"]?9O]S2B0R'/I'66B*ME2LOCF2G MMOKR2W:K;2P&C$!8(/]O]6ZW>>E(+N1O]D6N'+V\:_TB3?_*P&O7$OVE]?[5 M@8.";\(L8'/P0(GP#CB\ECG/=`P9OQ/.`!:ZXJ-0/;]`$/*9E`LB7(;5-:&+ M7P*_O#;MX6.:+!04$EP"0A4.:OT,K@.("^5PY.\!K$9G@Y1=<:EUH9B5#2(N MI$CXE,.Y\"@'&(0KAH2>]6=8T'&Z2H%A]60_?%"S&,XAIRNCZ!TRHOV[=/UK M(\9>&VD74H8TNS-1^?V)H+8U.!-#/V"UU;<59X+>!RSKX5N/,]'JPZAPR`ZU M'7%NS:7?#CJ'_1'2*ZBLW-=)+ZN3;O^.<-OKI'=(%[94NH](H9(2I24(E[9V M!_YZVM"'WIVW:;$&K`0+DUX)Q]JJ)7F'W>$.>GM)=V-2''%ZQ^(EQY-E+2Q M)F4CN1U4Z(G<[U833"IIFY>&',!.9X"XQLZ6V>G8,%9F-&RTL+@!+M$\FE=" MNM7&'JQ".FIAW6QC/UZ\PZP[>L2Y\&@![VZ:`AOLT!JP-SFCS;7O75/KW;!2 M'B@1Z\=7,E$\LV\7B1-;UQLW]6VMF^3:#"3DF[(4]P9C5<6-PEF_#PBTP?EC?-??$#F$+Y7>*_ M)LYU:9;%_@,Z2(7;R03Z'#W!(K@3=UV;$$ICFN/1`<:"^_,`%#%G42MS,,3< MG@L^)R\$%L%1UM*2J::^L55(M_5`NQ(6)B38>D:](4R51-1Z0KTZ'7PRY2"9B;[\1,P7#/Q^NB64G3+2NK#_F&8GNWM'@3V!YSJ!YQ61.L(IXEM MC-+=\QFD(QC&5AT0B(XIP$RXR+)X7NDC].^W!38>QDO'\>*!O/Q(3KU'7X;N MU6KC%Z7;5%ICV=L)E:"LVLXU!G"L^LX>J[VQZVI@[G*6U>L1=(O,;@G+R@VZ MJ*$UJ&^7T(^D4_T;\N&#<$11`&MJZE1WL1^FU&>W,O7B7'"RG,?R*%0O4$L" MDJ]'/?9VT`Z4.Z=.:AO"G>7+WJK8%%_BUEHQ9^YJU^'<:XE62-)87M9S>5>[)&`EU^8KNYBLAI>?%?R?I+$%JX(CEC^BF41 MU>O[.&3TJ&K5:H);C_WM@YKB8KE^__75:^S>[2US>^U$>!KW%EMT^#S$/IG# M,5C"4E&\.-\6Q:23%_=R0.P^P^>![\M8M-#U#Y1@\=%/ZOW?T^N9C-D-<;X% MPCY:A+#*K3IP3'L5461RB`3SBP\QH(A4:)N2MDX<'AM9TPVOJQA9E\^+NR"; MQOGQJ,WCH.#Q0^(1*Q4&QR"T+%#E9YXEO?S?ZI M;R5K;1ZXE*Z+,^>\M;Q6A%#YZK3DR+<+&JZW/@ZG1=V9EH%QK1P/&Z-'7OH/ M9`YGSI$/)DZOFSHCCX<<@>862N'(N:JU-;TIP+FF,$#\&E"Z$A(3OTE7=#M# MJ8?URM`"N@%CD+/?0!@EI?["D#Q+?5""CU)/RS9:(]J\GW\I]'P*#XYO]02P,$%`````@`C7ME03Q,F=Q+ M1@``U<@#`!4`'`!N9VYM+3(P,3(P.3,P7VQA8BYX;6Q55`D``VHAF%!J(9A0 M=7@+``$$)0X```0Y`0``[7WK<^-&DN?WC=C_HW/@)78=!%.W<$*.'$UJ[SSA&FV`7OUCD M-X(_^O[]I_>?_O1O[S^BIS@^_/3AP\O+R_N0MHU$T_=VL'_W3GSMRHH(=T+' M/OOM^T_\+Y[K__Y`_H2(Z'[TEV\RO%X?0N]]$#Y^^/;CQ^\^R(;?\)8_O49N MKO7+=[+MIP]_NUML[">\M]ZY?A1;OIU2439E=)]^_/''#^ROI&GD_A0Q^D5@ M6S'KS%JYD+(%_=<[V>P=_=6[3]^^^^[3^]?(^8;T`4)_#@,/K_$.,0%^BD\' M_)=O(G=_\*C@['=/(=Z52^&%X0=*_\''CW0$Z1?^[1WY"/_"_Q2__@;11E_6 M\X0+XW",/A#%>+2L`V?B60_8^Y#0?!A&OA]I#WSZ(2O?@GZX*.1Y=_Z8XR6( MA)1$R\R7E*D]$99U](((E!,5O\;8=VC/\]]2%A7*QX>,*BUC2MD&=HZA1S4X M"//@_4=_3\!]^O;CC]]]Y-#(;_Y^(WS!U'=F?NS&I[F_"\(]LX#I0Q2'EAU+ M1DQ\SDF3[D,B(B6=AGDYK="6K,F/-;!%BP]V0$S[$+_S>.=R\ET8[!L))L0( M&A#]W7OPSA'EX(0X"HZAC1N-8Q9%T_[E$A$G1RBIM\?^NR^;;_Y=DB++=Q`G M1AEJ])ND_S]_YM_O%Y*<7=C'AH2&.30WI7Y_#DC',+*>,<+V^\?@^8.#W0_4 M5N@/S&C>??PD?2OY50)A2]B>02S^>5PC4(E'=?W\;Z.I=/F'U<-+VXPUEE/R M18=^]=:S'DOD/OO[^*-9*J``J M:0NG"TK!S_6AT!!$)Q12J/6"$TCU8"0PNO$KMD(]S07"UO70^' MU^2SCT&H=@QGK:#<0JFP>:>0:P+@$DJ^KW((K"F2;4>>$8+]/O`W<6#_OGFR M2#>LCC&]5Z`7*VIW5TD$-E=H0#F;."HH(&:16G&44PJC1(QT@C@QRE!WU:F= M%3TP*/)"A2D6]N+DBN5]J=^OZEF^[9/L41&[%P7LSTG&U MK0TLJG--Z$;3O.9"%>>OP(\"SW78_>J5Y=$+2:)_&,=1Q0'\>.HWC2(B2HVB MG3>"4:ER4;/*DV]QKB;C=>JU%3U-?8?^9_:/H_ML>41WHFE\;87AB7B;KY9W M/%]4-J2%&8)&P+(CHT4XNETWD*IHV(2(73^Q'S+D$V3%2')`C,4@]VL'>?JZ M&`KA=/,SFBYO$/MA]I]?YE^GB]ERNYF@&?GMZA;=S];SUS MS_/E#*'449O^@%-RN/EFC8ES=FTR&W9QDHVYP+C+EF"S MCK,AB]%=:"OY"HJ:$R`F.#_'NZ"%+DI`F__+MY/OO/[$IC/SXZ?N/$\(H.F`[=I^Q=WH+ M9UMS_YF@#L(3Z0)%=^6;P-A.F9A96\G^'6Z_=!_B@^4ZL]<#]B-,_.XJ?L(A MW\U5^RLM2IBN;P`J.R(:9*,[,6V9"O8O*)$@99;,B!&G!O=I[:%Q&+:XG[`8 M!?0Y3LWD;H)9U!H`K*KKC/P8JAL'L>553L8:@FXI$V-4]#X,R*X^/MT3&5G0 M+UE8'^BIJGH*K2:!\NOU,/(.7=T>P)/7"5/BPCG)!#$B'DTNR=C"%,YW-P>S M7MW/UMM?V;D//?*YOYLMM^F2U+:/^Z/'#NL=?""+5I?'RM.UZ(^3;S]^R]>B M/TQ^^/X[S5]H[T7NMS$#@OKJ?J03U2J*6K/JS\DK:> M;A"[T]!8?=D*FCM?;J?+S_.KQ0Q--YO9=E.JM-8^"&/WOU.E_?3M#UQE/Z*: MO=/@OJ<+^(0T63<2:O0FH4>2P3"P8AP.-[`I-CY#HR?L.7#N)+,`7A(KK5Q1 M*MK".(Q*P;,>HK0AW.Z72U*YS(-=K*M7Z4#+<]5R=[6=+H1WA%R4MQ!O/&U; MN-:#Z[FQBR.R9&(!,4^!YQ`'1Y=/\:DF%$"?'$9CF\++ZK0N+:"K$&>C]]:) M'J7JG>6?-X8]Q2\7O>S\/M\2KM-G^X,7G#!>8[;&RFA)=?]KT,$,A3:@[*C4 M$H%:17AL,#`5[<%LHQK`F7F4-X:,=SJX=&;$5H17#Y[[R/8?-:-01P05X:0# M)1_:5$4!$--4+TY)H`@C0HP*9+4*+-24/@ MJRIMD?/W55Y*9H0JIV=%^GOD,AIP!5<#4>AZD<"XM6;M4:4&G5$KSNHCS%HB M4]:=YQ(U67JFM(:M/FM!+0+_\2+6GXF)U[LR`QQ7C9N"G(OK)V'PN;?R6'HQ MGU[-%_/M?`9X-DU?:;KQGH5:^\YUX,=D28M]6ZV?E11`_KP>1,Z3JYN/[\/K M9"EYWIA0\,=061HPK]T9AET%8\RWP0UO9\R[CVEV`V/BG4OFT7GEN\U",SCW M4R;NN<_)MH$*ARF7H]0ZR1(JXH_W_^7]QX^?T,$*T3.EF:`WGSY^G'SD_T,1 M?]IO'>.G('3_&SO_&_WI^\FW/_S;Y,>/WS/;_M-WDS]]^F'R;=K8C:(CC9TA M?PS2E`#T&>>&=#;>/^`0??=Q@JB"L%8WV!:__<1^^PDZM*991XHL"%]Y]\T9 M>L#(9<=A#^DM[]YRG;DOUMP92*IK'`U"H/L<;4BYBYU:*C@GN,:QY?K8F5FA M3VPCFJ8Q9S=XY]JN:D;2(81ZG*D+*?\>LXX*;I"*LZ?V,L&L@"ND^N" M1%K&S1BPNZZ$TR1.!G(?7B%0U>8\B6J/"^FE1M^G-X%0V+RSP/;-=G7]UY]7 MBYO9>O.O+,Q]^RO@!"_?>=X&X8UXY5E\2EH3LM&,!]"TWP9H;@70A`%HO$TZ MYZ6/),C/'F8ID7QGFHE#5S[34(?G],0>+)JGU^XY"_[IA3?4CJ]?^95OE7A= MB.2\7?6L!\XGWKJ^&^,%V2XZYT\',EV4[0I%A[9A!&,6[2%G#:`YE]%7(VU% M+&@S9_2.<4(E3V`RW%"6'B?+L%>P(41`B3L[/`FD1 M!IX;%?+FIA,X<4:PT.9*N!U^D`+<;%0B%O9PWA[23\J1%WF'5)S/5(#!D"10)SG?;P#JD^ M>7E9UO))5=IR,)^DC27OE`(3,K#/?3O8XR3'=TV(A;(U5):,2N'SB3%*FXYN M")5R5"=03XA8=L#5`8<$-.(5.H;R\/1&C]C_X@W.'QV;1RI4QLI6P-=Q%4+ MG[N-*V\Z?E;^*CF*;$H:R2:$V% M54X/^490JX4R4?/K@VP+N.79YS"(HOLPV"G#*'(M8+JS1,AL7V;^/+HG*'R[ M8#NL!>)-8"YX-61WI51P7D-/3`Y!Q)-0ED#%R$"72:%_Z& MS-E>P"X7JX>EA@:L+$$]D+,B!&H"P'@W[!&>CT2J.RO\'6?,6+7>JB``6G;7 M0LBMO)6MX0:AX$%UYPECY@>M>6'T-8U"@F(::ME.YMB&6=[HBLN?>`>)T%@T M-V#!P\\E%F295H6)=\OB_%@K8;QQC]R,7W\R'*P=9=VN9VM9YLMBQI>;7^>K9'4YMG?[F?+ MS>PM>H>6,\#]:&I^MT1C^&/.(S'+]/#W"N^"$/-V6^L51W>N'X1N?))]0-9+ M>2X\I/H.QT^!0RN@1/SI9^5Y]4@20-XBC-K)Q9N)43X/=-LQ(K82EY293!$= M>)2*D;U$>6""B&<0B+-'&?X3.2\S*2?$Q9&M>1`ZKF^%)S2/\5XD[2#<2;]X M?";G&&`FQVM9ZA[?1OD*D6$L1B@KC"/E8?/RM;0[HKI?!% MUU)H"N0&%'*H3)8T3RHGO1$4PRR'M6H7-$+`=1Y8RYA20;-Z MG&L`F`M9/'N5T9@UEP/JYD"9CVO$SR4\5K0=W754"U*<<7"9&F8`K3)]E9H\W/TS7@'?@YABLKJ?$[Q*]UE#<,7/2%%0%-DV M5?8)8NUA'L,T$9W]#=%B/JXP6X^9+5FC\C@Y4VRU%H0Y)GGC>L=8&5FL;&V& M69X)7V68HBFX:>;DT#).06&&>5:++_YZ"2:J!03.3'_![N,3?2Q'H%F/>'FD M6916NT(,<3N[0=.OG]'RR]T56>>N;OE2=X-67[:;[71Y,U]^-M]ZJ];# M#7F8;;?*]7,C!L9:;-5ZKZ&Y`B[%^T#+E^@O$K,E,->_8C'-"1F\A%=`$(Y> M]]E:8RY&>9@ZL!H^1L7"%"]3+5]/RP*8VZ9^$,N5S>5YFW9`(=,KB]=DJ]VU M%3W=>L%+7;1[-0E4#L5Z&/ELBNKVXS_BJA6FR8M`R@(Q'D:\"%SBF$IT'P;/ MKH.=J].7B.:024++IC1A,,_Y5ZUV;1B!762UA'QVV]60"V`V/.>_CB(&8!NL M,>TCU\.Y^[IMT(\:#/,IJ!S)PW5;/JMR_]^!4S8F9.0&?DF&2(725)/`#+X. MC.P@5K4??QF;"ASC67PV<:P";+X)C#67B9FUW>S?`5>O.;6X=7V+K(_\1YH90<]YGI.8 MX#K+8:@=9[X]L-LL$Z;6,!,BQ*C,<#*MD-#E!*_(@^PR*".7TU@=6!YJ(G+- MTV)%8\"R&DK1"Z4U"BT!CH'48A13^=#&-'GI%]^-$:="E&S0)[`Z^7P:HWCW M8)'-)M'T/6W*C>`="A@+0-5?8[+1=6UZF$NEK,UQ4-H8++E!A>AG60U*6HZN M^E5BE!1ZEXU1W@J`-;\1B`K-?['"T))5&,,4+$L;"/I:)J2U>F\P_V_F=$A4 MZ:K/&JC-`.Q-34.(9\]L-*GAEKI%&8NU5;2'KXS4E(%3PZH>LB(=Q#,I3:'* MWDPQ$O1&$K\E^]7DC`VE#.#>9+<&]T;2OB4+9(&3@+,DN#!A,&%AJF0A_1+2 MXA'!;@>XCB@BIB\F??(U=4GG&AI3C*P$2+5U90@,,*N"-+KVE"$TQX[JT2@, MR%6C@;22^Q`?+->I2]U11V:*K93#J3:7/(T!%E,FD*[1"%KXI""M0"EL)XB? M<(AL7HU.5+0QR8CDY'IOG>C$./6=%94X69AF2BXVGK"U>)IB?BTZ0F^AJ,$0 M;KFO'T/2.>C&_&";;D$VHWO?IJ*5/H)FP6"2!7HXH3>4"_%<;U&::2SE!!,S MVAWI;(NNIYN?";K-[.8MFB]E]K'E9S2]WLZ_LKJPQ@7!\=0I/03!53(RRBXU M(&O89P47P+@DZR1"K*;V/XXNS:BC%8BA00<4H:0+*!>F5$ZU/#VU?CBL4E MAB9Y3-BE9CQ)BM,S1L9876.HPOQ8I/ZAM%+S):Q2.J].S%^5=%N-F+);4(K6 M=+>0,#)UM]``:7&W,%]^G6U,WRTDH41==PN5C(RR2PW(&O99P<44.ZT54<]> MA;EF0N%2?@:DB>@-/#/?V\7JEPW/-7X[7TZ7UZ;8+\%G8^RP3*EK?!!KAM4N M#1!AS_R*J%6KCO;\P)ZV=.N`LWP3$:'DRZ3 M2+JW*/"1S6C0SK+I[<:)A5I`!FEF0`7^XQ:'^QO\0+=B(N9J@^UC6.5=F[&` M"NAL#C,?YJE/#Q#\V52XDI#0C/4ARN1=3+@@RF:2^;?@AQ;L_G;UX+F//`4Z M/U^0?TZ_!W70T&>?T"ZQ!3*/`H<\Y\LX)%H0GGJ854AKP*YV/*F\AB=3$<+/ MB=605!-B.95QM\;Z"]8F#$S?;W;;9\(-(A60>8OHB>K3,]$L&JV`0Y>6;,A' M,RB&L1D+H`+'+6#FRA\WH!]]9FPN7'&G3(\(^-Q&?LAPF2#.!Y6$:\$<[/6` M5J1*7\^FFQG!,^,_L2,^=F1`2SRQ'V;_^67^=;J8+;>`YP2;X^'@L<0]EB<3 M_\SX+VIS,&F1`CV\:P`K]PQ/@P[RY02OA7-ON:J4VODFL$7DLF*659"C?P=] MAB)K#57VYUDKX$H[>6%+*^SP)G"5=;+?KZBH0W;UM!UX&1T=<6,F[J%$W!'K MH]+03EK5B[BE]*+)=Y(5'RO\55]DCG>(*Z$A M^JJ)II8*:F^C!2:_G:DD`=C!:,A3LFE1'-,A20AE2>WP)%%!_/S-04??H<]& M##F4$YYA%=Y;82S^P>*;(I>B.X\L%*%/SB?5Z4]K=D!G01WAYTZ&6O(:Q#!U M;N0[R5N2EG:_#WR>J8`GL'%8CKSS2%-T$'%P@]AQ9?Q%OX`)!WZR6[8NG,LYK0,@M1)F<7O7.3+%'VFT:DL.[403=N M9'M!1'IABU_C*R+F[T.,0^EG+M"\*KJK-TLK^<9E&9T20'&?FOG,!.4^Q`PQ M9VOE]ABA]'/H-_I!Q+X(MYL=I^N6T^V7]8S6G[KZLIDO9YL-V^]>33?S#?VM MV/A.%VBSG6YG=[/E%MVO9QORW^EVOEH"I@/F3Y/)OOZ>](VMD5.]@@`HEV4M MA%PF2V7K\?-8UHA23`1VW.^M\,2*N;B/OKMS;8M,@BD?)!D9,1=F9"Q"K9OA M=(F![JT:0"\N)Y'%L/GAUGIVK?&^3?D`6.0 MK8!FC;(1@]$-LX5T)3?H9]D*C)@JU'#J)@DM2K"X&UU09^$X=60`P22:,FGH MFV%'!QV@D5W]\O/\:C%#T\UF!ADV>%[OOLYJ*MK#V$HM@*R%*!N/;AJZMJ/IM)X@JOM=GG9?T@P=X.0$ M]G$O#W5[Q<'OJ66^_??#JK/*36NT-T.A2]UT;6-PE:[S;PJ='MI3M]%J32@U M:CWT1--:^M7=W6J)-MO5]5_1+]/U>@KZ.F.-/?I*D\:)G+8$0$3<"8WUJMD[ MUY-!/2'6@Y-_-EQ-`_!46$<@1;2N($:,&F7)C=@6J[#I;X\;<3!+"S6WRPW( MC=%-_3UFA8(:MH_NCG6U_9GL(M:SQ70[NT'WT_7V5[0E'G]#H\A72T"__R6B M3["CV-T3B*H7SN>-8*RI7%1J,(2H1L9!;*'LLX6A_\*SCR9-)OR&^X1^$_\% M5/!6`$!KU&&B+_39[`U^QE[`HLQ%)0/>FTH+UJ`$JUZG"TJJ>D,T<&?=MZ[O MQGCA/A/G634\&G1FG',K`D(WKMB?8$<;)WC,XTU]4+1,#76U3_ M_#AD>^*U&_W.;V?I3PH[J:0`>K55#T+:1@/I![.*:G&+)PR9UH@VFLCK?OX/ ML^RA`[A,]C8*2?SQZE/DI^VZZ>G*OH(":U&M!I).YMO2#646UN,6-FVR- MLF_L3;.&9J"R2$R(*RL\S?(=&2/!HHOT(\P:<(*.-6L,6AI1#V@',ZYV\*HB MSXJ!!S144K(R(/RL/]C7'GU!&1E6OR/%=GZ]3)]ZV71?YGK'&#L-3;4A-VAS M;06^:+*=4(]@MDUA5IEN,4IBPIX'VLR$!4?C++AK#UP'^\,Q?7;UD`!V!&`L MN^6-%T316W0@O1/1+_5X22V>GJQVM>\7CLKB[ET8`5QK=X*WXC+N17@' M$;L\47HC.+X%#PH9J`.B3`=8:0<3_>4L6MC MXC,?7!\[:WS@KSSIC\_8/Y[G+VU,#>"(FH-+O(\^Z;@NIZE2#"!<2O]@3Q(D+8$&69`AIP)C#\9&62//F/N.^ZSZQ"G=.VY]+UWA8=0 MMP7P!W6")]:O:CBNK5=+47*6))LCT7Y0*Z[3[X;2B[_2*='R/%GS7>!P$U[> M"<8EM1\+B4'I;3I88O)XE9^AD[V1?+F:/%S5V%FTX0)@O>W!)G;=G,6X%M]6 MOM:OFD?;2M1YBP&0VRGR2"*WQD=>ZUK&AM[*`0V7(T$FRUY;,;XAHI*]%,M& MKSBV;,;"G!P*=3#E`647?(.=2C8$=*Z8B](WZZ<)DCP098(X%U$R`>+HL2/, MV6Z':5$2C$(*AU\>,&*S+.Z:IE'UXZL@#(,7ZG>L`_F+LBI0,Q;F6%P=S"J+ MT\4WJL55`-*V.,$#)4R0Y&**P35`*<'LK5=W?]R3C;#KV^Z!++JM/3U(8T6Y M\J7TS++$*1-S=8RCF,S5!&P#$RRA- M.K`R?T4/T@Y[W+82>8.0Q2(TJ.4`?J-LP#:=O4&T$D`QA1@G#"`.5<>"M>; MQKZ%`=['(%QGT5RR@N)1%BCAP:OI9;B,YC?JS&L$J!HV-HZ+'!5KKYDA>/Q>21!@5;J3 M>B*('!&Z4-)$$744(V>+T!.G*@:S28JU<2RC!U"%P%*@'!(#((%,>T?V^Z*Z M)4^.0;XX0)?PHV_J M#`Y!3-JX]*:>Q]G2\W!Q">6V>^2B#$/).RR-F^Y:$I"@%"T8F=B4RO9CAZAH M"*.1PM*P110$T#AK*)& MW=AM#R,&U+F:1U$UB?.TJE0V5.UMVJ/5<]B1$9>.N7 M^N5Y>(V)`NZ**Y^4UZ!=9;_``"-XT[7]#=YA6HZ=OK+&?L2+0Z:G1+^X\5/Z M"J)PGJ2Y7^OG(]![NCZ[JKCO&Z*/1M@;]M0I5?M'^0F4_4;V`!:]D*^@]#.3 MLA-;`S::PF>4!CXHVL#H?*F@4F4K)1Q,X\Y%.E<8\7>PJ((^9!Q/$SM:;=VQ M2'_L8?2_[^Z1IC-4OPQF=3UVQ+DQ].;5.Y[GJ#(JT)>KJMS=&KNF9O00615: M`$SS*C0@'CFS0F/)FI=`,&:C]8<"6Y]/HB^TH4![8&CC#!GW%^T M=EZ->$%OL%H`+^ZC.B`>8;O4#&+5KDAMLA/T<#K[,_C61P_W]-55+2F;,#"K M7HL:8IK%MRVVP32V$9CJXBR_T5:&J-Y-L+?<\\FEJB&\*N5%+E.9$ZN.8DIIH$Z&95`T9RG=I`_L&4I4;@0@"B M;(YH>Y00@![K#(T!?!:N.\ZI)X-WDU5P:N;9\8]5-`37+G@VU`$(O;)R8WY( MKW=)K&H-=#E<+7SN4KB\Z?B7P55RE-XI"@)S3B0N`X7616];&'V^@%M@*\)) M_BC^Z+],WO)V$(_G*P1.7\J7-!KY6;Q2@N)3:MHTDVN--QXF=@B'52_"F\J< M9DFSAI.Y_H%^5[%[MZERPG?./*\:2-ALR$YB> M]FD*&U-A#ZP=4,Z'=L+V:!]3WR=S73996IF<9:T`K$0M;&(HQ2;CVHKJ^X5! MY0WSF?1`=%!;XN%%K37NIKTK\_BQQ'[#F'B9)N2>\!+;O<'\OW-?%!Z([JT3 M/9^?^@Z[H%H1N[9H_8"%:SW0=$\NCI2CP'FA-Y+K6P)3UIN(D.#,,C;PRZ^$ M.P-W1)52+'%\;45/]V'P[#K8N3I]B6AP M^*WK6[Y-\$YI*LHJN(0!HAR09$%O?]Y0+@3U6Y0P0BFG<0/?^T,ZVZ+KZ>9G M=+]>?9W?S&[0U:_H=KZ<+J_GR\^(5D/_.M_.9X6"Z,.><&H_=BD<%.J5%K/RD@,62@Z;0[5M8UDW_X\6Z/I9C/;CN=KI*!G$^1UI:3GZX`D3 M7DS9H_?U;'_P@A/&XO`]L_:H%ES2O9.11AE*\"%H"XJ,1G@D6.Q,O":$]E,A M&@MMT@"TQ8!?:;_CR)"5Z]1Q7*H#EG=ON60A=VT=W#0;#7WII,*3$")*21?G M@G:"LB_;P,:G!V`'0OF.`+,Y[>B#L\:Q16M(R?4;T:'C_L@,_@;O7-M55Y_@ MA&FQT3<96B2(WT*-36M<61`.;SGZH##=>0H\!X?1[!]'-SZI"@MF&OXKXDT+ M6:GNK<&<6.U>3AO)EG+B[QX3/)@1C.^O/"]X(5M-?!N$-\'Q(=X=/;G"6&,; MN\\:*Q+)`^V"$$DNZ7%+R@=^END#KL059G!9N3YP9!_(\Q6()4'J`@Y$4IPK^R#C/=+^4]0\@4V M(6>_,4'R*^0G^IT):Y)\:O0^RLQ=/$_;EX=4-639P$2IU;(8@X M@HBG]7.'`U#=]U&\VFUP^.S:RK,MVH@5#1;-X+I91]C59HM6MV@]^SI;?IF- MWJ.?L8]#RZ.&[>Q=WZ5G4#3@;L87R`JI!14WUAP=$H10G=X=CY6C&W]A@SV/ MGN#ZSIT5_H[I.7VU[(*`R9Z00`]#TD`<7\P]\F6'"^"J.J*@#=" M;Q;LK-6DM:06@MD6S9?7J[L90;#:;,#V'[K=[8KN9D?;HRM%=IVB$#+;!*HS M&XK)\M**=16S.@RVGB++.QMC)[H-@_T:'\1;9/J\B_A@UR9K17K5I7^U)?DA M&MZ`WJ0L">:W*.7*;OHFXUWJ:0QBWUV1`6L30M"AI6M,NM-9A=35KW:56]W\ M&$I21/9(E)@J[VRXC6_#@6H$+(6RHX>_:2(C:H-)EB:Z&:0#AB;(QVPMFWE8 MFYQ=`MSM\9@/>I17%\E"V\!=[>G+>1A*SLHUGOOHNSO7IKMFOM6G130#S[6) M+=,@Z2M/?3*:(48I-9+DZ#?*`#$.HU]S]P/PR]W==/TKW15MYI^7\]OY]72Y M1=/KZ]67Y9:&)]RO%O/K,8,3DO,1G3H0XQ3DT#FVTI(6YNHU9:>\\"/0%>5\>C5?L#@<-%W>H,UV=?W7GU>+F]EZ0U#^YY?Y]E?( MD4MO]QL,5TIDU@#I@UD1%[2=K>]09GP,N`"I$=M0$VF.PP0C2&(HQ:E&G9=- M(T4E@0%=WQC$_6P]91/P[&_WL^4&0.L5@8\)DG1+5(.E--131'IFXGI3?@:, M5V_@6>3G[6+URP;=KE=W*!U8@,!/=?QR`DQ$#=06[1#!RI)#?B@%$P/&L3/2 MZR>:V"UBH=A\L4G70%XV+H?L&W\RQ3II'&74GW4F["[".IN#/[?.^?+K;`-M MG9OCX>#)(EGT$,H+7F;\%W5XLJ1\5%D)3$EMP-!U`??E_GXQNYLMM],%NIEO MKA>KS9?UC&Y>DW$D(WB[6M\1#[M:`D0O1=@*[2<::,[+%U-8U9)2*;C,W*(E\6"6H!*Q_!`MB?P"?KJC*_7UE_5Z1L\J2P_5QM/@8CQT MC1I7$<#H272EYQ^M7AV3Q]L[_:B7T0>Y\? MJ1-,5#0&>$1?*WKREE[9_//5#+_+7OKOO%0)@RN4;_!#/?>(S&-QL'H%-S/*S8=)SI!\>,?W=FIY? MW%FO[OZX5\Q(71A"53KHV@5I;8.^L`\VXW4"6XQ,>J!1=9+;))^[8X(X2Y3R M9+]'C.L$";X0\V:OO<"3T>PL-Q0QD.C9\HX8'8C03_1/P8'%?^S+\9I@Z[SH MN?N,RX"[?BMSU^)IFL4WZ(AZHV_1`P!VKP>YJ>DG7)76SUF;9?WM^D+;`91# MAJBO0`]W:'QA]L6../!A:?*36!_5R6L;3M"U%1J#+E96:(UV,,-N!Z^JJH+D MDWO.)<\N11D%Z"/+?E#/HMC=LR6*E86*RT_+1SS(M/]Q=$/L5-3*_06[CT\4 M-NDHXJ6^1'AW]!;N3E4.I1M+H&/1'KHA.3WM$?]PAZS=`!>?;7)V2)2#]\KK M0$^09(H$5\39(LH7Y-BVWWXHP,LYMO)3D`XG8;(L+G^=63F=:K0'.`_3`9`< MB54U'O=4K%X2537*2#SL-6!RZXR$O_"E#]KVK-0"?3Z#'@(K=.@/#C$KFRCR M,(\0:D_-^@$6/^$L./K/(D#`,[4*MU6R2EEC6A?&P>%J=^M&MN7]BBU5/99> M.,-,YCUVBIS3!^B-P:;V?N"?&X>8V!>JB;UL!3]!"7=J,)P_HA^`F.J'Z9<< M0FJEE^(,EL0;;E^P]XSO`C]^4E6CZ3#KA=0F6?`:\G0$K$!MBMRG$?LR5\B/F M&IAOI&KDQ&C^=%&V23ZO.CYKS>UB[#,+OH.%EJ$VR48%S#ZME+*\$#M5H"HMZ#)4SNQ0[S4)O;Z9EF`VR4@&R1R.E'"_#1A78B>W\<%$F2MKV M9Z*,V<68:`9Z!Q,MP6R2B7*0?9KH4%G[^C?1-X M"<9:V@GM++82O2%F>PZW']NU*-=+LN"Z;M@^X1`S5$8:\^TQ/H:X#%?U2Z%N M+(TS9^UNT+#GQO@A#%H'<%.+7N)89=:9:R%T9Y%/PV:=&:!S^@_^4E61MZ*G MV2L.;3?"=^S:NNQJO*P51-5XI;!IM?A"DY&KQ"N^7WSP1G,6R);H-]X6J":\ M@3+75X!O)#06+?NL54T9>SB*B*/2LR!%8R!#JA0]9T^E+<=MJ>S MB$%69C@$+:-KA8%FG!W*!GFQ%.RL_$P-"AF9I4)10P1DDUI01,DB<%LMC,D.%-M+7J8&8U<1FF93;I7&RZO'*-OSHWH(2R[ M!<#4R!L0CVSOC26K+&0DZAC):&>S_,"04('\0V^0N&?(U7#JUV_T]+Y0E,?& MSG6F0.J4RO7(LK)=G=(F][Q,PI3([:S8`\DH+1YYXT:V%T1D4Q_5G&L-_$V@ M-XMC=&3RNG','ASLZ&SH+BN\F*3,WCU0;BC[193Y),U^F6TG/HO8=R=(?'F" M,D53,Q\'/FX;NT.[OF"Y`#?'\V2G3\\C5G%]^V3YHL_X6[3S/+-]>[[68ER8 M,^S8W9W]8T_];)[+;-^Q`WA1D1$_(PUBXJ"8R)/Z6"X22I)-OY%2C5Y'S9"N M%_Y6+)3AO.F=]5]!N"5?B58[FIE#U*.-3QMLTVLGFGCYU56]A-&FAO%=#<%) ME],2U6">0A_&N98Q2L1(Z>S-TL;(.L#$:E-ZLMHA'`HK':/T\":@S\K::Z*D M-U87\P`;:&,Y,DA]3*!TT$C.`U`GTS0G/!T]SU=$RVJN\2$(>=H36G'\ZG1M MQ?@Q"$\5OK(U-^C$/:W`%Y/W=$(]W"JL-R0X#>A"RO) M$MS]GH,7@M5YW7HR&.75A2.UM"F.P=110_!B`9>"KJ54G;RHXCIC)HO>WEHV M37]\6OD5<0%5K0&N*NJ%3RXFU$W'O8:HDZ,86R4)D*1`A`0V.*`QB,]6Z-HT ML:']'C@FH$/_[V3_!WZO40$LY^'J&$RLD>3\C^@A",/@!>J>KD5?!YF^MEASP&LWGG[\K`29 M8KVD:`M4*Z)*\*1,A([$@RV'5"(68SIRJ?755S>=(K$RV>:GCR%F)X7W9)8Z MOR*H;PX2?54K?B;N2MEV[(BK&D'J-"&A08P(*,:J+0A1IL!*0!P&`Z$1;M4O M"D"/?1\&!QS&IWN/5EKGAU<'?NQ/#Z8JSG"T*&&\>0-0TK>W0#.8I]<3_US% M)-4$,;KD)/'`LZ)32O"C%24R*EWEZ8H6I6':5@15JVUJ-.-K6T[\5MH&?FJ] M<'V\VEV'V'&3'2O/R$>6RU=LJ<]+YI*_Q2?50K4A$ZAJ9VV@IA70NF`<;LW; M%%2Q4IK/#J$YB^0,2&:>I)NFA`V2?&#JIW5$.GVV7(_E#+8YUB/+.BG^(0]? M($N^L+J+JP@* ME)(@3@-VAMH.":W0'(0Q^LIB]M"=93]1W_!F\_7N+8I3<"I4XUD*BZ.Y#B(V M&?,WP$EU=X695)/`V(@.#&D@3>0?S#IJ!#Y7*![:1=OSQ8]\KY[00-A%0PRW MF&Q&=\0@QJ1>>+JQ$(GKCTKJHK(:L3!N+P2 M*I`::23JT`UF0LW@-$L206,$>,0,XP&^EZW`FB)=6OOJ?6UC+L;I:158#5W5 M00FAKPI831.;9#66,AHD"$&\M68'D/@/#3OSI`HN_HC3Q]61]U:O2 M((OFY*96GB)1?3B(HC([VG"A?LP>'8=[%R=OD044[)!F]*"K_P)@[BS M5\6JI)^BCQ.3C['L,?QSB'Z/_I&E>)"?I&MH^E'D^ND^%:7?!7SH"=^-8=*- M-(&-R[OQC4<^^);^F?[2IIUYR'3FFR/OS; MNM`&*`%&F:"Y)!?9!N,GLBA^O33=@6@F:O%!96%J+&_?Z5H$6WI#,8_Q7IF6 MI=@.5OL*`I=I8-((3`O/)*C61':?Q5K#JV,#P0=2R?1A/ZW=>%2&'#:@@U79 M6D!E*JPD`E/I&HDJ5?Q-)@6%H'X[]+(DQF%-/J`+!=;$G#M@`]RJKNDS]8H[ M@,S?83:;!0'E;E(IV6#;Q:PHA3J5]&_@9^I,BLJ`@%P+P!$MO^BOD&[8455> M>XMQ!8_$NK->W?UQ7SFV9VV@WJ:7")J^/Z^0<+`1/A>I^(Z<_1TT(*.KC"-J MHNO7:V*^#9`FE@F::&*5A,-IXIE(A5'F?X?5Q(XR=MB:L'L`D?TFJ29?MNQ2 M-`38?%2*G.PV2EN-N[VH$*$8Z\4N4D1C]!MMCEA[F/>^C43?KJ[_BE;WV_EJ MN8'9$S3OZ8`W-B_?9ZN$G69FW&R6,M.0G)<522OS)MKID6+?&6Z8;$^!Y^`P MXKEXED&,Y?WN*N21IBH'WP,_Z"PW+3N@F.>F(_+AU+4#U*I<-UEN_RKS.%&& MDR04`P5A$D#-#O01X/34=U_(3'[B"@[PN<&BY#V%3$68GG0E#RM4QT?-V9CS M^D<';M7[GR8X![/4%L"TWP!)/KFTQRDK4YX!-82;Y!5U?>0)Z&>O@)!M'7K< M]L@O.E+B:^M0MK`L;P>PZ:D2.-GSE#4:=\NCED`YZ$Z:YNBZ.,;C[!]:B9U5 MS<(^8I1=6F>Q>[2H*>E@!SM3WUGC**:E`;E+2'(-J'.,:9,"V%U#6(DI:M*- M:YV-A"I)-\2HV=,A22]GJ#11!VB:LOX`AA*@F(>L3$IMV'QF`V*4'/J,?5CC MY\`CX[;%X=[U^1Z[>/=9W13`[FO$3NQHX&MU2 M_#AM/K#"ECZ'JFMLAM(6'S=5MP17W*P8FJJKN"D&4][&$/I4WYLCOL*[(,1W M1&N>MB]$]M/&?=V^!-NGX!@1OT]FCNV3&\88^^HU62LV`"K?`6YB#"UXC&LF MK04L)DYCICBSO.SN8QEQ@_$M+L%GWTI#%Z-ZEE7REVF=13I?D6_J&;IIG&18? M9&KPDINM]`G!+::/ZFW:.8^J*I.-.)AS#5L#LNH&5A/=J)>O:CC:]ZXI"T1X MH)2)*3>N^AAE,&GF^`SM,)[0_`X*4`:97&46!VUJ0TVM/(=#2U1P)J9,#VYXXL5+RR;IZO80M60T M`*0592H:CUQ7IE:2$I5G))D+4DXD2NK"%)FY#!CUI6?:XTBK&>RMF):L/-'I MC]`9MMPLRYNAT=Z<^:V03T/E94LE'W4.DZ)JSEJJ'!OC*4Q>_(H7Q64-851$ M+;+4C7I9!U.*4N$*\_RY%@"_/\X+79FXL[RI"8I0GH)31]Z1E$&93+.@#N#/ MELM3QISII`"D:DI1(AAU6LF*K#VU+-1)<\:L?_`0S_TH#MDR[,J* MW&AS"+'EK/RO5NC2V6]MQ:KEB38U5#V$1N#2N@BM4`VF&0YT.LAI)]==>/N#0#GB4UK+P]$:/V/_B#\'@1,ML?(-=FE3 MH`>P%6(G;ULUY!W,4A0"%EZDTF9(M)L@UG)"<\."/"_M6>9.>?(/-*'P%Q^+ M7-R..MY!W18D!WZUX)F,]^4-Q\YO7R5%269TUAQEVD-7N6\&0+Z0GB`LH`0A M.J;$,._9!AR%+BERRA-%I`^"KDYIDWOK1'\U?;%"9TEF2C;;\9?IZ5089>JE M_X+I$W7L3$GG6(\XE[2_K(\@I8%(]@/>^6E&(3!11DY;!(RS.-'2K[U[8*]7 MLR*AC$PTLWFVG9`+,<$0D4PD;I$9+C+"H8QT2(J'A'PH7]$#*+V1D2.">$_; MV1&Q\B,29=H=Q(A8;$1\N@?@(X+YB+B9$0DR(_(B1\02(X)S94E@9BKC1J1& M;U$ZX:=97=(/TKV9S29.]-TG%G?W:6Y\9AKG/;WM[GT0'ELC$B724 M0="?3`<5Q[`)=02LK2;5J,NLRB6D*5VXC!%1+S"3 M;'4.>R-'IFZ:91\HEJ`U8TT"T6&J&G*&+R^DV$:M,!H*]0=99+0:BD'7&8TD MNORE1@NXXZ\V$B'_7UQP]#9"0ZXY<':$()<=$/-H'R-4M_:0_RRL/LPZ^[X- MPAUVXR,9NJGOL#-\QG2XJ79T&4V<>8$&:LC3\TX"&C8O@Z`?_:0](S-[HYV1 M^N+G;8-&<,"3^=W9".+\"%[TO&[&"-9/\^S6V^Q)7O,R8^8[ZE>+1HCUQYC* MVPZ'`7??B4P7/V&W`VSR;3@BL@J7_X>9E/LN3'=-I7WA,+_-*"'<2>-`4KOT!K9 M8,;>!$KAWE?0(DG,3@M4%@UA@%W0\5*`N74=?J4_]WFO_=7RCGBUD[9;ML@J M-`'8KBK$3+:.9W\?=QM7^O'"<+)6]$F:;`>R8FXHZPMO![/Q:B+K*NW7/I/$ M2I[S*#H6EJNE+0",HUS(Q#;R?Q[7-,J^K5XX\%8@=F&,H+56H27I,O@I8[X1 MBTF-75-9Y[AZ! M!Y[PCH,E7ZG(=7?6!D:_2P65.EHIX6!Z=BY2P8FR(:8-P%/:M3>$%*3OW!-X M2VN/*U/B#?,I0P^R.W2;]A%V#_T%=WC=KH.J+`D\&V#K8^9%3\K^NR1/E^VP\9V;\J%6MV[\D7>CCQ^M&#LC^K*JWDSN93J] M3C/6@2D?`(SGT"I$^,,XN-IN'M#A:??O)3G`J@X=WR%6/`O[@[C()OV=<9FM M7_H8ZS`SZ][EL223[;B?_L,X2&6WCK,!+N_/2W*(91T(NNTE;9D<@^QW^0WY MS!_3!>KT<-L'%SUVRB:VPO@BNF7(E(WWGA7MK?LP()^+\;5%?%JXQ5$LZN,;AZ3H(#S\[MCH_>7>>`*%)?75$$L;4E>&X(4_]2%M0 M:,X62;Z(,T:4,Y*L$>6-.'.4<$>4/2+\8>B'[9B#[!B;=TQ, M.\:3'4/-%CWQCG&2CK%IQSPY=I\1EM>!%_@*<%4N4(\.P,TU`92X,AVB<=V5 MOD0E]9L):97!0;N<(;&!NXW.X"H<0K^F?T\^%&("Q&YA_PV((=8Z3:&EBQI= MRI%7+\W$*LXZ";W)CF$8HSF+ZU,*I M;WFGR(VVV'[RB0=[/`DL4?TBHCM3B!5&7UV1+C^Z*^3.T7<(XK&,LV3%QVC&>[)BA7.0>Q^&I5__8 MA2.0<^S>"3G/V)[=^&ZQJZRE*LZ8-C/\G3$.T90>,<@5#M@E\$[PR<6[.^RX MMN6M=CORJ;#"OZD;0[BN.M%3KZ1J.;+#J1:CJ":T/1($2%!`VT,K#'N!(>`4 M,'GAANW^+EE0:4X7?DE'',IK?+2\Z4,4AY9]7@BZOCE$UM!Z\=-LGNJV(V?9 MK!-$D7E'D*`W@N@M^DW2`5ED6R0\PV,Q,`0*+Q/\E7.DG#'6!+;JI M\Z)-HW_,6ZV5=\@`RS2>[4!\"2@KW!@]E5N3X7!O0K6:5&J;[N0?\6HGTF$+ MESKW9Y;]-/5]E_1>9(6GTCWSF)^_I.HS[;NW>Y69YM^^D&HR;8$-D*(EX[2$ M+#2MG)`F.1(BJRXJ$,I(=%GE1_KK\:P/?"95[ M%,H7I,J'J?)9J41]WM*U[TB>+3M[W%I>966XSUS43%+;73W,&,IO7,K,4`-@ MB!E`II[/WP(`%5$9N_MR[IQ27YP[;Z4QNF[[G_^IU&]+E8FRMUW2<4.F:.YX M-OV53>C\+3^VR8_;@/YJ\.?MC3]_84<3+;NWK[NFMOUJWI%&\XX<\E:*BR&3 M>S!!Z%T-_?5XK]X'OJ[JTM7'P\%CWZ#A.<))EN\9+L=%CN4+_S!.;W#O=KEN M;&Q_]0=Q25K==GGWY_JHA[@[[^OK%^^D>KTS'Z97+\&A#7!7WLK-7>(M^6"] M/,M=BA?"I\:L)81]*W2#^Q`_N\$Q\DYK?`A"@J3TA8`^&53E'STX:4&?9CB& M,_AZP8OE=SC)!*5$2%*!O3'J"*81%HB26S=XA\-0Z3%^<>.G.?$(SZYSM+S9 MJ^T=J7LHN!&:I_$^B.(0QV[(?8TH%'MUVKHQ_5+*AK0EOR48RS^O5\O+7,&A MBX29VS/GSLI\B4;V%\&5K+Y[9-H\`20@3 MNF!C*.BG4YZ,AOZ)%A-2"@5>EPUDB-4EX.#$@7&4T-TOW9\I_3Z84P/LZ'-7 ME7B"J\`_"M\2!H0'\STL3H>T5[D5Z`I_!92TZ];8XSFQG]S#-ICYL1N?*HOW M->8"8YXMP4JKZHAR,&-H#NMOV6T/B^`/M,Q;U-2<'%.`/^A2 MKM#%HRW>E'U[N?A0V'@4]^M/EKME5X_421 MS_UL"]>WW8.'J\['.O*$,>->.D):9J\],)BQ=85\;C^$'TJ;HSQ'%(2(\Z0Q MW[EF@BW\H]A[.R6`\PN[6LD'OZDK$U5]19=I;T0QT(<`7ED-VF7).ZM! MOC+N2ZL!(91L_NBWQ(,I\C6^H:-'G;D/(O%%>L8I4G)D/\H>T]+/,L+$(,6G M0=Y;`70B?T*DS$HRSJ,K>-Q4!^R<\AQ2Y;$S^5PRRH.E\MB)\MC\TX`OKZ8> M8XZ=\N`^^GC"CU2G`;K$,(N49M#D2J0=IL&6&]H@SO4V('PU<;6<4%S+9TF!:@-=%AZ-*D!=`5DM)4U`7088R=(@0(D8Y M9-JN6OWO""C.`-H10(\,$*]\#).#NE]`DQPBN$7NW">>!6^M5UKEU`NB8XAI MKNPK\LG?%4O;:A*8!:T.#+F,;2+_8(O7&H'/M8@W1Z0]2@G0;Y0$,1J0>)&F M();7J[L9VD[_-ML8I?&*\@E:%,;H>UD1!<4@J:0?4]LSXJJ5'4<=$_8K5CV) M/%BG@D95:X"53KWPR1I'W73=Q_6 M*UTRU$9QW7YS)4FV,$>J300OCI_7P[7:#%;+HI MGBF,;W+:O'C=;K=8@=-[ZVPO"T"T)6,V%/`Z@4IR"5%$`/%NM! M)(\3]:4?[!2D6MS"HT/K%?'F*-M^@C@%Q'E?,P"WF$:`\-0`$8V#1FZRC813 M_(7KTX@8!D/.D+/7@\MC56Z(F*I*/%J4,(;0`)0TB!9H!C,,/?'/]8M2L8`S M;B22D#Y/DJ2(TD)82CM$4S+1."+[[!HSFW$DO.ECB/E;JKT5'T.V/BL!=P') M#Y>!S[.>T>UF?)K[41RR*3:Z#<(==@DZW'M!4\V/7EBJPT9=V3G#8>,^A"AA MH25D@VR;X-)<4D&,WCJ_>]V,SJ)<2'F-GG`.4(6#2"82>"(N&\H(AS+2F9;0 MT\P!J>DDLDD@1NUY%U?M8U`%[E3+R2>-1;IIS!78S2CP+J/`+W)L+#$V^5*E MPP0LJ5;3@Z\F!DCT2S[]3NDK)EEG<5'9?=OVZ"],1XF2*8UZ_&0J9/,_C2(< M1_3>B'>`YP4O5$#%8EV+$C9]B0:H\[PC#=`,9N)ZXBLS?="C)4XW00DE2D@A M3*P=HE1X2[:B?ADY$FE,D%J47X_7%TL<\WB(11!%\I&51AB1'AW`D4?.3KT-5N9H6^ZS\FW5%Y@]$3;Z`G>WUV3/*B;X@>&6S6ZZL+ M"L>N&;XH98PD9T1'`F5XL\`EP3VU),B;F:&Z)E.7(E\9$31^.Z2WIS>8_W?N MK^(G')*E-H$=TI4W6S\H?(`V-5A<=Q-PF1CO-J@&LU1]&"61IHP"O9&T;^EK M<$:.4GJQ?.W7U'[DH'S\2"]>5*;6'ML;2?J6+%`%3((M8-BL`B#Q\X)\G_R; M_(O\0#?/Y!__%U!+`P04````"`"->V5!!%M5C)DH``"XNP(`%0`<`&YG;FTM M,C`Q,C`Y,S!?<')E+GAM;%54"0`#:B&84&HAF%!U>`L``00E#@``!#D!``#M M75ESXS:V?K]5]S_P]KQD'NSV[NY4.Z;LLEJY/,4XHF(0D3BE2XV-;\ M^@MPD;@`(,!%`"&_)&X;`''.^0`<')SEIW^\+QWC%?@!]-R?/QT?'GTR@&MY M-G3G/W^*@@,SL"#\](___>__^NE_#@Y^OYH\&+9G14O@AH;E`S,$MO$&PX5Q M[7M!,(,^,%[6Q@2^@M!X]F;AFXE^DXYOG!\>'QZ??3D\,A9AN/KQ\^>WM[=# M'[<-TJ:'EK<\.$B_=F4&:'34+_[LR>%Q\A<'NG^^H#\9:.IN\/.GW%CO+[YS MZ/GSSR='1Z>?LX:?DI8_O@>PT/KM-&M[_/GW;P_/U@(LS0/H!J'I6MM>>!A2 MO^.O7[]^CO^*F@;PQR#N_^!99A@SLW9>!K4%_M=!UNP`_^K@^.3@]/CP/;`_ M(1X8QD^^YX`)F!GQ!'X,UROP\Z<`+E<.GGC\NX4/9C]_MV'D\(HFZX`"&T3*?II$J#M)[A2#`/U/ M%(7-/]&>[]%R:?KK\>P9SETX0])$B\&RO`BM!G?^Y#G0@D!(#IP#MI[Y!+QZ MSBL:\]H'-L0K^!E8D8_6\&CN@YA7`M/F&JWUG.^1X-PY?''`*`C$MH1JU]:S MN?:62\]]#CWKS]],WT>"$ID0L7?K.8W1GN)/@(//9+3'A.LI&CDP+='MH&:< M':V;WM9/A^NH#*RIB7YL@\QL@!WQ^`:$)G2Z9_%FW%WL5.)$B`S:.4;$ITL= MH:^Y3<%[&`GI-W4#];'?BC.2-4B_NZ_X7/F&ZU1WO#:#Q9WCO355'7/]^Y"W M\.;*&*.OE7/$'P!/SG!;HBB5P"R/T[ M6!V(ZO%*_#Z5[]9>FN8*AJ;S`,Q`#/_%?CV@J@'J68-TRZGFB&>-T@_6Q<\' M]C"=(K^!EDCJW7[/?;P>?[N=CGZ_?1;99O.].MCW,<^GYGL3Y9G4N1\\"9^5 MS%%ZQ;SX^N0:+9WS*F?R>4!3+$P>M06N#>QL^GCTMG;/='P8XJ&.CHP#(VN? M_]%T;2/I;.1[QW-&LW8\JS!1!]N4/;^.S?@W?["F-WH)0A_ID-E`COD"G&0D MSGZ?A::8LC*V;0?`.IQ[KY]M`#_C6>,?XND?'!VGENV_H5]MYC%%PY;F6?[S M'Q>G9Y7Y\>79^<79U\NSG(SS(M^Y!=G:_I6-C;ZL2+WHC$^;?%Y%=MM M#ZP%=#:0F?G>4HB!Z2P\3FH\WP;^SY\NCCX948`FZ<6;ZA;@?4IBA&9FX]G= M.>:<((K"WX`C+E`SJKO?3 MY[)5IS=;3\F9K&C<.3[&YIW-"QCZ^=IS`\^!=NP5F?8UDL[&#]]=,[(A^LO? MQ>P\>#D)D$57'Q"=,X`N9O9#PBLJ'3$1K\!_\0(0MY4C MZ"??6P$_7#\Y9K+Q_!7!%6;:(Z")G=5%.1!P"+.*`&$*Z9K*T/!0?CM'%-^^ M6TZ$+SN_>)[]!AV'@@N>KGK@HS&E=*/ST'`2>]&DU'NNE=BB*,`@MM4#"?RD MT?7DH8D^<_5EZ`1Z")=!"^/!0DRSM'UN\%IZ#*`WP"1BN:_1!WN[*H:.IIMB*8'UTAAP;MIL@/U:J?90#2"M! M,W'#2;P^8,G[@(U?'#A/8J)JE8C:?BJ#AE/*5:0TH[J?Z^GV>#J1OL_4[RHJ MPZ'C/:37JP9903F7M'EXRR4,8Z]XQ,-K+XZ-`:Y%1P2CA^X($25=GQN*L.8Z M(%VU8Y`T4UK;WWOD@R3WK/^KZ43EQSU:,^4`TU[ M-]6WT&\R;#H$$?9PPTN: M0RB8``L@#KPXX!&$U\RG%E:784)"F")]''7NW5=$I.>OZ0Y]^2;#E&\M!?K8 MMI]\L#*A??N^`FX`T.Z6"YCC>&V;ZG>??>-%+.(N[(^49#%C(')?J8`W[!Q>B??&]_, MM1BR5.O(Z"._AI1$?LE!Y\Y3]\FZI*_4]D,6MAA1^MRO?P$N(MS!IDY["=TX M:WX(7T'*!MH*9_=2#@ABTB5L!0WHU>R85J^=S&#(R)3-IL[LS6H@ M'C$HW=:OT`V!;A&AM!X^DOA(8M2>')IB4RB039%VHO/*+<)=0JOPJ/3+CC7I_:T2W?Q:+DT_352$^#9/B'7Y M@E+;#>ZDO,&E`^&]+#>4L1W+V`PF+WU8CJ2Z>NZ,#E)\2UCBJ=M*^#HKMT'4 M"ZW@8=*<2$W6\@2\>LXKHCK)#H,3"P(KPB^6H[D/0#X@?KN03\L+>3.*D0P3 MZRG90,9V)$EI?[+<-W>FA;.CU-?A9761LI*M!;`C!\V*,#>>QY[]!ATG=I(HDK"=;,WB%1Q#DCV` M,J^Z=F!DI/4H)3F\@XVQ0F@*\KQ M.8IN,,@1?NL;$*;?S]H?A+,1I8H;@!K$% M[7@`S;,<\N[$)?Q$NDO;SYNOB6U5<1%"-;6Q$A?9$I^*]&A2&O,(_32#!X'" MG@IM*`F,"5B:$">)N/)\WWO#W#57Z&\AR1XO.H!F4&&1VE.%'B4Q$]NI!%2G MM/T0%`\.,C:29K_92'E=,]TY&+U#DK]+[F^J":*`I\W#V7:^=*5.&I._`9Q/ M@,;F[*^R2C97<%!@:C8[M=CZS7R'RVA)96SI[U)96YQDQMS2#/5Y\/F&#CVF M:(I_5U$TQ1GJD]B#M)WBW]V'8$E+;UG31_G3@9,.EI`55*K2$ME-U7!Z=]7D M68$G2^6FDZ7/]DHV6E@^,`,PLFV8T+5A@9T2#:8_=7TT?XMT2F[HH*.'N/2AP<%/%\IV5@@GJRUR";'NS M$9HK\JL8OZ:&V9+YH7I/9S543:94M8PT^52@IPKJ8L7IWGC8Q,P("G+3*3@VSF366>+<4ZZJ.'(H@ MVNQUW)1H^HA9/*1O0&#Y<)5D-,L?TO'IS:6]U`TQT.>'9L0R*[.HI-HDS`'^ M%/A+Z"8RJ1Z%[*;*'X;LZ;.>$$2DX_3E&$:8.?%DK&LL>0520<82$<_YJ(20 M;B*0%'OZAB-%IV^('^MG^#Y]\Z8++PI,%Q\UTP7T0P!<^@';:!B5!$LY;AO1 MI=S1VT;V=U[4A>S+P^@B^S)=RH53TV4_FH7`;RUZX5&&(7EALC0-J";:T[WE M$L;U_>X`>`(^#D`VYR+.'-015-/)A*W)5,I2?)PKHUGO"!^):UQ3;&2]!WX+ MXZ8S4^KKC%S2+V#I8WAN+T54_(+H!T0'8LX^@UC^G+3LDS/?[?L*)BDH;LP0 M'`NL]DI/#5=ZA<:>2J'*#0JJQ#/3(H!X/$)KD,74'UG:WLH*$067C-! MUM(U%$LK&MCSXP1>.9*"<$L6W<3&W76`,A8C<"BFU3O'>[M>A]X2A/X:*1[X M9Z0N@Q"IRSP2%^L_5+&+4:FI=97!Q(KI@>\0SW732C-[X/')[Z8.`P8N"`AY MV5CE(>H[*;A0Z>8M#GJ4.WN[RK'U5P31W!EL*Y4%_AZ`6>0\P!GIHMQN.'DE M.W@70;9TV]&I*988S'@$Y7VD9JW&'8:#ASI*4HE?MI5XZ(6F,P!YCRPK6D9Q M08Q\TD8Q#%`'T0(75.I83Z="6`&^.GM#_8;)?#GE[SX,;(C3Q0H'T.P-)7UW M(CRE5%*9TM]2C'24CS<5H1"JTK6E/IU:;9=!OH?PD::I'I<_CJK;&6V'9G92 MIL*7",P+&[4X>5T9\/+GN`JU99!">_MN.1%._)4M,`HH>+H6>'=^V/>_A6A&:4^F;C8`MEYB;NG_.>Q+I?&-G\<)_EJ^;QP3)OJTB30 M5Y;,!>$L($PU79C2G8SJL%3ZN\)B(3LFE>:O3QJQ?%6R5Q#$X2E)S<$)6*$+ M?VR:CUSL@W=MAF#N^:04-,5M3G`D/??EQNSHRMNA*]-'&KU]W0\O?9OLX6+OC#]W'5(HFMIDJ MA;*K=86:T9OIV^-XVL$VG>G6>$6S(<52ZO=[LL#7]Q:;1>`HW9JIQ[`4/C MFP`+8.^EL4NP\-(TOYI.VL.*EQ']A(-T(_OM?&.>!/=!$(G`0*C_GB!"B"?* M)7ZF("6[&SWY,,X:$I/&C1.1WON!$A&.J%"\A0J+%7:`_>Z"E!Z;;BV@MQV, ML8!.0I^;_`Y]#6+E9@)BO_8GTP_74X3!`-?_1@BG>AU\+7L=Q,,8Z3A&/)"1 M'TENSA0:?8P+9WT7N0\@M/E=K0M_J?5/$!I'6MDK3OE5GS.$R%/KE9)OZK12 MB`*=Y5O>&H!Y4^Y/@%!UY4M]GB(U4FT5T@%)$I*:+@%(.[.B$-WI?L7:&>(K MM`'#0X#=7`4!D3T#V//6QZQ'@2KK):.^BX[[9/6!H:_$!4Q%DR-P2:R_"DN0 M!;S-!4.,+.5,C-TLUY@)UUX0NSB]XZLX&*\`3DJ):]57EBJ[N31?V28(SY8G MFR3EQ$Y9XZF19#P;N6Z$*Q6Z49"WK9#6=7V?P0F4DZZ=>1OLT)SPC(L^):\F M,VPIQWF4*O:#X],CX\#8-(V#%MS`S,"C&/$PQ@_?73.R(6HC MQ8JPF5>.M)J@8'87&5OM(PCQ3)Y\[Q7I?O;5^GN`8]@WF\T(H?LU/=42R/FKVR/YWE)A3@ZDW`9;G6M`!B$V)=?7!"]#ONX%;'Y]2 M#I`=`:R*W)UQ3X67BZY\B8OO^SE>7)LK&%)O*^(#[`\.6_)$A8?U7H_AY'VJ M@V.8,9!R:.OH&!8E69^MBL*0.^B::)]O#R;&0+J"291D?78FS`V<\!:'-/P5 MP5?3P5K#"'')]]>((;^:3D0KIL75=_"0:4YE9T5W5K$+(IJX'^X95"35X-DU M5G)E>%K?$Q.PW+JV3#_K:+5R8L:93L:XV^07M384CJZ#WU,:$\FLB3VLD^?> M#0&25/ADPG(^&U(3]63>5(:D>U(-G?K8D!(+Q-1\!P%3\(56>LN^GE1][B[Q M&\NCYUJ(:=L;G&MO%/#XV;3FB!`;1#WP"!X6'9#;4XT_.5IH;#AZP/:D\8L# MY['H`K2,(DP%5?]D]E(.(QW(G*2=BC-!GY,GY>;8QV^[Z3_B!,]![-9?30"> MY'ZFU0]M.MQ^0*U3[NAS_)'OAURQHTV&4`YKW=RG!8CM*OPJ7]E!;9MO:UNO M9*ZZ>K MKPG&7##'[GL2,99?9`6V0!?G4$S*WG-L5M2^^X.JYNS01S>G\6"";D0^M!#6 M8Y656^-J/-X'[)JQ2"-3!;?+2VLWH:&`3=3=IXT?4:\N'VHI^UDR.R^UP"#N MK(`?KI\-6A@*J]F[9+7G2ATU5^DE8=54?65:<;QLM01QAC?;M^*5DPZ4' M:+Y`AX6]5F,J!\>6SOQ$SX>.V=.919868WFJ"CB??'1=@EGL,#?^BMWV$6(< M'-#'0E8E'VLD;ABG0.,&3:[//B*FCGQ]]'7ZAIQD0"5D%Q/INH_@X>2"/@K[ MUG07)[ED'U#DQLKA9&?AM*3G'FX.=19`0%-^SB7%$F#"DQRLV(#"1A2Y\0>B M&G&H=W5:$J**U<(WSPLX'P]?_?1BEP]TM>!3W_FQ)4'L!J#I6Y"4!HG4Y`-" M`GSI)_A6.F2*2X?35,[N]`&K5ISJ.V.7)*#%O`T0)7>>?^-%+^$LVMN4*)0G6+F:Q\&I!WFDR241XG3&U=R2IX?799K4B1]C;BSD?4V?DCZ"V:0 MK"^GE'V`E<.8V;R3#*S9L$D)HIA4G*CT"HWQ)VE&[/;2,J]R\'63:)5-@G*I M<[LN!!(S:>$YB,P@B21X]$*0,67L3^!\$08T$'0PGNH@Z8!$EM[?:2WG'>ZL MY0M/6I_GN+RQ7AR='9=WUFU?(^F\*>]S+"4S[R^>9[]!QQFY=H6LS;QK<@@( MCB%CT=]!%X;@`5<>+$_Q+@KQ]')7VM2.RRAQU&XXF6I5(WEGJ=;;D:WI><)@ M"KJ?B($G[B"K`$,7:X0#*3&-G>5>(CN^J0<%$N]F(?#_!4S_#G40PTG]:)J# MJ)X!&<).S_=FNR$PI3-X[3.RJJ#:HS.,Q@\O(E7W:CK0GH(JICT#U?'>[U13 M]/ENMJITI/V$54J\N#5^AC9CWO$`KY/T5?"3"Q+UG&@W"]S4Q%*6//W5-^;>8NET:&$6[RU2JFSC%M:L%[@;ZR M9"X(9P%A9I2I)N[,F9&=UNG><>GQ+>@S`8!R%`;IE MVG')>:*/#*M+P8'U_.+LR\69O,7=]7Z`P MZ-='Z=@RB<+3JW6%CZ,WT[)0DZTMGL7[;]1S.5?\+Y,A5F?']01EGWR M2X4RJ!1%)ZZT.)YEISQ)JZDT44F%H6AE&TVF,OGL15ZSEX;;YH;@"6NI#6`8C->+<4[FHX^Y'D4KM&1(T M/$2">SNY_:##0T0'1&=( M^=*U9UEG4%F"T%]WBI,V(PX3)&THSA#R]?!418C<`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`$&37'1TY5+7K^DYIG@T]T&\QXR67N02 M94=N)S6*CA>"&[F1:1B0G*;`7]*M(94F`Y1.?OK*E>K@B1/?P(NJ6C&;#TMD M3%+Z21_?1_K(#>6DV&-*FT&=4L4`X+9*GJ.('6""-6-*K<'7QX4L6\G%J*[W`9+:FL+?U=*G.+D]S6 M/2S,4)^@U&_098NF^'<515.*5N+K7(HJH$/5U6>];6<7WH_&LH'?3+X2,QBI(JNYVP9B^8G?VKBJ\OH1; MZ^V]BR8'@G!BAN`9I_#'K]X6%M4.O:XUFRO>)'HQ4F MGW2`\/940=;\5BM>JCIS'M^E`?+.M*"#1K_QS3>7KAK4=AF62&O)&8RGYG9Y7Y\>79E\N++Q<7\C9<0=SF7<7KB>I[]SU3:*US[E)Q M6UT0P$]<9_>5_!.!"K)/N<0I_;2UKO)GD==9LA39""CY[B'$%QYA0-!H1%]6#;TU-#QL=90'C7M<#AC?1$PGK2L2TSH*0Q^^1&%2A[$: M-I)+)4%`2Q>##@Q`79"HRC)RT+LI= M/90DU5RDV@'8I1?EWOPIP7:[+,+8=<6MFQ0]E.C!WV"XN$=0?(5V9#JW[Y83 M85Q6]C2[$%0Q$ MY:H4IBY'%:X^)(5I]&IG\J:C1@4<=3%<77GR9*7P>JK,&+-A`IPD/]8"KJ;> MK1MB/PU6W3?A462B5_86DL>D,.-Z@1+-86D!P>P;L*%E.N/9#%K`I[\:,AK+ M%'9#?&]=ENAD*>>,WLV.$%-\^PZL"'M6LN3.U6.@PN>B3=.*)`I';`Y3`R&' MD:I8GT^WF%)%0G4_(DJ5W>P^(DJ5%4WO6_M#3:7:74[@XS15[C[_4(D.KBN^ MU4V*P9S9GB/2E]E+*OM66I]0A21C6NW")E!M+<]CF6IU#B MU"Z9DD+[Z/#X_(*03$5O?-?P\5<08+[%^?^!A7Z<>OA7O6?<%OZ\-LCNC",; M6)\>?Z"ZR,1F1>EV_O5]P;1HC;BCPX]]FGG>_>+3O>=[^=*^()5(_`:51Y=? MR%OM@!\V&G,L_@\^FM"J3MAUW#4BB9_0'HI$JC<8/#D].[U4!H-=UP/8DIUF M+AG/TDKW*>/OW5O36HQ<%R(:`M-?$R__N_R\ZGCV6+W4&ZPX`8&(3J)'TK@2S-^%YZ`_XVW_%?$#=5A@=MV[J&.(IDW: M^7KZD.HXZY/VK>WGZY%V=^61$P^>!K]55B@VC+D!S7C#VUEU](C2LT7$$5:[ MSOJ&Q`XC=NX?K\??;J>CWV^?RY$Z)\='Y4B=-%O'U'P'@8SPG.3[Z//;6=7$ MYC![2(K,+$\((_4*??)/?AIR760^N'+(([_>V(3L[)5TE\LKHQA0X^'8JTQN M.)P&Z^T1O(TL"^>JPU=MWW/1CU;R##KVL[,_WP*Z%EPAG8$1H]9RS`&MV):4 M*AR&$J>#QH0\6\`UT6P8,5>4MC+EV`FL"SBA3-E]J`L&\3]:HS7S_5%Z$`*9IJR2-T@[#Q)@-?P3.P(C09"((D(@W8 M=XBC^!TR2B17W:>8^G1'8TO3OT361N$QMQNZY;Y"_?09T_5B!@#]X_\!4$L# M!!0````(`(U[94$D=I5A:PP``.9_```1`!P`;F=N;2TR,#$R,#DS,"YXDDOC?GR%%R9*LJQ/':H]>=F5Q9C@S M'\D9WI337UY]SWK&7!!&SWK#O?V>A:G-'$)G9[U`])&P">G]\O-__W/Z7;__ M[?SQUG*8'?B82LOF&$GL6"]$SJT+SH1P"OC679URCZ3(U9N(X7!`J)"(VCBB M]PC]JX1<%4]!OUC\&KW19GA\?#S0I3U+(C[#\A[Y6"R0C5/D%+,9ILPGMC"U M#`_VCP_WHPIHX.>KXT@^D,L%'@`%YL2.&1BMP<-H/^;#'E:X7C/N7V(7!9X\ MZ_T=((^X!#L]"TG)R320.$40T`2)J7E&_4:V*;T<&;,D/7TT"`LC4FB22O$5 M\"X24TT(4B:1A!:H?ZLWBP6A+C,_X87"YX0S#T]` MA*4>OC[>E-J@:`;W6-Y`;_'Q+33^!\R?YM"&+[%$Q!,3_"K!,SV+.&>].H2Q M-I$^#G8))5KO_2_[1T.K;UT287M,!-"I^A8(M4*IUB, M].]/!UF9V>H"Z&UC^K-^7G`LH"EHI]W""\-M2,HX;>39@; M6D;<9SH4C/L3+TK]?E#N]\[;.=Y^DLS^:[Q0E:8;?5Y! M1>3XDO6^EF$9(5VSWSC$5\?VRJ"^24SO@,H#Z@(MB$3>+8:L7.3E8&4$%3#] ME(7)R+)"85VV50\AYON,ZL'G#\0YHM*X;6@`*BZOP.?'M=PXE&5&.B-M!=.P M`ZBR"^5TFHHP7]5-.I]7!/KU"%_E\?+0WCF\;D`OB>15$#0)X1T@M<)"?OBN M)*L*$@=U@D07S.M.RB6B,S+U\$@('&,QC*;F!:45&'U>"^0K258H*L:G"^)U MNU-R1:NXN&(]Z\>:O:=;R2H+]DCJ-78Q=B^0F%][["6.^GE%I9@,#_=UQ#>, M&A(JF$<\N(#XG(Y@:8M MD+V^&%.+LF+(.\[V*RW4,E(M+=9*RNW6`39,)ZKRB,H$HEG^T,'3(&](I7H5 M-%4YQ%J>5YQ#=#G>!EB5@E2)3GUP.E#R0'G$S\Q[)G1VP3$$\1%UGK`=<"*7 MHQG'.N"G<&I`7P'=81:Z6+05RK80A;3#2+=B\1V@Y4EAX/N(+\?N$YE1XA(; MHLC(MEE`);CV`?(YFV1V/INQ5,"Z-EP:Z2IK3,BW5A5840T=LHW&S^0\K*"L M8A)69_3L)F!O[6O1_TTZ6\Q3BN#GM_6VZ*D#M_&\K<:$K6JEM_%,K4.IWORL M<&)6A4B]&5D'0XW8E!^5J@"HCD>=\S?+X6LG[U40;9JU=\!MG#\TR1NJX'M# MOM`AF+?]BR3X<>R>!X)0+`1TJ7,DB!B[UX0B:A/DQ0OG#PF7F!WB3;DK4%X_ MVZTK4B!'5>ENJBM3;^/J$NO_R0H[["NV7\8+S%'JU$5N6?D&S$&##9B5T&X# MI@*G<^2IJSA/NINW']Z/[; MGV#NWJOO121*?LF=0XULUD.FXD@$XO::E+6;B""$0322D",.(N4C`8"?8D_F M$I:J1_Q@(0\T';R;\8!84^,S(&_)]HM5+5LRW4/3IJ8#"_:V:/2MDK\E#Y#U1^)6^1WH*=C,N+9I[G[?H=G%X>_F6V5I0"8OZ MU8_X^NI5?WC0/QSNO0HGTK&)"BL?-%,AXFNL@I8EL+TW8\^`)TE>S"W2(9=' M/?17S!LX(/^^U-/%XSS% ME:.(OB%?YI;D=>D90HO:H.0R#K`G1?3FO2#:#)YR;.HU4OQJSQNWTIA)/S5V M0DJ67L+AR\8Z)/FB'YMILG;MON9@$3$H`([JU5=Z<_\-;5'+>AL.A#YC(1O# MD&`SST5JF$\MZ$QGS&5,D/[6["83`& M@$$K&\H^U+8;ZI!GXH#[+SRBEB$SEA27[QB4&KM>!8UR$\Z6M4B8B#&@87QY M"7!X,(=Q)A!))MB>4]WP[K`_Q3RRN#9Y:KQQF($_5"[U-V#BZ5D/H;D!(!1 MSS-,U>JJ*#*N&<^N+;SPD!!8C-WL+OI:H*LF;%FC7#NMEM_]*LE:9E9!A,ZQ MK`YERXPK/>M48&8SGI89K#`B4F^XE:!81-$R8_25^3AHC7R55\5C?FY94F%H MJUA"=O:.*H=+43(JFH8;,F<]6T?:"D,FF/L/6EC*AN3KI/J1>S[4XR.(&\B# M(0Q#'B`7DB<#IGR2O9>68".GE8B'LLBY4N(&B#[H_8QN19;%+!+"3_2`RO_@[(0G]; M%-G$@]G8F&8:8!G%KEN@'C_'@52#LOHP;DXPSBEM:3A.Q80XAWC@Q,:KCE1" M\F%=J+`MF?%)ZQ-]I*6TJS3A2(5U3?B1<3V9GRI1>7EK^/X=LE5'GLR7*GD) MIMK(=T_";PG5@D6.&8FREB7>"25'CJ-WAY%7/9\HH6V9@V&3.`@&I##2XR9QPB3%--\B-6/^1]E^S8%/[LZPM MM'_D2LPW,K\Q9]NLOX5$D":6T*Y>%X0O,PM4I30[7T71ZF#G*\4FNW4R$ZK" M\K:!H;-L_;<^()U:@,_#6*`R\IDF/5^N2![04J]YOB#NW#,:9BIJ\JA.08!= M07B%8S4=^P.3V1R"Y@C&933#J;E`G/3L4(/0^]&Q%>6ZKY1\[#YQI?FBN?V_ MALMW-.PO[P+"EK7XEP(16;ES+!HJ\D^`H[D3KAEW,5%7^]3503U&AW?"WA6= M#]?KWPE6S3'\BCKIS*$5JK0`DM^1%^"QFUV.6WO]4?/T>AM2^5M0.U]"'WE3 M`HXQ6J4;7'[9SE/4!P$'SUPII)7=/,!@QMLS5Y*FT4 M2%``AN<;'P;G$47>4I#$635CDLB'^NV"VNB;\/3>6QWS%BFM\\J<8/<..^IB M^=AU06F>,;B8H&VV9'<,\HZ*EY&T;7=DT^3M=QBPU,'W\#00M,ZQJZ>?V#&6 MW]`K9,]'E!+U]U`AQWESOKA)E=L\M[1-[X9)8[(E&5/?[L42T3O?[;Y4BX^A MBO'.M:N^C$`<\SD1,$4?CV*)_>PY\Z!8P?\,TH!AKIQP0X%106D+3CAL=UUO]RN+K5]#S/]KS_FC53W: M'8Y;IX/PRC(\_@]02P$"'@,4````"`"->V5!P'-QR,!7``"O_@,`$0`8```` M```!````I($`````;F=N;2TR,#$R,#DS,"YX;6Q55`4``VHAF%!U>`L``00E M#@``!#D!``!02P$"'@,4````"`"->V5!WF1/_7<-``!NM0``%0`8```````! M````I($+6```;F=N;2TR,#$R,#DS,%]C86PN>&UL550%``-J(9A0=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`C7ME0=EP#@<7$P``6G`Q0````(`(U[94$\3)G<2T8``-7(`P`5`!@````` M``$```"D@3=Y``!N9VYM+3(P,3(P.3,P7VQA8BYX;6Q55`4``VHAF%!U>`L` M`00E#@``!#D!``!02P$"'@,4````"`"->V5!!%M5C)DH``"XNP(`%0`8```` M```!````I('1OP``;F=N;2TR,#$R,#DS,%]P&UL550%``-J(9A0=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`C7ME021VE6%K#```YG\``!$`&``` M`````0```*2!N>@``&YG;FTM,C`Q,C`Y,S`N>'-D550%``-J(9A0=7@+``$$ ?)0X```0Y`0``4$L%!@`````&``8`&@(``&_U```````` ` end XML 40 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

Capital Leases
9 Months Ended

Sep. 30, 2012

Capital Leases [Abstract]

CAPITAL LEASES
NOTE H — CAPITAL LEASES

On September 9, 2011, we entered into a master lease agreement for an equipment lease line of credit with Garic, Inc. The facility had a 12 month draw down period and each schedule has a thirty six month term. The lease had a fair market value option at the end of the term at a price not to exceed fifteen percent of the equipment cost or the right to return the equipment. The facility expired and we had borrowed $658,000 over the life of the line at an interest rate of 16.12%.

In June 2012, we entered into a five year, $1 buyout equipment lease of approximately $495,000 for the purchase of laboratory equipment with Wells Fargo Lease Equipment Financing. The lease has an interest rate of approximately 6%.

During the nine months ended September 30, 2012, we entered into several vendor lease arrangements for approximately $1,555,000, primarily for the acquisition of lab equipment and to a lesser extent computer hardware. These capital leases are for 36 to 60 month terms, have either $1 purchase options or were fair market value at the end of the term, and had approximate interest rates between 8% and 16%.

X

- Definition

Capital leases.

+ References

No definition available.

+ Details

Name: ngnm_CapitalLeasesTextBlock

Namespace Prefix: ngnm_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_LeasesCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

Other Related Party Transactions
9 Months Ended

Sep. 30, 2012

Other Related Party Transactions [Abstract]

OTHER RELATED PARTY TRANSACTIONS
NOTE I — OTHER RELATED PARTY TRANSACTIONS

During the three months ended September 30, 2012 and 2011, Steven C. Jones, a director of the Company, earned approximately $52,500 and $50,000, respectively, for various consulting work performed in connection with his duties as Executive Vice President of Finance. During the nine months ended September 30, 2012 and 2011, he earned approximately $155,000 and $148,500, respectively, for various consulting work performed in connection with his duties as Executive Vice President of Finance. Mr. Jones also received $55,000 and $2,500 for the nine months ended September 30, 2012 and 2011 as payment of his annual bonus compensation for the previous fiscal year.

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 1-4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6

Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2012

Summary of Significant Accounting Policies [Abstract]

Use of Estimates
Use of Estimates

The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America. These principles require management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the consolidated financial statements. Actual results and outcomes may differ from management’s estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these consolidated financial statements include, but are not limited to, those related to revenues, accounts receivable and related reserves, contingencies, useful lives and recovery of long-term and intangible assets, income taxes, and the fair value of stock-based compensation. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected in the consolidated financial statements prospectively from the date of the change in estimate.

Research and Development
Research and Development

Research and development costs are expensed as incurred. Research and development expenses consist of cash and equity compensation and benefits for research and development personnel, amortization of intangibles, related supplies, inventory and payment for samples to complete validation studies. These expenses were incurred to develop new genetic tests.

Intangible Assets
Intangible Assets

Intangible assets with finite useful lives are recorded at fair value which is our cost, less accumulated amortization. Amortization is recognized over the estimated useful lives of the assets. The Company’s intangible assets are related to our license agreement with Health Discovery Corporation.

Concentrations of Credit Risk
Concentrations of Credit Risk

Concentrations of credit risk with respect to revenue and accounts receivable are primarily limited to certain clients to whom the Company provides a significant volume of its services, and to specific payers of our services such as Medicare and individual insurance companies. The Company’s client base consists of a large number of geographically dispersed clients diversified across various customer types. Over the last year, we have expanded our relationship with a large oncology practice with multiple office locations. For the three months ended September 30, 2012, all of the affiliated locations from this oncology practice combined represented approximately 12.9% of our revenue compared to 13.5% of revenue for the quarter ended September 30, 2011 and for the nine months ended September 30, 2012 represented approximately 15.4% of our revenue compared to 8.8% of revenue for the nine months ended September 30, 2011. All other clients were less than 5% of total revenue individually.

Income Taxes
Income Taxes

We compute income taxes in accordance with applicable accounting standards. Deferred taxes are recognized for the tax consequences of temporary differences by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the tax basis of existing assets and liabilities. Also, the effect on deferred taxes of a change in tax rates is recognized in income in the period that included the enactment date. Temporary differences between financial and tax reporting arise primarily from the use of different depreciation methods for property and equipment, stock based compensation expense and the timing of recognition of bad debts.

We evaluate tax positions that have been taken or are expected to be taken in our tax returns, and record a liability for uncertain tax positions. As of September 30, 2012 we had no provision for related income taxes because we have large Net Operating Loss positions to offset our current net income.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for credit risk.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6480020&loc=d3e61044-112788

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number SOP94-6-1

-Paragraph 7, 11

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 113

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 55

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14537-108613

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 825

-Section 55

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6487554&loc=d3e32600-158583

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 55

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 01-6

-Paragraph 14

-Subparagraph m

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13531-108611

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6480020&loc=d3e61082-112788

+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 11-15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-URI http://asc.fasb.org/subtopic&trid=2144471

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 144

-Paragraph 7-18, 22

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IntangibleAssetsFiniteLivedPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for income taxes, including investment tax credits, and the related regulatory treatment (for example, whether deferred income tax accounting - normalization - is allowed in rate making).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 980

-SubTopic 740

-URI http://asc.fasb.org/subtopic&trid=2156927

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 980

-SubTopic 740

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501382&loc=d3e54053-110423

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 8

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 71

-Paragraph 9, 11

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 980

-SubTopic 740

-Section 25

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6501382&loc=d3e54136-110423

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 29, 117, 252, 253, 254, 255

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_RegulatoryIncomeTaxesPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 8, 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 6

-Paragraph 5, 6, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 42

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2127266

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 11, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6

Revolving Credit and Security Agreement (Details) (USD $)
9 Months Ended

Sep. 30, 2012

Line of Credit Facility [Line Items]

Debt Instrument, Basis Spread on Variable Rate 2.00%

Revolving credit and security agreement (Textual) [Abstract]

Effective rate of interest 5.25%

Available credit under credit facility $ 300,000

Outstanding borrowing 8,000,000

Commitment fee for capital source 80,000

Debt Instrument, Description of Variable Rate Basis The libor shall be not less than 2.0% and replacing it with the libor shall be not less than 1.0%

Amended and Restated Credit Agreement maturity date Mar. 26, 2015

Amended and restated credit arrangement [Member]

Line of Credit Facility [Line Items]

Debt Instrument, Basis Spread on Variable Rate 1.00%

Maximum [Member]

Line of Credit Facility [Line Items]

Current maximum principal amount of credit facility 8,000,000

Increase in line of credit facility cap 10,000,000

Increased facility cap 9,000,000

Minimum [Member]

Line of Credit Facility [Line Items]

Current maximum principal amount of credit facility 5,000,000

Increase in line of credit facility cap 1,000,000

Increased facility cap $ 8,000,000

Minimum termination fee, grace period 5 days

Due before march 26, 2013 [Member]

Line of Credit Facility [Line Items]

Minimum termination fee, percentage 2.50%

Due before march 26, 2014 [Member]

Line of Credit Facility [Line Items]

Minimum termination fee, percentage 1.50%

Due after march 26, 2014 [Member]

Line of Credit Facility [Line Items]

Minimum termination fee, percentage 0.50%

X

- Definition

Increased facility cap.

+ References

No definition available.

+ Details

Name: ngnm_IncreasedFacilityCap

Namespace Prefix: ngnm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Minimum termination fee grace period.

+ References

No definition available.

+ Details

Name: ngnm_MinimumTerminationFeeGracePeriod

Namespace Prefix: ngnm_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: ngnm_RevolvingCreditAndSecurityAgreementTextualAbstract

Namespace Prefix: ngnm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The percentage points added to the reference rate to compute the variable rate on the debt instrument.

+ References

No definition available.

+ Details

Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.

+ References

No definition available.

+ Details

Name: us-gaap_DebtInstrumentDescriptionOfVariableRateBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount borrowed under the credit facility as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 22

-Article 5

+ Details

Name: us-gaap_LineOfCreditFacilityAmountOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of the fee for available but unused credit capacity under the credit facility.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 22

-Article 5

+ Details

Name: us-gaap_LineOfCreditFacilityCommitmentFeeAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.

+ References

No definition available.

+ Details

Name: us-gaap_LineOfCreditFacilityCommitmentFeePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 22

-Article 5

+ Details

Name: us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Date the credit facility terminates, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 22

-Article 5

+ Details

Name: us-gaap_LineOfCreditFacilityExpirationDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Increase for additional borrowings on the credit facility during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(f))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph f

-Article 4

+ Details

Name: us-gaap_LineOfCreditFacilityIncreaseAdditionalBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The effective interest rate during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 22

-Article 5

+ Details

Name: us-gaap_LineOfCreditFacilityInterestRateDuringPeriod

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_LineOfCreditFacilityLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 22

-Article 5

+ Details

Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 44 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6

Net Income (Loss) Per Share (Details Textual)
9 Months Ended

Sep. 30, 2012

Net Income (Loss) Per Share (Textual) [Abstract]

Outstanding stock options 0

X

- Details

Name: ngnm_NetIncomeLossPerShareTextualAbstract

Namespace Prefix: ngnm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 45 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

Consolidated Statements of Cash Flows (Unaudited) (USD $)
In Thousands, unless otherwise specified
9 Months Ended

Sep. 30, 2012

Sep. 30, 2011

CASH FLOWS FROM OPERATING ACTIVITIES

Net income (loss) $ 178 $ (1,329)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

Provision for bad debts 2,434 1,740

Amortization of intangibles 126

Depreciation of property and equipment 2,549 1,484

Amortization of debt issue costs 29 30

Stock-based compensation - options 488 257

Stock-based compensation - warrants and restricted stock 211 121

Changes in assets and liabilities, net:

(Increase) decrease in accounts receivable, net of write-offs (6,552) (3,870)

(Increase) decrease in inventories (704) (208)

(Increase) decrease in other current assets 61 286

(Increase) decrease in other assets 38 (37)

Increase (decrease) in accounts payable and other liabilities 649 356

NET CASH (USED) IN OPERATING ACTIVITIES (493) (1,170)

CASH FLOWS FROM INVESTING ACTIVITIES

Purchase of intangible assets (1,037)

Purchases of property and equipment (2,263) (338)

NET CASH (USED) IN INVESTING ACTIVITIES (3,300) (338)

CASH FLOWS FROM FINANCING ACTIVITIES

Restricted cash 200

Advances (payments) on credit facility, net 4,137 1,030

Repayment of capital leases (1,637) (1,146)

Issuance of common stock and warrants for cash , net of transaction expenses 503 3,176

NET CASH PROVIDED BY FINANCING ACTIVITIES 3,203 3,060

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (590) 1,552

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 2,628 1,097

CASH AND CASH EQUIVALENTS, END OF PERIOD 2,038 2,649

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

Interest paid 809 519

Income taxes paid

NON-CASH INVESTING AND FINANCING ACTIVITIES

Equipment leased under capital leases 2,845 1,255

Common stock issued for intangible asset purchase $ 1,945

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 8

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph a(2)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase during the period in capital lease obligations due to entering into new capital leases.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CapitalLeaseObligationsIncurred

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 27

-Subparagraph f

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of obligations incurred but not paid and other operating obligations not separately disclosed in the statement of cash flows.

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other noncurrent operating assets not separately disclosed in the statement of cash flows.

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow from financing activity for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash inflow or outflow from investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 9

-Subparagraph c

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3098-108585

+ Details

Name: us-gaap_ProceedsFromRepaymentsOfLinesOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or outflow from cash and cash items that are not available for withdrawal or usage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 5

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.5)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow associated with security instruments that either represent a creditor or an ownership relationship with the holder of the investment security with a maturity of beyond one year or normal operating cycle, if longer. Includes repayments of (a) debt, (b) capital lease obligations, (c) mandatory redeemable capital securities, and (d) any combination of (a), (b), or (c).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_RestrictedStockExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph i

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_StockOptionPlanExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowElementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

Net Income (Loss) Per Share
9 Months Ended

Sep. 30, 2012

Net Income (Loss) Per Share [Abstract]

NET INCOME (LOSS) PER SHARE
NOTE E — NET INCOME (LOSS) PER SHARE

Basic net income (loss) per share is computed using the weighted average number of common shares outstanding during the applicable period. Diluted net income per share is computed using the weighted average number of common shares outstanding during the applicable period, plus the dilutive effect of potential common stock. Potential common stock consists of shares issuable pursuant to stock options and warrants. Diluted net (loss) per share is computed using the weighted average number of common shares outstanding during the applicable period. Potential common stock is excluded from diluted net (loss) per share as such amounts are anti-dilutive. Calculations of net income (loss) per share are done using the treasury stock method.

The following table provides the computation of basic and diluted net income (loss) per share for the three and nine month periods ending September 30, 2012 and 2011: (in thousands, except per share amounts)

Three Months Ended
September 30, Nine Months Ended
September 30,

2012 2011 2012 2011

Net income (loss)
$ (975 ) $ (143 ) $ 178 $ (1,329 )

Basic weighted average shares outstanding
45,175 43,104 44,944 42,570

Effect of potentially dilutive securities
— — 3,282 —

Diluted weighted average shares outstanding
45,175 43,104 48,226 42,570

Basic net income (loss) per share
$ (0.02 ) $ (0.00 ) $ 0.00 $ (0.03 )

Diluted net income (loss) per share
$ (0.02 ) $ (0.00 ) $ 0.00 $ (0.03 )

For the nine months ended September 30, 2012 there were no outstanding options or warrants excluded from the calculation of diluted earnings per share due to anti-diluted affects, as all options and warrants were less than the average market price of the Company’s common stock for the nine months ended September 30, 2012.

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stock Options (Details) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2012

Sep. 30, 2012

Stock Options (Textual) [Abstract]

Supplemental options vested 200,000 200,000

Deemed value per share $ 4.00

Stock option to purchase 5,826,135 5,826,135

Exercise prices $ 1.02 $ 1.02

Maximum [Member]

Stock Options (Textual) [Abstract]

Exercise prices $ 1.71 $ 1.71

Minimum [Member]

Stock Options (Textual) [Abstract]

Exercise prices $ 0.25 $ 0.25

Chief Medical Officer [Member]

Stock Options (Textual) [Abstract]

Stock option to purchase 250,000

Common stock exercise price per share $ 1.43

Stock option term 5 years

Stock option vested 25.00%

Stock option valued $ 428,000

Stock compensation expense 118,400 158,000

Chief Executive Officer [Member]

Stock Options (Textual) [Abstract]

Stock option to purchase 800,000

Common stock exercise price per share $ 1.71

Stock option term 5 years

Stock option valued 505,000

Stock compensation expense $ 60,225 $ 149,999

X

- Definition

Deemed value per share of consideration payable to common stockholders in event of change in control.

+ References

No definition available.

+ Details

Name: ngnm_DeemedValuePerShareOfConsiderationPayableToCommonStockholdersInEventOfChangeInControl

Namespace Prefix: ngnm_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Share based compensation arrangement by share based payment award value of stock options granted.

+ References

No definition available.

+ Details

Name: ngnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfStockOptionsGranted

Namespace Prefix: ngnm_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

Share based compensation arrangement by share based payment award vesting percentage of granted options in each anniversary.

+ References

No definition available.

+ Details

Name: ngnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPercentageOfGrantedOptionsInEachAnniversary

Namespace Prefix: ngnm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: ngnm_StockOptionsTextualAbstract

Namespace Prefix: ngnm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph g(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph d(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance on stock options awarded.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 49 173 1 false 24 0 false 5 false false R1.htm 00 - Document - Document and Entity Information Sheet http://www.neogenomics.org/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 0110 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://www.neogenomics.org/role/BalanceSheets Consolidated Balance Sheets (Unaudited) false false R3.htm 0111 - Statement - Consolidated Balance Sheets (Parenthetical) (Unaudited) Sheet http://www.neogenomics.org/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) (Unaudited) false false R4.htm 0120 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://www.neogenomics.org/role/StatementsOfOperations Consolidated Statements of Operations (Unaudited) false false R5.htm 0130 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.neogenomics.org/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) false false R6.htm 0201 - Disclosure - Nature of Business and Basis of Financial Statement Presentation Sheet http://www.neogenomics.org/role/NatureOfBusinessAndBasisOfFinancialStatementPresentation Nature of Business and Basis of Financial Statement Presentation false false R7.htm 0202 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.neogenomics.org/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R8.htm 0203 - Disclosure - Revolving Credit and Security Agreement Sheet http://www.neogenomics.org/role/RevolvingCreditAndSecurityAgreement Revolving Credit and Security Agreement false false R9.htm 0204 - Disclosure - Intangible Assets Sheet http://www.neogenomics.org/role/IntangibleAssets Intangible Assets false false R10.htm 0205 - Disclosure - Net Income (Loss) Per Share Sheet http://www.neogenomics.org/role/NetIncomeLossPerShare Net Income (Loss) Per Share false false R11.htm 0206 - Disclosure - Stock Options Sheet http://www.neogenomics.org/role/StockOptions Stock Options false false R12.htm 0207 - Disclosure - Common Stock Warrants Sheet http://www.neogenomics.org/role/CommonStockWarrants Common Stock Warrants false false R13.htm 0208 - Disclosure - Capital Leases Sheet http://www.neogenomics.org/role/CapitalLeases Capital Leases false false R14.htm 0209 - Disclosure - Other Related Party Transactions Sheet http://www.neogenomics.org/role/OtherRelatedPartyTransactions Other Related Party Transactions false false R15.htm 0210 - Disclosure - Income Taxes Sheet http://www.neogenomics.org/role/INCOMETAXES Income Taxes false false R16.htm 0402 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.neogenomics.org/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) false false R17.htm 0504 - Disclosure - Intangible Assets (Tables) Sheet http://www.neogenomics.org/role/IntangibleAssetsTables Intangible Assets (Tables) false false R18.htm 0505 - Disclosure - Net Income (Loss) Per Share (Tables) Sheet http://www.neogenomics.org/role/NetIncomeLossPerShareTables Net Income (Loss) Per Share (Tables) false false R19.htm 0507 - Disclosure - Common Stock Warrants (Tables) Sheet http://www.neogenomics.org/role/CommonStockWarrantsTables Common Stock Warrants (Tables) false false R20.htm 0602 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.neogenomics.org/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) false false R21.htm 0603 - Disclosure - Revolving Credit and Security Agreement (Details) Sheet http://www.neogenomics.org/role/RevolvingCreditAndSecurityAgreementDetails Revolving Credit and Security Agreement (Details) false false R22.htm 0604 - Disclosure - Intangible Assets (Details) Sheet http://www.neogenomics.org/role/IntangibleAssetsDetails Intangible Assets (Details) false false R23.htm 06041 - Disclosure - Intangible Assets (Details1) Sheet http://www.neogenomics.org/role/IntangibleAssetsDetails1 Intangible Assets (Details1) false false R24.htm 06042 - Disclosure - Intangible Assets (Details Textual) Sheet http://www.neogenomics.org/role/IntangibleAssetsDetailsTextual Intangible Assets (Details Textual) false false R25.htm 0605 - Disclosure - Net Income (Loss) Per Share (Details) Sheet http://www.neogenomics.org/role/NetIncomeLossPerShareDetails Net Income (Loss) Per Share (Details) false false R26.htm 06051 - Disclosure - Net Income (Loss) Per Share (Details Textual) Sheet http://www.neogenomics.org/role/NetIncomeLossPerShareDetailsTextual Net Income (Loss) Per Share (Details Textual) false false R27.htm 0606 - Disclosure - Stock Options (Details) Sheet http://www.neogenomics.org/role/StockOptionsDetails Stock Options (Details) false false R28.htm 0607 - Disclosure - Common Stock Warrants (Details) Sheet http://www.neogenomics.org/role/CommonStockWarrantsDetails Common Stock Warrants (Details) false false R29.htm 06071 - Disclosure - Common Stock Warrant (Details 1) Sheet http://www.neogenomics.org/role/CommonStockWarrantDetails1 Common Stock Warrant (Details 1) false false R30.htm 06072 - Disclosure - Common Stock Warrants (Details Textual) Sheet http://www.neogenomics.org/role/CommonStockWarrantsDetailsTextual Common Stock Warrants (Details Textual) false false R31.htm 0608 - Disclosure - Capital Leases (Details Textual) Sheet http://www.neogenomics.org/role/CapitalLeasesDetailsTextual Capital Leases (Details Textual) false false R32.htm 0609 - Disclosure - Other Related Party Transactions (Details) Sheet http://www.neogenomics.org/role/OtherRelatedPartyTransactionsDetails Other Related Party Transactions (Details) false false R33.htm 0610 - Disclosure - Income Taxes (Details) Sheet http://www.neogenomics.org/role/IncomeTaxesDetails Income Taxes (Details) false false All Reports Book All Reports 'Monetary' elements on report '0603 - Disclosure - Revolving Credit and Security Agreement (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '06042 - Disclosure - Intangible Assets (Details Textual)' had a mix of different decimal attribute values. Process Flow-Through: 0110 - Statement - Consolidated Balance Sheets (Unaudited) Process Flow-Through: Removing column 'Sep. 30, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 0111 - Statement - Consolidated Balance Sheets (Parenthetical) (Unaudited) Process Flow-Through: 0120 - Statement - Consolidated Statements of Operations (Unaudited) Process Flow-Through: 0130 - Statement - Consolidated Statements of Cash Flows (Unaudited) ngnm-20120930.xml ngnm-20120930.xsd ngnm-20120930_cal.xml ngnm-20120930_def.xml ngnm-20120930_lab.xml ngnm-20120930_pre.xml true true XML 49 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

Summary of Significant Accounting Policies (Details)
3 Months Ended 9 Months Ended

Sep. 30, 2012

Sep. 30, 2011

Sep. 30, 2012

Sep. 30, 2011

Summary of significant accounting policies (Textual) [Abstract]

Oncology practice combined represented revenue 12.90% 13.50% 15.40% 8.80%

Revenue of all other clients individually less than 5%

X

- Definition

Individual clients revenue.

+ References

No definition available.

+ Details

Name: ngnm_IndividualClientsRevenue

Namespace Prefix: ngnm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Oncology practice combined represented revenue.

+ References

No definition available.

+ Details

Name: ngnm_OncologyPracticeCombinedRepresentedRevenue

Namespace Prefix: ngnm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: ngnm_SummaryOfSignificantAccountingPoliciesTextualAbstract

Namespace Prefix: ngnm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

Revolving Credit and Security Agreement (Details) (USD $)	9 Months Ended
	Sep. 30, 2012
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate	2.00%
Revolving credit and security agreement (Textual) [Abstract]
Effective rate of interest	5.25%
Available credit under credit facility	$ 300,000
Outstanding borrowing	8,000,000
Commitment fee for capital source	80,000
Debt Instrument, Description of Variable Rate Basis	The libor shall be not less than 2.0% and replacing it with the libor shall be not less than 1.0%
Amended and Restated Credit Agreement maturity date	Mar. 26, 2015
Amended and restated credit arrangement [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.00%
Maximum [Member]
Line of Credit Facility [Line Items]
Current maximum principal amount of credit facility	8,000,000
Increase in line of credit facility cap	10,000,000
Increased facility cap	9,000,000
Minimum [Member]
Line of Credit Facility [Line Items]
Current maximum principal amount of credit facility	5,000,000
Increase in line of credit facility cap	1,000,000
Increased facility cap	$ 8,000,000
Minimum termination fee, grace period	5 days
Due before march 26, 2013 [Member]
Line of Credit Facility [Line Items]
Minimum termination fee, percentage	2.50%
Due before march 26, 2014 [Member]
Line of Credit Facility [Line Items]
Minimum termination fee, percentage	1.50%
Due after march 26, 2014 [Member]
Line of Credit Facility [Line Items]
Minimum termination fee, percentage	0.50%

Net Income (Loss) Per Share (Details Textual)	9 Months Ended
Net Income (Loss) Per Share (Details Textual)	Sep. 30, 2012
Net Income (Loss) Per Share (Textual) [Abstract]
Outstanding stock options	0

Stock Options (Details) (USD $)	3 Months Ended	9 Months Ended
Stock Options (Details) (USD $)	Sep. 30, 2012	Sep. 30, 2012
Stock Options (Textual) [Abstract]
Supplemental options vested	200,000	200,000
Deemed value per share		$ 4.00
Stock option to purchase	5,826,135	5,826,135
Exercise prices	$ 1.02	$ 1.02
Maximum [Member]
Stock Options (Textual) [Abstract]
Exercise prices	$ 1.71	$ 1.71
Minimum [Member]
Stock Options (Textual) [Abstract]
Exercise prices	$ 0.25	$ 0.25
Chief Medical Officer [Member]
Stock Options (Textual) [Abstract]
Stock option to purchase		250,000
Common stock exercise price per share		$ 1.43
Stock option term		5 years
Stock option vested		25.00%
Stock option valued		$ 428,000
Stock compensation expense	118,400	158,000
Chief Executive Officer [Member]
Stock Options (Textual) [Abstract]
Stock option to purchase		800,000
Common stock exercise price per share		$ 1.71
Stock option term		5 years
Stock option valued		505,000
Stock compensation expense	$ 60,225	$ 149,999